



CHARACTERISING THE PEPITEM PATHWAY IN 




A thesis submitted to the University of Birmingham for the degree of DOCTOR OF 
PHILOSOPHY 
Centre of Cardiovascular Science 
School of Medicine 
The Medical School 
































This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 








Atherosclerosis is an asymptomatic disease which is regarded as one of the most fatal 
diseases. However, the mechanism of the immune response is not well understood. There is 
accumulated evidence supporting the idea that inflammatory response initiates the disease. A 
new novel peptide has been discovered in our lab which down-regulates T cell recruitment 
during inflammation called PEPITEM (Peptide Inhibitor of Trans Endothelial Migration). We 
are interested in testing the action of PEPITEM on PBL isolated from atherosclerosis patients. 
We first demonstrated that PEPITEM did not affect the levels of adhesion of PBL from either 
diseased or healthy donors. Interestingly however, we did observe that PBL isolated from 
atherosclerosis patients adhere more readily than those isolated from healthy control subjects. 
Therefore, we studied the surface expression of certain adhesion molecules and chemokine 
receptors on the PBL of atherosclerosis patients. We found significantly higher surface 
expression of Beta-receptor family (Beta-1 and Beta-2) and PSGL-1 receptors in some PBL 
subsets in atherosclerosis patients. In addition, we looked at the effect of PEPITEM and 
adiponectin (AQ) treatment on the migration of PBL and we revealed for the first time based 
on our knowledge that there was no effect of treatment on PBL isolated from atherosclerosis 
patients.  
These observations will contribute to understanding the potential therapeutic 
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1. The cellular constituents of blood and the process of their derivation 
 
Blood is composed of a liquid component called plasma, which contains many solutes, 
and a solid component, composed of blood cells. These cells can be broadly sub-classified as 
red blood cells (RBCs), white blood cells (WBCs), and platelets. From the embryological 
point of view, the production of blood cells (haemopoiesis) starts in the yolk sac at day 14 
post-fertilization, whereas in the second and third trimester, the liver and then the bone 
marrow become the major sites of haemopoiesis. After birth until ≈4 years of age, the marrow 
in all bones is called red bone marrow, because haemopoiesis is taking place; however, by age 
25 haemopoiesis is limited to the ribs, sternum, vertebrae and pelvis  (Rodak et al., 2002).  
1.1. Platelets 
 
Platelets are not considered true cells because they lack a nucleus and therefore DNA. 
They are derived from bone-marrow resident megakaryocytes and their life span in the 
circulation is approximately 10 days (Harrison, 2005). Quiescent platelets circulate within a 
physiological range of 150 to 400 x 109 /L (Rodak et al., 2002). Platelets play an important 
role in many physiological functions in the body such as haemostasis, wound healing and 
inflammation  (Rodak et al., 2002) however, activation is essential for their efficient function, 
for example during haemostasis in vascular injury. In this context activation promotes 
responses such as adhesion, aggregation and secondary messenger production which work 
together to form a thrombus (or clot) to prevent blood loss (Rodgers, 1999). In the context of 
pathology, platelets have been shown to interact directly with intact monolayers of 
endothelium, for example in models of atherosclerosis, where they may promote the 
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recruitment of inflammatory leukocytes to the diseased vessel wall thereby propagating the 
disease process.  
1.1. Red blood cells (RBC) 
 
 RBCs are non-nucleated discoid cells about 2-2.5 μm thick and 6-8 μm in diameter. Their 
main function is oxygen transport between the lungs and the body’s tissues, which is 
facilitated by haemoglobin. The life span of RBCs in the circulation is ≈120 days, and as they 
age they are removed in the spleen for destruction by the reticulo-endothelial cell system. The 
normal range of RBCs counts in males is 4.6 to 6.2 x106/µl , whereas in females it is 4.3 to 
5.6 x 106/µL (Tefferi, 2003). These numbers account for between 35-45% of blood volume, 
the haematocrit. As well as gas transport, RBCs play an important role in inflammation being 
responsible for the margination of WBCs to the vessel wall during the process of recruitment 
of these cells to the inflamed tissue (see below for details). RBCs also possess the Duffy 
antigen receptor for chemokines (DARC), which promiscuously binds a number of 
inflammatory chemokines (Hadley and Peiper, 1997). The binding of chemokines to DARC 
does not activate signalling pathways in RBCs, as it is not a G protein coupled receptor in 
these cells (Comerford et al., 2007). Rather, it is thought that DARC regulates the plasma 
concentration of biologically active chemokines by acting as a sink for their removal from the 
circulation and by neutralisation of their function. (Fukuma et al., 2003) (Lee et al., 2006). 
1.2. White blood cells 
 
The production of white blood cells is called leucopoiesis and it occurs in different 
locations depending on age; for example, it takes place in the yolk sac during early 
embryogenesis, then in the spleen later in ontogeny. In adult life lymphoid tissues (i.e. 
thymus, spleen and lymph nodes) and the bone marrow are the major sites for leucopoiesis 
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(Dalton et al., 1993). White blood cells (WBCs) form a heterogeneous population, with sub-
populations being derived from distinct progenitor pathways (Rodak et al., 2002). These are 
generally classified into two major families: 1) polymorphonuclear leukocytes (PMN); 2) 
mononuclear cells. 
1.2.1. Polymorphonuclear leukocytes (PMN) 
 
 In adults PMNs are formed exclusively in the bone marrow where they are stored and 
from which they are continuously released. They make up to 50%-70% of the total circulating 
WBCs count, and the production and their release into the blood can be increased in response 
to leukopoietic signals generated during infection and/or inflammation (Bagby, 2007).  In 
general, these cells are highly granular in appearance due to the numerous vesicular bodies 
within their cytoplasm which has given rise to their alternative name of granulocytes.  Based 
on their staining characteristics, granulocytes are subdivided into 3 groups: neutrophils, 
eosinophils and basophils (Figure 1-1). Neutrophils are the predominant subset of circulating 
granulocytes composing 40-65% of the total WBC count. Eosinophils and basophils are 
relatively rare in the circulation; eosinophils account for 1% - 4% of total blood count and 
basophils for 0.5% -1.0% (Bagby, 2007). These cells are intrinsically linked to the innate 
immune response. Indeed, neutrophils are generally the first leukocytes recruited during 
inflammation and/or infection, where their phagocytic capacity and powerful array of 
cytotoxins form the first line of defence against invading micro-organisms. Eosinophils are 
also stored in the bone marrow and can be mobilised rapidly from this depot. They are also 
recruited to tissues, although they are most prevalent during infection with multi-cellular 
parasites, e.g helminths and roundworms (Dalton et al., 1993). They also play important roles 
in the exaggerated responses of the immune system in allergic conditions. Basophils express 
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receptors have a high affinity for the Fc regions of IgE and hence have important roles in 
protection from multi-cellular parasites. They are important mediators of allergic responses 
including anaphylaxis (Rodak et al., 2002).  
1.2.2. Mononuclear cells  
 
 Mononuclear cells can broadly be divided into two major classes; monocytes and 
lymphocytes and both of these classes are also heterogeneous in nature (Figure 1-2). Thus, 
monocytes, which constitute 2% to 11% of the total blood count (Bagby, 2007), are again 
divided into at least two further sub-populations depending upon the expression of surface 
markers. Therefore, all monocytes are positive for CD14, however, ≈10% of these cells are 
also marked by positive expression of CD16. The CD16+ cells may again be divided into 2 
populations which are marked by the presence or absence of the chemokine receptor CCR2 
(Geissmann et al., 2003). Upon recruitment to tissue, monocytes differentiate into 
macrophages or dendritic cells which play important immune regulatory roles. Whether 
subsets show a preference in their differentiation pathways is unclear and there is limited data 
on the functional distinctions between the subpopulations of monocytes (Imhof and Aurrand-
Lions, 2004). The literature in this area is complicated by the preponderance of studies 
conducted on mice, which show a different profile of monocyte subset distribution. Moreover, 
in mice, sub-sets are identified by surface markers distinct from those in humans. It is 
probable that there is limited concordance between the functions of monocyte in these two 
species. Indeed, a recent comparison of genes expressed by monocyte subsets in humans and 
in mice demonstrated that far more genes were differentially expressed than were expressed in 
common (Ingersoll et al., 2010)  
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 Lymphocytes represent the most complex of the leukocyte families. They constitute 
≈30% of the total leukocytic blood count, but their numbers are expanded during immune 
responses (Bagby, 2007). The lymphocytic system evolved in the vertebrates to support the 
adaptive immune response and through time has developed a cell based system with the 
plasticity to respond to millions of distinct molecular variations (antigens), the facility to 
discriminate these from ‘self’, and the ability to generate a cellular memory of this process 
(see below for details). Lymphocytes can be generically sub-divided based on their origin of 
maturation; cells derived from bone marrow are called B-cells, whereas those derived from 
thymus, after seeding of this organ with progenitor cells from the bone marrow, are called T-
cells (Rodak et al., 2002). However, within this classification it should be appreciated that 
there are many sub-divisions of B- and T-cells, which have distinct regulatory or effector 





Figure 1-1: Haematopoiesis (The development of myeloid progenitor cells). 
Hematopoietic stem cell is the earliest leucopoiesis precursor; it matures in bone marrow to 
common myeloid progenitor cells when it undergoes stimulation and mitosis. Because of the 
complexity of humoral factors such as interleukins, cytokines, and receptors expression of 
precursors surface, myeloid progenitor gives arise to different types of granulocytes (Rodak et 









Figure 1-2 Haematopoiesis (The development of lymphoid progenitor cells).  
Stem cell is the earliest leucopoiesis precursor; it matures in bone marrow to common 
lymphoid progenitor cells when it undergoes stimulation and mitosis. Common lymphoid 
progenitor cell matures to several cell types. The thymus and bone marrow participate in 









2. The blood vascular system:  
 
 The blood vessels transport blood all over the body. Vessels carrying oxygenated 
blood from the heart are called arteries, while vessels carrying deoxygenated blood back to 
the heart are called veins.  Microvascular capillary beds bridge the two and are the sites of gas 
and metabolite exchange from blood to tissues and vice versa.  
2.1. The arterial circulation  
 
 The arterial circulation is a high pressure system, and arteries are thick walled with 
significant muscular and elastic structures conferring strength and maintaining vessel integrity 
(Rodak et al., 2002). There are three layers in the artery wall from the inner layer to the outer: 
the tunica intima, the tunica media and the tunica adventitia. The adventitia is composed of 
irregular fibres of connective tissues, fibroblasts and adipose deposits. In large arteries an 
independent circulation, the vaso vassorum, enters the vessel wall from the adventitia and 
provides vascular support for cells far removed from the blood circulating within the lumen of 
the artery. The tunica media is bounded by the internal and external elastic lamina and is 
composed of concentric layers of smooth muscle cells which are interspersed between lamina 
of elastic tissue. In muscular arteries, the former dominate the structure of the medial layer, 
while in elastic arteries the later are the major structural components. The intimal layer lies 
between the endothelial cells lining the lumen of the vessel and the internal elastic lamina 
(Clark, 2005). The importance of these layers to the pathogenesis of atherosclerosis will be 







 Arterioles are the smallest vessels on the arterial side of the circulation. They are well 
endowed with SMC and are reactive to many vasoactive molecules which regulate their 
diameter. As such, blood flow in capillary beds can be tightly regulated. Indeed, arterioles are 
otherwise known as the resistance vessels of the vasculature, as changes in resistance (due 
either to diltion or constriction) regulate the rate of blood flow to the 4th power of the radius 
of the vessel (i.e. there are large changes in resistance and blood flow for relatively modest 
changes in vessel radius) (Carola et al., 1990). Indeed, dilatation and constriction of the 
arterioles determine the level of peripheral resistance in the vasculature. As a result, arterioles 
regulate blood pressure as SMC responds to vasoactive substances such as angiotensin II 
(Ang II) and nitric oxide (NO) (Clark, 2005). The arteries and arterioles, besides providing a 
conduit for dissemination of leukocytes, do not ordinarily play a role in the trafficking of 
leukocytes to the tissues.  
2.3.  Capillaries  
 
 Capillaries are relatively simple vessels comprising of an EC layer on a basement 
membrane. In unspecialised vascular beds the EC form a continuous monolayer, however in 
organs with specialised function (e.g. endocrine tissues or the liver) the EC monolayer may be 
discontinuous or the EC may possess fenestrated sieve plates, which maximise contact 
between blood-borne solutes and the tissue parenchyma (Clark, 2005). As stated above, 
capillaries are the sites of metabolite and gas exchange between tissues and the blood. 
However, in some organs such as the lung and the liver, capillaries may be major sites of 
extravasation for leukocytes during immune surveillance and/or inflammation (Vonandrian et 
al., 1991).  
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2.4. The venous circulation 
  
 Venules collect blood from the capillaries for delivery to veins and thus to the heart, 
thereby completing the vascular circuit. Being a low pressure system, the venous vessels lack 
a robust medial layer. However, as they carry blood to the heart, often against gravity, many 
have none-return valves along their length to avoid movement of blood in a retrograde 
direction. Veins generally rely on the contractions of adjacent skeletal muscles (peristalsis) as 
well as the opening and closing of the intra-luminal valves, to facilitate blood flow back to the 
heart. Although large veins do not play a role in leukocyte trafficking to the tissues, post-
capillary venules play a very important role in this process. In most tissues these vessels are 
the sites at which leukocytes traffic from the blood to the tissues during inflammation. This 
process is aided by the structural and functional characteristics of these vessels. The luminal 
endothelial cells are highly responsive to inflammatory stimulation and in response express 
molecules, which support leukocyte trafficking (see below for details). Being part of the low 
pressure venous circulation, blood flows relatively slowly and these vessels are marked by 
low wall shear stresses, a necessity for efficient interaction of circulating leukocytes with the 
endothelium. The rheological properties of blood flow in these vessels allow red cells to 
aggregate and form rouleaux, a process which facilitates margination of the leukocytes to the 
vessel wall. Lastly, migrating leukocytes encounter relatively few obstacles during transit to 
the tissue, having to cross the EC monolayer, the EC basement membrane and the single layer 






3. The lymphatic vasculature 
 
The lymphatic system is separate from the blood vasculature, but its vessels are found 
in all body organs, except the central nervous system and non-vascular tissue such as the 
Cartridge (Schulte-Merker et al., 2011). The primary function of the lymphatic system is to 
reabsorb the extravasated tissue fluid and return it into the blood in order to maintain the 
interstitial fluid balance (Figure 1-3). It also plays an essential role in the packaging of dietary 
lipids in to chylomicrons (lipoprotein associated lipid particles) and then transporting these 
from the small intestine to the blood (Oliver and Srinivasan, 2008). Animal studies also 
suggest that lymphatic vessels help in cholesterol clearance by participating in Reverse 
Cholesterol Transport (RCT) (Martel et al., 2013). Importantly however, the lymphatic 
system also plays a crucial role in the adaptive immune response. Lymph nodes are the sites at 
which foreign antigen is delivered and presented to B and T lymphocytes which initiates the 
adaptive immune response. This process is achieved by supporting the migration and 
transport of leukocytes from the tissues to the lymph nodes (see below for details). Although 
the lymphatic system is discrete from the blood vasculature, it separates from a common 









Figure 1-3 Lymphatic vasculature. 
The lymphatic system is separate from the blood vasculature, but its vessels are found in all 
body organs, except the central nervous system and non-vascular tissue such as the Cartridge. 
The primary function of the lymphatic system is to reabsorb the extravasated tissue fluid and 











4. Innate immunity  
 
 Even though the innate and adaptive immune systems work together, it is important to 
identify the specific characteristics of each system because innate immune responses are non-
specific and are not intensified by previous exposure to infectious organisms, while the 
adaptive immune response is exquisitely targeted against specific antigens and is intensified 
upon secondary exposure by establishing populations of ‘memory’ cells (Abbas et al., 2012).  
Innate immunity is a non-specific response to infection or injury which acts quickly 
against invading pathogens. It includes physical and chemical barriers and utilises the 
inflammatory response to deliver effector cells from the blood to the tissue within a time 
frame ranging from minutes to hours. The major cellular constituents of the innate system are 
neutrophils and monocytes which are phagocytic cells capable of recognising and rapidly 
eliminating foreign agents (Iwasaki and Medzhitov, 2004). The immune system recognizes 
the foreign invaders via signals which are released either from the invaders or in the case of 
viral infection from the damaged tissue. Signals that are released from foreign invaders are 
called pathogen-associated molecular patterns (PAMPs) whereas the ones from damaged 
tissue are called damage-associated molecular pattern molecules (DAMPs) (Tang et al., 
2012). When the immune system recognises PAMPs, it initiates immune response 
immediately in order to eliminate the pathogen and this is why in some articles PAMPs are 
called signal 0 (Akira and Hemmi, 2003). After pathogen recognition via PAMPs, Toll-like 
receptors (TLRs) become activated in combination with pattern recognition receptors (PRRs) 




5.  The adaptive immune response 
 
There are three basic strategies by which adaptive immune responses fight foreign 
pathogens (Abbas et al., 2012). Antibodies which are generated after interactions with B-cells, 
T-cells and antigen presenting cells bind to a pathogen and then disable its normal function 
and prevent infection of other cells. Antibody binding also activates the complementary 
system which leads to the destruction of pathogens by lysis. Antibody binding also 
‘opsonises’ cells, marking them for efficient subsequent clearance and destruction by 
phagocytes.   Phagocytes engulf and ingest pathogens with help from Th (T helper cells) 
which also reinforces the microbicidal effect of phagocytes.  Cytotoxic T Lymphocytes 
(CTLs) destroy infected host cells through recognition of foreign antigen associated with 
MHC class 1 by the T-cell receptor. 
There are three levels of the adaptive immune system; the afferent arm (Antigen 
recognition), the efferent arm (lymphocyte activation), and immunological memory. The 
afferent arm enables the system to distinguish between what is self and what is foreign 
antigen. Importantly this system is able to identify and respond to millions of distinct 
antigens, thereby conferring specificity to each response. The efferent arm delivers the 
molecular and cellular response against the antigen whereas the effector cells of the adaptive 
response are composed of antigen presenting cells and lymphocytes (O'Gorman and 
Donnenberg, 2008). Importantly, although single B-cell and T-cell clones only recognise a 
single antigen, collectively they are able to recognize a wide variety of antigens due to the 
hyper variability of their antigen recognition receptors, i.e. antibody on the B-cell membrane 
and the T-cell receptors (TCR) on the surface of T lymphocytes (Alberts et al., 2002). 
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The immunological memory amplifies and accelerates the immune response against 
secondary exposure to the same antigen (Vesely et al., 2011).  
5.1. Antigen recognition 
 
   APCs degrade the antigen proteins into peptides and display them on the cell surface 
bound to major histocompatibility complex molecules (MHC). MHC molecules are display 
molecules specific to the adaptive immune system. Once activated by the inflammatory 
response and having acquired foreign antigen, DCs migrate from tissues to the lymph nodes 
via the afferent lymphatics. Here, they reside in the node where they can present MHC-
antigen complexes in association with co-stimulatory molecules to naïve T and B 
lymphocytes which traffic through these organs (Paul, 2012). 
5.2. Lymphocyte activation  
 
Naïve T lymphocyte activation takes place after peptide–MHC molecule recognition 
by the T-cell receptor. This recognition is crucial to the efficiency of immune response. 
Accessory signals such as the B7-1 and B7-2, which are delivered from the APC to the T-cell 
upon ligation of MHC, ensure a robust and specific activation of specific T-cell clones 
without significant involvement of T-cells with antigen recognition profiles inappropriate for 
responding to the specific invading pathogen (Akira and Hemmi, 2003). Although some of 
these T-cells will become antigen specific cytoxic T-cells, others facilitate in the activation of 
B-cells and production of the humoral response, i.e. synthesis of antigen specific antibodies.  
These helper T- cells are essential to B-cell responses. The displaying of antigen peptide on 
class II MHC molecules by APCs activates helper T-cells and induces the expression of 
costimulatory ligands such as CD40L and B7 molecules. Then, due to a chemokine gradient, 
the activated helper T-cells migrate toward the lymphoid follicle where they interact with B-
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cells which leads to their activation because of the presence of CD40L and some cytokines 
secreted from helper T-cells. Finally, a foci of extra-follicular B-cells is formed in the lymph 
node medulla in which B-cell derived plasma cells differentiate and begin to secrete 
antibodies (Gray and Skarvall, 1988). 
The activation of B lymphocytes results in antibody mediated humoral immunity as 
these cells differentiate into antibody producing plasma cells. CD4+ helper T-cells can be 
important for the activation of B-cells, although there are mechanisms that allow B-cell 
activation in the absence of T-cells (T-cell independent activation). Due to the B-cells’ 
activation, B-cell clones expand and some of their progeny differentiate into cells called 
Plasma cells. Plasma cells secrete antibodies which have the same antigen binding site as the 
B-cell receptors (cell surface antibodies) which originally recognized the antigen during the 
first encounter (van Essen et al., 2000). Pathogen proteins stimulate the production of 
different classes of antibodies (IgG, IgA, IgE) from a single B-cell clone.  
Antibodies classes have specific roles in different tissues.  For example, IgA is 
important in mucosal protection as it is removed from the blood and secreted into the mucosa 
by epithelial cells. IgG plays an important role in protecting the new-born. It can cross the 
placenta allowing transmission of immunity from the maternal circulation, and after birth it 
provides immunity to the baby because it is present in the colostrum. The half- life of most of 
these antibody classes is a few days, however, IgG has a half-life measured in weeks and can 
therefore deliver longer lived protection (Figure 1-4). Importantly, plasma cells can remain in 
the bone marrow for years releasing antibodies and conferring extremely long-lived and 





Figure 1-4: Innate immunity vs Adaptive immunity.  
Even though the innate and adaptive immune systems work together, it is important to 
identify the specific characteristics of each system. Innate immunity is a non-specific response 
to infection or injury which acts quickly against invading pathogens. The major cellular 
constituents of the innate system are neutrophils and monocytes which are phagocytic cells 
capable of recognising and rapidly eliminating foreign agents. Adaptive immune response is 
exquisitely targeted against specific antigens and is intensified upon secondary exposure by 









6. Immunological memory 
 
After the elimination of a pathogen, a contraction of the specific immune response is 
required. Thus, clonal expansion of lymphocyte effectors stops and established colonies are 
depleted in order to re-establish homeostasis. Some plasma cells migrate to the bone marrow 
where they may reside for years producing specific antibodies which are released into the 
circulation, thereby ensuring long lived immunity (Alberts et al., 2002). Moreover, a small 
number of memory B-cells differentiate which can recirculate and provide a long-lived 
memory population that is available for rapid expansion should reinfection occur (Paul, 
2012). The immune response mediated by T-cells against antigen, generates specific memory 
T- cells which could persist for life. The long survival of memory T-cells and their swift 
activation is attributed to many unique characteristics; the number of memory T-cells for a 
certain antigen is greater than that of naïve cells for the same antigen. In addition, memory T-
cells express a group of proteins called anti-apoptotic proteins such as Bcl-2 and Bcl-xL. 
These molecules enable memory T-cells to survive after the elimination of an antigen and in 











Figure 1-5: Immunological memory. 
Memory B-cell and effector B-cell development is a two stages process. The first stage is the 
production of plasma cells which predominantly generate IgM; they are also called short-lived 
plasma cells. They are generated after the primary response and are located mainly in the 
lymph node medulla. The second stage is the production of memory B-cells and the seeding 
of the other type of plasma cells which are called long-lived plasma cells which are located in 









7. Inflammation and leukocyte recruitment  
 
Inflammation is an integral component of the immune response. It has been characterised 
since antiquity by four cardinal signs; Dolor (Pain), Rubor (redness), Tumor (swelling), and 
Calor (heat) (Carola et al., 1990). More recently loss of tissue function has been added as a 
fifth cardinal sign of the inflammatory response (Lawrence et al., 2002). The main goal of 
inflammation is to expedite repair of damaged tissue, either by aiding in sterilisation of 
infected tissue and/or by promoting the repair of infected or damaged tissue. This complex 
process requires the integration of many cellular and molecular mechanisms, but the principal 
aspect of inflammation that is of interest in the context of this thesis is the trafficking of 
immune cells from the blood, across the endothelial cells and other structural components of 
the blood vessel wall and then into inflamed tissue (Luu et al., 2013). 
 During inflammation, cytokines such as tumour necrosis factor-alpha (TNF-α) 
Interleukin-1β (IL-1β) and interferon (IFN-γ) are released from stromal cells at the site of 
injury/infection where they act locally on endothelial cells to induce gene expression 
programmes that support leukocyte trafficking. These agents are thought to derive primarily 
from tissue macrophages, although other cells such as fibroblasts are quite capable of 
synthesising inflammatory cytokines (Pober and Cotran, 1990b). Other vaso-active substances 
such as thrombin and histamine can also induce adhesion receptor expression more quickly 
(in minutes) than cytokines (in hours). Some bacterial products, e.g. lipopolysaccharide (LPS 
or endotoxin) can also directly activate endothelial cells with the same consequences for 
leukocyte recruitment.  
As a result of endothelial cell activation, leukocytes are recruited to the vessel wall 
and activated locally so that they can penetrate the tissue in a precisely targeted fashion (Ley 
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et al., 2007). During inflammation, leukocytes transmigrate through postcapillary venules into 
inflamed tissue. These vessels are marked as sites of low shear stress which facilitates 
leukocytes attachment to the vessel (Springer, 1995). Specialised receptors of the selectin and 
immunoglobulin super family (IgSF) families are unregulated on the activated endothelial 
cells of these venules and mediate the first contact between leukocyte and the vessel wall. 
(McEver et al., 1989).  
During inflammation, vessels dilate due to the release of Prostacyclin (PGI) and nitric 
oxide (NO) which relax vascular smooth muscle. As a result, blood flow and the delivery of 
leukocytes to the site of injury increases. Experimental studies have shown that vasodilatation 
is very important to inflammation (Pober and Cotran, 1990a). As a consequence of 
vasodilatation, plasma leakage increases, so elevating the haematocrit inside the micro-vessels 
which leads to change in blood rheology. The low shear stresses and increased haematocrit  
allow aggregation of red blood cells in rouleaux which force white blood cells to the vessel 
wall in a process termed margination, thereby increasing the rate of leukocytes-vessel wall 
collisions and maximising the localised recruitment of leukocytes (Schmid-Schönbein et al., 
1980). 
Inflammatory cytokines such as TNF-α and IL-1β modulate the expression of 
endothelial adhesion molecules which are essential to initiate the leukocyte adhesion cascade. 
This cascade is a multi-step process by which leukocytes enter the inflamed tissue to carry out 
the immune response.  The cascade consists of four main steps as seen in the figure 1-6 
below: step 1- Capture and rolling; step 2 - Activation and firm adhesion; step 3- Endothelial 





Figure 1-6: Leukocyte Adhesion Cascade modified from (Ley et al., 2007).  
This cascade is a multi-step process by which leukocytes enter the inflamed tissue to carry out 
the immune response. During inflammation, cytokines such as tumour necrosis factor-alpha 
(TNF-α) Interleukin-1β (IL-1β) and interferon (IFN-γ) are released from stromal cells at the 
site of injury/infection where they act locally on endothelial cells to induce gene expression 
programmes that support leukocyte trafficking. As a result of endothelial cell activation, 
leukocytes are recruited to the vessel wall and activated locally so that they can penetrate the 
tissue in a precisely targeted fashion. Finally, leukocytes transmigrate through postcapillary 
venules into inflamed tissue. These vessels are marked as sites of low shear stress which 








Step-1: Capture and rolling  
The molecular processes that support the initial interactions between blood borne 
leukocytes and the endothelial cells lining post capillary venules (the site in the blood 
vasculature where leukocytes are recruited during acute inflammation) are well described (see 
Figure 1-6 for a schematic representation of the steps in the leukocyte recruitment process). 
Therefore, in response to the localised production of inflammatory mediators, such as 
histamine, or the cytokines tumour necrosis factor-α (TNF), Interleukin-1-beta (IL-1β) and 
interferon-gamma (IFN-γ), activated endothelial cells decorate themselves with specialised 
adhesion receptors that form strong but short-lived bonds with counter ligands on the 
leukocyte surface (Huo et al., 2000) Thus, the selectins and the immunoglobulin super-family 
(IgSF) member, vascular adhesion molecule-1 (VCAM-1), are capable of tethering leukocytes 
from flowing blood (Barreiro et al., 2002). The sequential formation and dissolution of these 
bonds also supports a characteristic and dynamic form of adhesion, referred to as rolling 
(Lawrence et al., 1995). Rolling adhesion does not require leukocyte activation. However, 
leukocyte migration through the vessel wall and into the inflamed tissue is still dependent 
upon the receipt of an activating stimulus (Lawrence et al., 1995, Muller, 2009) 
 P selectin is found in the α granules of platelets and also in Weibel-Palade bodies of 
endothelium and is released from these granules stores within minutes in response agents such 
as histamine or thrombin (Butcher, 1991). Endothelial cells also express P selectin over 
slower time scales in response to cytokines such as TNF. Whether this requires de novo 
protein synthesis or mobilises granule stores is not clear. E selectin is induced on endothelial 
cells as a result of stimulation of cytokines IL-1 or TNF or endotoxin (Bevilacqua et al., 1994, 
Butcher, 1991). It requires de novo synthesis and in vitro expression peaks at around 4-6 
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hours post-stimulation and wanes by 24h. L selectins are constitutively and highly expressed 
on most circulating  leukocytes (Bevilacqua and Nelson, 1993).  
 The counter receptors for selectins are sialylated carbohydrates (Bevilacqua and 
Nelson, 1993), in particular glycoproteins which carry the sialyl Lewis X (sLeX) motif 
(Smith, 2008). The major ligand for P selectin is P-selectin glycoprotein ligand 1 (PSGL1); it 
was initially described as a ligand for activated platelets, although E-selectin can also bind 
this molecule.  (Ley et al., 2007). Specific ligands for E-selectin have also been identified, and 
endothelial cell-borne ligands for L-selectin have also been described, although it is not clear 
whether these are expressed on human post-capillary venules during inflammation (Hidalgo et 
al., 2007). They are, however, expressed in other vascular beds such as the HEV of lymph 
nodes, where L-selectin plays a critical role in trafficking to these organs.  
Interestingly, the interaction between selectins and their ligands requires shear stress 
to sustain adhesion (Ley et al., 2007). Indeed, an important feature of selectin bonds is the 
catch bond phenomenon, where the strength of the adhesive interaction with the ligand 
increases with increasing shear stress. During leukocyte adhesion, selectin bonds are 
strengthened when shear stress is applied and weakened when the shear stress is absent 
leading to detachment of the rolling cells (Phillipson et al., 2006). During capture and rolling, 
there is a rapid translation of the adhesive zone between leukocyte and endothelium cell along 
the vessel wall. Therefore, there is a need for rapid adhesive bond formation and breakage 
(Chen et al., 1997). The forward motion of leukocyte increases the force applied on bond 
formation until it balances the hydrodynamic by force which leads to the leukocytes stopping. 
Finally, the rolling leukocytes undergo a  jerky rolling motion because of the failure of the 
weakened bond in the rear and at the same time a front bond is formed as the leukocytes roll 
forward  (Sundd et al., 2011). 
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There is some evidence indicating that ligation of selectins can signal into leukocytes 
and mediate their activation. Therefore, human neutrophils rolling on  E selectin becomes a 
stationary adherent due to integrin activation via p38 MAPK (mitogen-activated protein 
kinase) pathway (Simon et al., 2000) (Ley et al., 2007).   
Furthermore, leukocyte rolling can be mediated by other receptors. The most common 
one in inflammation is the IgSF molecule VCAM-1 which, like selectins, is expressed by de 
novo synthesis in EC upon exposure to inflammatory cytokines. The counter ligand(s) for 
VCAM are integrins. Integrins are heterodimeric molecules consisting of α and β subunits 
linked together by non covalent bonding.  The α and β subunits have N terminal portions 
which join together to form a ligand binding site (Smith, 2008). The major ligand for VCAM-
1 on leukcoytes is the α4β1 integrin, also called the very late antigen-4 (VLA4). This is 
present on many mononuclear leukocytes, e.g. monocytes and some lymphocyte subsets, 
however, it is absent on human neutrophils. A fuller description of the integrins utilised for 
leukocyte recruitment and their function is provided in the section below.    
Step-2: Activation and firm adhesion 
In response to inflammatory cytokines, endothelial cells synthesise and present 
activating stimuli on their surface. During rolling, leukocytes are exposed to these stimuli 
which trigger activation of  the β1 and β2 integrins which mediate leukocyte arrest (Campbell 
et al., 1998). Chemokines (chemotactic cytokines)  are the major activating signals 
synthesized and transported to the luminal surface by the activated endothelium (Ley et al., 
2007). In some disease models chemokines from other cells such as platelets can be deposited 
on the endothelium. CCL5 (CCL chemokine ligand 5) and  CXCL4 (CXC-chemokine ligand 
4) have both been described to be deposited by platelets on to the endothelium leading to the 
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arrest of rolling monocytes (von Hundelshausen et al., 2005). Chemokines have high affinity 
for specific receptors borne by the leukcoytes, and these can oligomerize and make 
heterophilic interactions that modulate leukocyte responses. Thus, for example, monocytes 
arrest triggered by CCL5 can be amplified by CXCL4 (von Hundelshausen et al., 2001). 
Chemokines are bound and presented on the endothelial cells surface polysaccharides units on 
glycosaminoglycan molecules (GAGs) which may protect the chemokine from cleavage by 
proteases released at the site of inflammation. (Ley et al., 2007).   
The adhesive activity of integrins is controlled by an inside-out signalling process. In 
response to stimulation by chemokines, the leukocyte alters the activation status of the 
integrin molecules from a confirmation that does not recognise ligand to one that is competent 
to bind ligand (Harburger and Calderwood, 2009). Changes in integrin function may also 
include surface clustering which alter the affinity of receptor-ligand interactions (Smith, 
2008). IgSF molecules and matrix proteins are the predominant ligands for integrins. In the 
context of leukocyte trafficking across EC the former are the important ligands. Intercellular 
adhesion molecule (ICAM) is a major counter ligand for the β2 integrins (αLβ2 and αMβ2; 
LFA-1 and MAC-1 respectively), while α4β1 is the major ligand for VACM-1. Both of these 
IgSF molecules are upregulated on endothelial cells in response to cytokine stimulation 
(Smith, 2008).  
Step-3: Endothelial transmigration 
Transendothelial migration into tissue is the last phase in leukocyte emigration. There are 
two known mechanisms that support this process. Firstly, leukocytes may undergo 
paracellular migration, i.e. migration between the junctions of adjoining endothelial cells. 
(Schenkel et al., 2002),(Phillipson et al., 2006). Alternatively migration can occur by the 
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transcellular route, whereby leukocytes migrate through the body of the endothelial cells. 
(Phillipson et al., 2006).  As discussed above, leukocyte transmigration is triggered by the 
chemo-attractants which are presented on the luminal surface of activated endothelium, a 
process dependent upon activation of integrin molecules. When integrins bind their 
endothelial ligands they stimulate the formation of endothelial projections called 
transmigratory cups. The surface of these cups are rich in VCAM-1 and ICAM-1 and they are 
organised by the movement of cytoskeletal proteins (Carman and Springer, 2004); (Barreiro et 
al., 2002). Indeed, cytoplasmic signalling events leading to cup formation are triggered by the 
ligation of ICAM-1 by integrins which leads to the translocation of apical ICAM-1 into 
caveolae and regions rich in F-actin (Millan et al., 2006); (Cinamon et al., 2004) (Figure 1-7).  
 Transcellular and paracellular migration  
 During paracellular migration a number of molecules at the junction of endothelial 
cells appear to be important regulators of the process. For example ICAM1, ICAM2, 
members of the junctional adhesion molecule family (JAMs A, B, and C), CD99 and 
PECAM1 (CD31) have been ascribed regulatory roles. Endothelial junctions also appear to 
support transendothelial migration through loosening of the intercellular junctions by 
reorganising local adhesion receptors such as VE-cadherin. As an example, ESAM 
(endothelial cell-selective adhesion molecule) loosens such junctions by interfering with the 
homotypic binding of VE-cadherin (Wegmann et al., 2006).  
 The transcellular pathway appears to occur in restricted circumstances. For example, it 
appears to be common for leukocyte trafficking into the central nervous system (CNS) 
through the blood brain barrier and has been observed in some other inflammatory situations 
(Feng, 1998); (Engelhardt and Wolburg, 2004). Studies in HUVECs showed that only ~5–
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20% of migrating cells used this pathway (Carman and Springer, 2004).  However, in our own 
laboratory, and after 20 years of observing of neutrophil, monocyte and lymphocyte migration 
across EC of varying origin, transcellular migration has not been witnessed (personal 
communication Prof. Ed Rainger).  Since migration proceeds through the cell body, a gateway 
is required for passage across the cytoplasm, which is an organelle that has been termed as the 
vesiculo-vacuolar organelle (VVO) (Dvorak and Feng, 2001). Until now, VVOs have not 
been seen in vitro (Ley et al., 2007). 
 Basement membrane migration 
In fact there are three barriers encountered by transmigrating leukocytes: the endothelial 
cells that have just been discussed, the basement membrane of the endothelial cells, and the 
pericytes (Ley et al., 2007). Passage across endothelial cells occurs rapidly i.e. within 2-5 
minutes, however, passage across the basement membrane can take considerably longer i.e. 5-
15 minutes. The nature of the basement membrane, which is deposited by both endothelial 
cells and pericytes, appears to be essential in regulating the process of migration with 
deposition of structures that can either assist or inhibit transmigration. The endothelial 
basement membrane consists of a network of protein, predominantly made up of collagen 
type IV, laminin-8 and laminin-10, linked together by basement membrane proteins such as 
heparin sulphate and proteoglycans like perlecan-1 and nidogen-2 (Hallmann et al., 2005).  
Studies on unstimulated mouse cremasteric venules showed areas of low expression of matrix 
proteins within the basement membrane, where the expression of vascular laminins was low. 
This suggests that these may be areas that enable the efficient exit of  neutrophils (Wang et 
al., 2006) and T lymphocytes (Sixt et al., 2001). Studies on IL-1β stimulated mouse 
cremasteric venules revealed that the transmigration of neutrophils temporarily enlarges these 
areas which co-localise with gaps between pericytes (Wang et al., 2006). (Wang et al., 2006).  
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These areas of low BM expression are permeable to chemo-attractants released from 
extravascular tissues and may be important for generating a chemotactic gradient into the 
tissue. Indeed, heparin sulphate which binds to chemokines may serve as a depot of such 









Figure 1-7: the Regulation of CD4+CD45RO+ T-cell trafficking across blood vessels 
endothelium (BVE). 
BVE is stimulated by Cytokine (TNF and IFN) which leads to memory T-cell recruitment. 
Then T-cells receives stimulating chemokines (CXCL9–11) which is necessary for integrins 
activation which subsequently causes T-cell activation and immobilization on BVEC surface. 
After that, the DP-2 receptor is stimulated by PGD2 which is required for T-cell 
transmigration through the BVEC monolayer. The lymphocyte chemokine receptor CCR7 
function is promoted by PGD2 signals which leads to CD4+CD45RO+ T-cells transmigration 
across the lymphatic vasculature in response to CCL19 and CCL2 (Ahmed et al., 2011).  
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8. Chronic inflammatory diseases:  
 
 In the 1980s researchers from the University of Washington noticed the presence of 
macrophage, T-cells, and IFN-γ in diseased tissue, and since then it has been widely accepted 
that inflammation is an important contributor to chronic diseases such as diabetes, cancer, and 
atherosclerosis (Couzin-Frankel, 2010, Romano et al., 1997). The main distinguishing feature 
of chronic inflammation is the persistence of the inflammatory response. This may be due to 
prolonged production of pro-inflammatory mediators such as interferon-gamma (IFN-γ) and 
tumour necrosis factor α  (TNF- α) (Davies et al., 2001). Alternatively, the inflammatory 
response may escape the resolution programmes that ordinarily play a role in terminating the 
process. Thus, it could be argued that inflammation starts as an acute response which then 
transforms into chronic disease with altered patterns of leukocyte recruitment. The 
mechanism of this transformation is not clearly understood, but there is data suggesting that 
the IL-6/soluble IL-6 receptor (sIL-6R) complex is a key factor in this process in diseases 
such as arthritis (Gabay, 2006). In fact, in vivo studies have demonstrated a significant role of 
IL-6 in leukocytes recruitment by regulating the expression of inflammatory chemokines and 








8.1. Atherosclerosis and inflammation:  
 
 Atherosclerosis is a disease that takes decades to develop, during which period it is 
asymptomatic. However, upon initiation of athero-thrombotic disease which leads to heart 
attack and stroke, it manifests into the disease with the most fatalities in the westernised 
world. Many suggest that inflammation is the driving force for the atherosclerotic plaque 
progression. The mechanisms of disease development are multifactorial. However, most 
studies now agree that monocytes recruited to the artery wall are vital in the induction of the 
atherosclerotic plaque. Monocytes that are recruited to the vessel wall ingest cholesterol from 
oxidized low density lipoproteins that are deposited in athero-prone areas of the arterial 
circulation. These subsequently form foam cells which release inflammatory mediators, 
attracting vascular smooth muscle cells along with other immune cells which contribute to the 
formation of plaque (Figure 1-8) (Glass and Witztum, 2001). The process of monocyte 
recruitment is poorly understood, but intervention in this process is considered a good area for 
developing strategies to treat and prevent cardiovascular disease. The inflammatory nature of 
atherosclerosis is marked by the mediators that can be found in the circulation of patients with 
established diseases. These markers are classified into endothelial activation markers (ICAM-
1 and CD40L, soluble VCAM-1), non-specific inflammatory factors (TNF-α, interleukin-1, -6 
and -18), and thrombotic endothelial dysfunction factors (PAI-1 Plasminogen Activator 
Inhibitor-1) (Balanescu et al., 2010). In addition the acute phase protein and nonspecific 
marker of inflammation, C-Reactive Protein (CRP), appears to correlate with the risk of 
having a heart attack, with progressively greater risk being evident for every milligram 
increase above 1 mg/l up to 20 mg/l (Kondo et al., 2005). Interestingly, there does not seem to 
be a direct link between CRP or other inflammatory markers and the burden of plaque 
(Balanescu et al., 2010). Other studies have demonstrated the relationship between carotid 
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intimal thickening and the circulating levels of adhesion molecules such as sICAM-1 and 
sVCAM-1 (Kondo et al., 2005). Nevertheless, there are other trials that reject this association 
based on a lack of correlation (Luc et al., 2003).  
 
Figure 1-8 Atherosclerosis progression stages (Simionescu and Sima, 2012).  
LDL (Low-density lipoprotein), CRP (C - reactive protein), Mon (Monocytes), EC 
(Endothelial cell), MLp (Lipoproteins), Pl (Platelets), TLy (T lymphocytes), Dc (Dendritic 
cells, Mac (Macrophages), FC (Foam cells), SMC (Smooth Muscle Cells), ECM 






8.1.1. The stages of plaque development in atherosclerosis:  
 
Atherosclerosis is a progressive disease marked by plaque formation, and is the focal 
development of lesions within arterial walls. It affects vessels supplying a number of organs, 
but is always restricted to the arterial circulation.  Initiation, progress and eventual fate of 
atherosclerotic plaque is determined by complex interactions between resident cells of the 
arterial wall (EC and SMC), blood components (in particular T-lymphocytes, monocytes, 
dendritic cells, mast cells) and pro-inflammatory mediators secreted by them such as 
chemokines, cytokines, enzymes (proteases). (Holme et al., 2012). Classical epidemiology 
suggests that vasoconstrictor hormones implicated in hypertension, products of glycoxidation 
associated with hyperglycaemia, pro-inflammatory cytokines, dyslipidaemia, and smoking are 
some of the factors which make a person vulnerable to Atherosclerosis (Holme et al., 2012).  
 Stage 1: Modulation of Constitutive Functions of Endothelial cells 
Due to their anatomical position, endothelial cells are greatly affected by any changes 
in blood physiology or interstitial fluid homeostasis. Thus, the constitutive functions of EC 
are modulated as a result of changes in homeostatic pathways regulating such processes as 
lipid metabolism (hyperlipidemia), glucose metabolism (hyperglycemia), and inflammation. 
There can also be secondary effects of these disturbances on the localised environment in the 
artery wall, for example, in experimental models of atherosclerosis changes in the barrier 
functions of EC leads to a prominent increase in transcytosis of lipoproteins into the artery 
wall in experimental models of atherosclerosis (Vasile et al., 1989). In response to the 
modifications in permeability there is a resulting deposition of plasma LDL within the intima. 
This explains the close positive correlation, experimentally established, between permeability 
of aortic LDL and the cholesterol accumulation in a particular segment. Animal (Faggiotto et 
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al., 1984) (Simionescu et al., 2004) and human models (Kruth, 1984) (Tirziu et al., 1995) of 
atheroma formation show that the LDL enclosed in Tunica intima becomes chemically 
modified by oxidation to generate oxidatively modified lipids (MLp). MLp(s) are 
heterogeneous structures with high levels of unesterified cholesterol and can often be 
visualised as aggregated or fused lipoprotein particles in experimental models (Tirziu et al., 
1995) (Kruth, 1984).  Importantly aortic permeability for LDL predicts the localisation of 
cholesterol-induced atheroma formation in experimental models of disease. (Nielsen et al., 
1992).  
Studies have long indicated that there is an increase of circulating oxidised LDL level 
in the plasma of patients with cardiovascular diseases (CVD) (Holvoet et al., 1998). In 
addition, it has been reported that oxidised LDL is used to distinguish between patients with 
coronary artery disease (CAD) from healthy subjects (Toshima et al., 2000). In a study by 
Huang, H et al, it was reported that the plasma level of oxidised LDL is 6 times higher in acute 
myocardial infarction (AMI) patients than in healthy subjects (Huang et al., 1993). This report 
suggests that oxidised LDL could be a reliable risk factor for CVD.  
A circulating pentraxin significant in the native human immune response, known as C-
reactive protein also acts as a stable plasma biomarker for low-grade systemic inflammation. 
There remains a persistent risk of cardiovascular events in association with plasma levels of 
the CRP, especially in patients having stable angina and established CVD (Tsimikas et al., 
2006). The EC also changes phenotypically as a consequence of this low grade systemic 
inflammation. The EC adopts a secretory phenotype, having multiple copies of the rough 
endoplasmic reticulum, Golgi apparatus, centrioles and numerous caveolae. The EC also 
undergoes functional changes, generating a hyperplasic multi-layered basal lamina which can 
entrap MLp (Tsimikas et al., 2006) (Simionescu, 2007). An altered response of the vessel wall 
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to external stimuli is also observed because of the disruption caused in myo-endothelial 
junctions and gap junctions between neighbouring SMC due to the proliferation of the basal 
lamina and the ECM. 
 Stage 2: Endothelial cell Dysfunction 
Endothelial cell dysfunction is demonstrated through the alterations in anti-adhesive 
and anti-thrombogenic surfaces usually presented by EC to flowing blood.  In the early stages 
of atherosclerosis in experimental models, surface changes are manifested by the expression 
on the EC membrane of new or additional cell adhesion molecules, such as ICAM-1, E-
selectin, and P-selectin, VCAM-1 and chemokines such as CX3CL1 and CCL5, CCL2 
(Monocyte chemoattractant protein-1;MCP-1) and CXCL8 (interleukin-8 ;IL-8), all of which 
can promote the recruitment of inflammatory leukocytes  such as monocytes (Simionescu, 
2007, Boisvert et al., 1998). Notably, expression of these molecules is also evident on human 
atheroma (Haley et al., 2000).  
 Stage 3: Robust Inflammatory Reaction  
This stage is characterized by the adhesion and recruitment of monocytes into the 
arterial intima using the molecular pathways previously described. Platelets also appear to 
play a major role in initiating plaque formation by assisting in the recruitment of blood 
monocytes. Indeed, platelets appear to participate in all stages of development of 
atherosclerosis, in addition to their role in arterial thrombosis, which is the terminal and 
symptomatic stage of atherosclerotic disease. In vitro studies have shown that ECs present on 
their surface von Willebrand factor (vWf) (Ohashi et al., 2010). The recruitment and 
adherence of platelets to the intact EC surface is supported by platelet glycoprotein Ib (GPIb). 
It now seems probable that  pro-inflammatory chemokines (CXCL4 [platelet factor -4], 
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RANTES [CCL5] are deposited on the ECs by activated platelets as a result of this adhesion. 
(Davì and Patrono, 2007). These molecules are potentially responsible for promoting 
monocyte binding to the vessel wall and supporting their migration into the intima. 
 Stage 4: Recruitment of other leukocytes during atherogenesis 
In the early stages of atherosclerotic plaque formation CD4+ T-cells along with 
antigen-presenting dendritic cells and some CD8+ T-cells can be found in the intima 
(Hansson, 2005). Circulating T-cells are probably recruited by the same pathways as 
monocytes, although definitive information on this is lacking. Within the intima antigens like 
MLp, it may be possible to induce T-cell proliferation within the plaque (Packard et al., 
2009).  In addition, type 1 helper T-cells (Th1) have been reported to become activated and to 
express and secrete a large array of cytokines (Romagnani, 1991). These agents may 
contribute to macrophage activation and the potentiation of the inflammatory response 
(Monney et al., 2002). 
B-cells have also been associated with diseased sections of the artery, but perhaps 
surprisingly were first found within the adventitia (Majesky et al., 2011). Immunoglobulin-
positive cells have also been found within atherosclerotic plaques (Majesky et al., 2011). The 
immune response during the development of the atherosclerotic plaque may be directed by B-
cells and their immunoglobulin products may perform protective functions during the plaque 
progression according to evidence from animal models of disease (Simionescu and Sima, 
2012).  
The role of polymorphonuclear neutrophils (PMN) was thought to be insignificant in 
atherosclerosis until recently. However, a relationship between the numbers of circulating 
‘activated’ PMN and the extent of coronary artery disease, as well as their presence in lesions, 
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has been reported in human disease and animal models (Soehnlein et al., 2008). How PMN 
contribute to the disease process is not clear, but release of oxidants and pro-inflammatory 
mediators in the vessel wall may promote or amplify the recruitment of other inflammatory 
cells, or additionally contribute to the oxidation of LDL (Soehnlein et al., 2009). Others have 
suggested that the activity of PMN in mature plaques may contribute to both destabilization 
and vulnerability, precursors of rupture and induction of infarction (Drechsler et al., 2010). 
Interestingly, aneutrophilia induced by hypercholesterolemia in murine models of 
atherosclerosis has been reported. In this model PMN were being recruited during the early 
stages of atherosclerosis which indicates a role in the initiation of disease. A significant effect 
of  PMN in atherosclerosis in this murine model was strongly indicated by the blunting of 
lesion progression in ApoE-/- mice by depletion of circulating PMN (Soehnlein et al., 2009).  
Although the ApoE-/- model indicates a possible role for PMN in atherosclerosis, 
these cells are still exceedingly rare in human plaques. This is surprising as the adhesion 
molecules and chemokines required for their recruitment are present on the endothelial cells 
of atherosclerotic lesions. It may be that rapid apoptosis of the PMN within the plaque may be 
the cause of the lack of PMN found in atherosclerotic lesion (Zernecke et al., 2008). Indeed 
there is a possibility that apoptosis is induced by the cytotoxic effect of free fatty acids 
released from modified lipoproteins within the artery wall (Lux et al., 2009).  
 In monocytes that are recruited to  the intima, a program through which scavenger 
receptors (i.e. SR-B1 and CD-36) are up regulated is thought to be responsible for their 
differentiation into cholesterol loaded foam cells. In the lesion monocyte/foam cell borne 
scavenger receptors are required to assimilate MLp, although their physiological roles also 
include uptake of advanced glycosylation end-products, anionic phospholipids along with 
apoptotic cells. The switch of differentiated monocytes into cholesterol-loaded foam cells is 
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facilitated by this non-regulated uptake of the MLp. In the earliest of lesions, the fatty-streak, 
accumulations of foam cells are the major pathogenic alterations in the artery wall. However, 
foam cells can be identified at all stages of plaque progression. (Tiwari et al., 2008).  
 Stage 5: Fibrous Plaque Formations.  
There is now significant evidence that indicates that the intimal thickening termed the 
fatty streak is the most likely precursor of symptomatic coronary disease. Hence, fatty streak 
lesions can be found in children in similar locations as to where advanced plaques are found 
in adults, although interestingly fatty streaks are known to be able to  regress (Velican and 
Velican, 1985). Areas of intimal thickening that develop into more advanced plaques may be 
either eccentric or diffuse in nature and both of these patterns of disease can occur adjacent to 
the other. The eccentric type of intimal thickening tends to be distinct and involves up to half 
of the circumference of the arterial wall. The locations for such thickenings include branch 
points and areas of disturbed blood flow (Velican and Velican, 1985). Molecular messages are 
sent by inflammatory cells through the factors they secrete within the plaque which reinforce 
the inflammatory response. However an important aspect of plaque progression is the 
recruitment of vascular smooth muscle cells (SMC) into the advancing plaque, with the clonal 
accumulation of SMC within the intima being reported (Simionescu, 2007).  
The migration of the SMC from the media into the intima through the partially 
degraded internal elastic lamina is a very significant step in the formation of the plaque. It is 
worth highlighting, however, that sources of intimal SMC other than the media have been 
postulated. These include circulating bone marrow-derived circulating progenitor cells and 
vascular progenitor cells present in the adventitia of the artery. An important aspect of the 
SMC biology, in the context of atheroma formation, is the phenotype of the cells within the 
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intima. These SMC have a secretory phenotype. Secretory SMC are structurally and 
functionally different form the contractile SMC of the media. They are hyperplastic and form 
multi-layered basal lamina and extracellular matrix which is enriched in collagen bundles and 
fibrils (Louis and Zahradka, 2010). Secretory SMC also releases inflammatory cytokines and 
chemokines (e.g. CCL2 and CXCL8) which again reinforces the likelihood of inflammatory 
process (Louis and Zahradka, 2010). These changes are probably an adaption for survival in 
the alien environment of the arterial intima, however, they then appear to contribute to disease 
progression (Simionescu et al., 2004). Interestingly, in hyperlipemic hamsters intimal SMC 
can accumulate lipid droplets and adopt a foam cell-like phenotype (Simionescu, 2007).  
Fibrofatty lesions may develop to a size large enough to significantly occlude blood 
flow in the artery and this can produce symptomatic disease, or angina pectoris, which is a 
pain across the chest caused by ischemia of the myocardium usually upon increased metabolic 
demand as a result of mild exercise or even from stressful situations. A similar situation is 
evident in claudication of the extremities (usually the legs), when disease in the femoral 
arteries leads to compromised blood flow to skeletal muscle (Condorelli and Brevetti, 2002). 
In peripheral vascular disease (again prevalent in the legs), loss of perfusion in the extremities 
leads to localised hypoxia and ulceration of the skin. This can lead to complications such as 
gangrene as the compromised perfusion of the tissues fails to deliver immune cells and 
proteins to the affected area (Magnoni et al., 1996, Regensteiner et al., 1993).  
 Stage 6: Plaque Rupture and Arterial Thrombosis 
Plaque rupture or ulceration is the terminal stage of cardiovascular disease although 
the precise mechanisms supporting these processes are yet to be described. In ulceration, 
endothelial cells become fragile and prone to erosion. Loss of EC leads to exposure of the  
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ECM which  has an abundance of pro-coagulant and pro-thrombotic constituents (Simionescu 
and Sima, 2012). Upon contact between these agents and circulating blood there is rapid 
thrombus formation. (Simionescu, 2007). Plaque rupture may also be caused due to the 
mechanical stress generated by arterial blood flow on the cap of vulnerable plaques. 
Vulnerable plaques are marked by a high content of lipid and foam cells. They also exhibit 
thinning of the fibrous cap.  (Tabas et al., 2010). Cap thinning may occur due to reductions in 
the synthesis of ECM by cells such as SMC. However proteolytic digestion of the 
extracellular matrix by matrix metaloproteinases (MMPs) can also contribute to thinning of 
the fibrous cap. (Berliner et al., 1995) (Simionescu, 2007). Other proteases (tryptase and 
chymase) are proposed to operate after secretion by mast cells that are located in the rupture-
prone shoulder regions of the plaque. The result of such ulceration or rupture is the formation 
of a platelet-rich mural thrombus and initiation of thromboembolic disease. (Brown and 
Goldstein, 1990).  
The blockage of vessels with thrombus is linked with ischemic episodes e.g. cerebral 
infarction and acute coronary syndrome. Occlusive thrombi are reported to cause around 80% 











In the context of this thesis it is important to introduce a family of agents generated from 
adipose tissue that play an important role in physiological homeostasis and in disease. For a 
long time it was believed that adipose tissues were solely depots for the storage of excess 
calories in the form of fats, in particular triglycerides. However, we now appreciate that 
adipose tissues play an important role in immunological and metabolic functions. These 
processes are mediated by a group of factors called adipocyte-derived cytokines, or 
adipokines. (Lang and Ratke, 2009). Adipokines were first described in the 1990s, and 
approximately 20 such agents have been recognized and classified (Housa et al., 2006). Of 
these, adiponection and leptin are the most studied because they play important roles in 
managing energy balance, as well as in connecting metabolic pathways with immune function 
(Lang and Ratke, 2009). 
9.1. Leptin 
 
Leptin is a polypeptide encoded by the obese gene (ob) to produce  a 16 kDa hormone 
which is released from adipocytes (Harvey and Ashford, 2003). It appears to play an 
important role in processes as disparate as bone formation, angiogenesis, neuroendocrine 
functions and reproduction. Importantly, amongst its pleiotropic actions is the modulation of 
the immune responses (Lord, Matarese et al. 1998; Howard, Lord et al. 1999). For example it 
can regulate the activation of dendritic cells and macrophages and also causes stimulation of 
Th1 cytokine production from lymphocytes (Mattioli et al., 2005). Modulation of the adaptive 
immune response is facilitated by leptin mediated increases in T-cell survival (Lam and Lu, 
2007).  Indeed, many immune cells have been reported to express Leptin receptors (Guzik et 
al., 2006). There are also reports that leptin plays an important role in the recruitment of 
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monocytes by cytokine stimulated endothelial cells. (Guzik et al., 2006). Moreover, 
stimulation of monocytes with leptin can result in the release of  inflammatory and angiogenic 
mediators such as TNF-α, IL-6, CC-chemokine ligand-2/CCL2 and vascular endothelial 
growth factor/VEGF (Tilg and Moschen, 2006). Leptin also has metabolic functions, such 
that it crosses the blood brain barrier (BBB). For example, it may cross the BBB by an active 
transport mechanism where it acts upon the hypothalamus to regulate hunger and reduce food 
intake (Lang and Ratke, 2009). Genetic ablation of leptin or its receptors in mice, has been 
found to lead to obesity and insulin resistance (Ceddia et al., 2002). The serum levels of leptin 
are an indicator of the energy stored in fatty tissue, i.e. its level is high in obese people and 
decreases after weight loss (Moschen et al., 2009).  
9.2. Adiponectin 
 
The 30 kDa adipokine, adiponectin, makes up 0.01% of total plasma proteins as it 
circulates at levels of approximately 3-30 µg/ml (Arita et al., 2012) and it exhibits a wide 
range of biological activities. Thus, adiponectin improves the sensitivity towards insulin and 
effects lipogenesis so that circulating lipids derived from the liver are maintained within 
physiological bounds (Lang and Ratke, 2009).  However in obese individuals, adiponectin 
levels are significantly lowered which might contribute to the dislipidaemia prevalent in such 
people (Kern et al., 2003). Expression of adiponectin also decreases in patients with diabetic 
or cardiovascular diseases (Hotta, Funahashi et al. 2000; Kern, Di Gregorio et al. 2003; 
Matsubara, Namioka et al. 2003; Kim, Kim et al. 2006; Arita, Kihara et al. 2012). Therefore, 
similar to Leptin,  adiponectin appears to exhibit protective roles by maintaining homeostasis 
(Lang and Ratke, 2009) (Figure 1-9). Broadly speaking, adiponectin appears to be anti-
atherosclerotic and anti-inflammatory, and at least some part of this protection comes from its 
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ability to regulate the recruitment of leukocytes by endothelium.(Ouchi et al., 2003) 
(Ouedraogo et al., 2007) (Kelesidis et al., 2006).  
T-cell activation and proliferation is also regulated by adiponectin. Moreover,  adiponectin 
may be able to regulate (inhibit) NF-ҡB activation in endothelial cells (Wang et al., 2014).  
Adiponectin treatment of cultured macrophages caused inhibition of their phagocytic activity 
and reduced TNF-α synthesis in response to lipopolysaccharide in these cells (Yokota et al., 
2000). There is also some evidence that it regulates NK cell function by modulating the 
production of cytokines such as IL-2 (Kim et al., 2006). Moreover, It is commonly known 
that Adiponectin regulates macrophage phenotype, therefore understanding the mechanism as 
to how AQ promote macrophage polirization is very important in order to improve treatment 
targets. Macrophage is responsible for accumulating lipids from the endothelium which leads 
to macrophage transformation to foam cells. Foam cells are a critical factor in early 
atherosclerotic lesion formation. So, it’s fate could lead to either an anti-inflammatory effect 
by prevention or reversal of cholesterol accumulation, or it could result in a cthrough the pro-
inflammatory cthrough the mediators. Recent findings show the protective effect of AQ on 
macrophage polarization by down regulation of the expression of scavenger receptor A (SR-
A) (Ouchi et al., 2001).  
 There are two major receptors for Adiponectin, AdipoR1 and AdipoR2. Both of these 
receptors show differential affinities for various circulating types of Adiponectin (Ohashi et 
al., 2012). AdipoR1 is expressed in a wide variety of tissues, including skeletal muscles, 
breast tissue and leukocytes, whereas AdiopR2 expression is highest in the liver. Importantly, 
93% of monocytes, 47% of B-cells and 21% of NK cells exhibit AdipoR2 expression 




Figure 1-9:Anti-inflammatory role of Adiponectin in obesity-related diseases. 
Adiponectin exhibits a wide range of biological activities. Adiponectin appears to be anti-
atherosclerotic and anti-inflammatory and at least some part of this protection comes from its 







9.3. PEPITEM:  
 
A novel peptide has been discovered in our lab. It is the Peptide inhibitor of trans-
endothelial migration called PEPITEM and inhibits T cell trafficking by a multistep 
mechanism (Chimen et al., 2015). The work in our lab shows that PEPITEM is released 
exclusively from B cells after they are stimulated by Adiponectin (AQ). After that PEPITEM 
binds to EC by Cadherin-15; this binding stimulates the release of a bioactive lipid mediator 















10. Hypothesis and aims: 
 We recognise that the adiponectin-mediated mechanism of down regulating T-cell 
transmigration is deregulated in chronic inflammatory and autoimmune diseases such as type-
1-diabtes and rheumatoid arthritis. We hypothesise that similar deficiencies may be present in 
individuals with atherosclerosis. If this is the case it may mean that this pathway forms a 
tractable therapeutic target for intervening in the process of atheroma formation. 
The aims of this thesis are: 
 To investigate the patterns of leukocyte recruitment using in vitro adhesion assays for 
leukocytes isolated from atherosclerosis patients and age-matched healthy controls.  
 To determine whether changes in the PEPITEM pathway are evident in such cohorts.  
 To determine whether deficiencies in the control of leukocyte trafficking can be 
























































1.1. List of main reagents 
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1.2. List of flow cytometry antibodies 
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Table 2-1: Conventional PCR Primers.  
 
2. Methods: 
2.1.  Static Adhesion and migration assay 
 
Dermal Microvascular Endothleial Cells (DMECs) were purchased from PromoCell. 
DMECs and were passaged 4 times in Endothelial Cell Growth Medium and frozen using 
CryoSFM freezing media (Promocell). A week before the migration assay, DMECs were 
cultured in 5ml of Endothelial Cell Growth Medium (Promocell) in 25cm2 flasks. Confluent 
DMECs were cultured again in 4 wells of a 6-wells plate. Briefly, DMECs were washed with 
1 ml 0.02% EDTA (Sigma), then 2 ml of TrypLE™ (Invitrogen) was added to dissociate 
DMECs Trypsin was neutralised using M199 20% FCS, cells were centrifuged at 1500rpm 
for 7 minutes and then Plated in 6-wells plate. DMECs were then stimulated with TNF-α 
(100U/ml) and IFN-γ (10 ng/ml) suspended in 1 ml Endothelial basal low serum media and 
kept for 24 hours in incubator (37°C 5% CO2).  
2.2.  Peripheral blood lymphocytes (PBL) Isolation for migration assay 
 
10 ml of venous Blood was collected in blood tubes coated with anticoagulant EDTA 
(1.6MG/ml, Sarstedt, Leicester, UK) from healthy adult volunteers or patients with 
atherosclerosis in accordance with local ethical guidelines and with approval of the South 
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Birmingham Local Research Ethics Committee (UK). Lymphocytes were separated using 
two-step density gradients of Histopaque 1119 and 1077 (Sigma, Poole, UK). 
Briefly, in a10 ml round bottom tube, 2.5 ml of Histopaque 1119 was gently layered 
onto 2.5 ml of Histopaque 1077. Then, 5ml of EDTA blood was added gently and the mixture 
was centrifuged at 2500 RPM for 30 minutes. The blood was separated into 6 distinct bands: 
plasma, PBMC, isolation media, neutrophils, more isolation media, and the red blood cell 
pellet. The PBMC was carefully collected, transferred to 15 ml Falcon tube, and washed twice 
using the washing solution (M199+ 20% BSA). The cell suspension was transferred to a new 
25cm2 flasks which contains 5 ml M199+BSA and left in the flask for 30 minutes at 37°C. 
After 30 minutes, the supernatant was collected and centrifuged at 1500 RPM for 7 minutes. 
We collected only the supernatant to remove monocyte that will adhere to the surface firmly 
and lymphocyte will be floating in the supernatant.  The pellet was then re-suspended to the 
final concentration of 1x106cells/ml.  
2.3.  Migration assay:   
 
PBLs were isolated as previously prescribed. Prior transmigration assay, PBL (1x106 cells 
per condition) were treated with(20 ng/ml)1µl of Pepitem, (20 ng/ml)1µl of Scramble peptide 
(0.5 mg/ml), 1µl of Adiponectin (15µg/ml). Before adding PBL, DMECs were washed twice 
with M199 0.15% BSA to wash off the excess cytokines. PBL suspension was added to the 
designated well for 6 minutes at 37°C. Then the non adherent cells were washed off and 
finally each well was video recorded using phase contract video-microscope. Seven random 
fields were recorded from each well to measure the percentage of transmigration. Recordings 
were analysed using Image-Pro 6.2 software. Phase dark cells were considered transmigrated 
cells whereas the bright phase cells were considered surface adherent cells. The total adhesion 
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of cells was measured in cells per mm2 by multiplying calibrated microscope dimensions to 




Figure 2-1: Illustration of a recorded filed instatic adhesion assay: Surface adherent PBL 
(Phase bright PBL) are adhered firmly on the endothelium monolayer, transmigrated PBL 









2.4. Measurement of adiponectin receptors on PBMCs (peripheral blood 
mononuclear cell) using flow cytometry  
 




 PBMC for PBL subsets and 2.5x10
6
 PBMC for monocyte subsets were 
transferred to Polypropylene tubes (BD Bioscience) and the tubes were centrifuged at 1500 
RPM for 7 minutes. Then, 2µl of FcR blocker (Miltenyi Biotec) was added to the tubes and 
PBMCs were stained with PBMCs markers (see tables for details) using recommended 
concentration of suppliers (see table 1 for details). Secondary antibody combinations were 
used to measure the expression of AR1/2, briefly; PBMCs were stained with the AR1/2 
antibodies for 30 minutes at 4°C, then washed to remove unbound antibodies. After that, 
samples were labelled with the secondary antibody conjugated to Alexa 488 (Alexa Fluor® 
488 Goat Anti-Rabbit IgG) and incubated at 4°C for 30 minutes. Following another necessary 
washing step,; FACS samples were then assayed using a Cyan (Dako) and the results were 
analyzed by FlowJo software. The number of events that were recorded per sample was 50000 
events, plotted as positive cells frequency or mean fluroscence intensity (MFI). When directly 
conjugated antibodies were used, PBMC were incubated with the relevant antibodies for 30 
minutes at 4°C and washed in PBS at 1500rpm for 7 minutes. 
2.5.  ELISA 
  
Human total adiponectin level has been measured in serum of atherosclerosis patients 
and the healthy control group using Quantikine ELISA kit (R/D Systems) according to the 
blood was collected in yellow top chemistry tubes and spun at 2500rpm for 15 minutes.  Then 
serum was separated from the blood because of the spin and collected by pasture pipette. The 
manufacturer’s protocol was used to measure the concentration. Briefly, the serum samples 
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were taken from freezer and were allowed to thaw at room temperature, then diluted 100-fold. 
Substrate solution and adiponectin standard had been prepared and reconstituted, and finally 
samples were added to the ELISA kit reagents and the optical density was measured using 
microplate reader Synergy HT (BioTek). Adiponectin serum level was measured using 
calibration curve and expressed in ng/ml.  
2.6. Measurement of gene expression:  
 
mRNA was extracted from PBMCs using RNAeasy kit (Qiagen) following the supplier 
protocol. Briefly, frozen PBMCs were lysed using RTL lysis buffer, transferred to a column, 
then after three washes, RNAase free water was used to elute mRNA. Finally, the mRNA 
concentration and 260/280 ratio was measured using Nanodrop spectrofluorimeter (LabTech) 
to test the purity and the validity of samples. mRNA was then converted into cDNA. Random 
primers (Promega, UK) have been annealed to 1μg of mRNA using Touchgene Gradient 
Thermal Cycler (TECHNE, UK) for five minutes at 70°C. Then, the master mix was added to 
make the final volume of 30μl. The master mix is consists of 10mM dNTPs, 1X Superscript 
Buffer, 10U Superscript II Reverse Transcriptase, 10U RNAout RNase inhibitor (Invitrogen, 
UK). The reaction was done at 37°C for 60 minutes, then another 5 minutes at 95°C.   
For Real-Time PCR (qPCR), Taqman Universal Mastermix (volume) (Applied 
Biosystems, UK), Taqman probes as well as reverse and forward primers were added with 2 
ul cDNA. Each reaction was a mixture of equal quantities of both primers, 18s as endogenous 
controls, cDNA, and nuclease free to make up the volume to 25µl (see table 2-1 for genes and 
primers details). (qPCR) The qPCR was performed using Real Time PCR 7500 (Applied 
Biosystems, UK). The gene expression of AR1 and AR2 was calculated using the delta Ct 
methods using 18S to normalise the Ct values.  In singleplex reactions; the relative expression 
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was measured by the comparison between the ΔΔCt normalised to 18S. The following 
equation was used to calculate the relative expression units (REU): 
REU=‎2‎ΔCt. 
2.7.  Intracellular staining 
 
A permeabilisation/fixation kit (EBioscience) has been used for the staining procedure 
following the manufacturer’s protocol. In summary, PBMCs were isolated as previously 
described, and then 1 ml of Fix/Perm solution (1 ml solution concentrate + 3 ml of solution 
diluents) was added to the cell suspension and wrapped in foil in order to keep it in the dark 
for 45 minutes at 4 degrees Celsius. After that, the suspension tubes were washed using 
Fixation and Cell Permeabilization buffer (FIX \ PERM) 1X, then the same flow cytometry 
protocol which has been described before was followed. Perm/fix buffer had been used in all 
the washing steps during this staining.  
2.8.   Protocol PBL binding on ICAM-SIPR1/4 expression 
 
A 96 well plate was coated with 10µ/ml recombinant ICAM/Fc and covered with foil at 
4°C overnight. The next day, the plate was blocked by adding 2% of PBS/BSA for at least an 
hour at room temperature. Meanwhile, PBLs have been isolated as described above, but PBL 
was resuspended at 4X10
6
 PBL/ml. In one eppendorf tube, 7.5 µL of IP-10 (80NG/ml) was 
added to 350µL of PBLs, then 50 µl of mixture has been added to the appropriate well plate 
and the plate was incubated at 37°C for 30 minutes. After that, cold PBS was used to wash the 
wells and finally PBLs have been collected by rough pipetting with cold PBS in FACS tube 
and stained for flow cytometry.  
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2.9.  Measurement of surface expression of adhesion molecules and chemokine 
receptors on fresh blood PBL by flow cytometry  
 
  In this experiment we measured the expression of the following adhesion molecules 
and integrins Alpha-L (αL), Alpha-4(α4), Beta-1 (β1), Beta-2 (β2), P-selectin glycoprotein 
ligand-1 (PSGL-1), CCR5, CXCR3, and CX3CR1 on different PBL subsets. We have three 
conditions; the first one is to measure the surface expression on freshly isolated PBL using the 
same PBL isolation protocol mentioned above. Regarding flow cytometry staining; 
conjugated antibodies have been used to stain PBL using the recommended concentration 
from suppliers (using recommended concentration of suppliers (see table 1 for details). The 
second and the third conditions are that the PBL which were used for transmigration assay, 
they are called surface adherent PBL and migrated PBL. The migration assay protocol was 
used to isolated surface adherent PBL and migrated PBL from tissue culture flask. The same 
steps were followed and then after 6 minutes of incubation at 37°C, cold EDTA was used to 
detach the surface adherent PBL (bright phase PBL) by adding 2 ml of EDTA to the flask 
with gentle agitation, then the supernatant was collected and spun for 7 minutes at 1500rpm. 
Finally, the pellet was re-suspended in the washing medium and PBL was calculated and 
prepared for staining. The remaining migrated PBL (dark phase PBL) and the DMEC, were 
collected by adding 2 ml of Trypsin which was neutralised after 2 minutes by using M199 
20% FCS. The mixture was spun for 7 minutes at 1500rpm and the pellet was re-suspended in 
in washing medium and PBL was calculated and prepared for staining. 
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Figure 2-2: Gating strategy for Adiponectin receptors (AR1, AR2) on PBL.  
Flow cytometry was used to measure the frequency of ARs; PBL was isolated from fresh 
blood samples, stained, and gated on their forward/side scatter profile. ARs expression was 




Figure 2-3: Gating strategy for Adiponectin receptors (AR1, AR2) on Monocyte.  
Flow cytometry was used to measure the frequency of ARs; PBL was isolated from fresh 
blood samples, stained, and gated on their forward/side scatter profile. AR1 expression was 







Figure 2-4: Gating strategy for Adiponectin receptors (AR1, AR2) on PBL subsets.   
PBL was isolated from fresh blood samples, stained, and gated on their forward/side scatter 
profile. CD19-PECY
7
 antibody was used to identify B cells. CD3-PerCpCy
5.5
 and CD56-PE 




Figure 2-5: Histograms for ARs expression on CD56High NK Cell and NK Cells.  
ARs expression on NK cell subsets expression was measured as shown on the above 
histograms. PBL was isolated from fresh blood samples, stained, and gated on their 










Figure 2-6: Gating strategy for PBL subsets when measuring Integrin and chemokine 
recptors.  
PBL was isolated from fresh blood samples, stained, and gated on their forward/side scatter 
profile. CD19-PECY
7
 antibody was used to identify B cells. CD3-PerCpCy
5.5
 and CD56-APC 









Figure 2-7: Gating strategy for Migrated PBL 
PBL was collected after static adhesion assay, migrated PBL are the dark phased cell which 
was collected by harvesting DMECs by Trypsin treatment. Migrated PBL stained, and gated 
on their forward/side scatter profile. CD19 antibody was used to identify B cells. CD3 and 






Figure 2-8: Gating strategy for surface adherent PBL 
PBL was collected after static adhesion assay, surface adherent PBL are the bright phased cell 
which was collected by adding cold EDTA to the tissue culture flask to detach surface 
adherent PBL. Surface adherent PBL stained, and gated on their forward/side scatter profile. 
CD19 antibody was used to identify B cells. CD3 and CD56 were used to identify the 











Figure 2-9: Gating strategy for Adiponectin receptors (AR1, AR2) on Monocyte subsets.  
Flow cytometry was used to measure the frequency of ARs; monocytes were isolated from 
fresh blood samples, stained, and gated on their forward/side scatter profile. CD14 antibody 
was used to identify classical monocytes. CD16 and CCR2 antibodies were used to identify 
non-classical and intermediate monocytes. AR1 expression was measured on the basis of the 














Figure 2-10: Histograms for SIPR1/4 expression on memory T cell.  
Flow cytometry was used to measure the expression of SIPR1/4 on memory T cell; PBL was 
isolated from fresh blood samples, stained, and gated on their forward/side scatter profile. 
CD45RO-PE antibody was used to identify memory T cell. Isotype control (solid red), SIPR1 








Figure 2-11 Histograms for Integrin and Chemokine receptors on B cells.  
Flow cytometry was used to measure the expression of the above Integrin and Chemokine 
receptors on B cell; PBL was isolated from fresh blood samples, stained, and gated on their 






Figure 2-12: Histograms for Integrin and Chemokine receptors on N-CD4 T cells.  
Flow cytometry was used to measure the expression of the above Integrin and Chemokine 
receptors on N-CD4 T cell; PBL was isolated from fresh blood samples, stained, and gated on 







Figure 2-13: Histograms for Integrin and Chemokine receptors on N-CD8 T cells.  
Flow cytometry was used to measure the expression of the above Integrin and Chemokine 
receptors on N-CD8 T cell; PBL was isolated from fresh blood samples, stained, and gated on 







Figure 2-14: Histograms for Integrin and Chemokine receptors on Memory-CD4 T cells.  
Flow cytometry was used to measure the expression of the above Integrin and Chemokine 
receptors on memory-CD4T cell; PBL was isolated from fresh blood samples, stained, and 






Figure 2-15: Histograms for Integrin and Chemokine receptors on Memory-CD8 T cells.  
Flow cytometry was used to measure the expression of the above Integrin and Chemokine 
receptors on memory-CD8T cell; PBL was isolated from fresh blood samples, stained, and 







Figure 2-16: Histograms for Integrin and Chemokine receptors on NK T cell.  
Flow cytometry was used to measure the expression of the above Integrin and Chemokine 
receptors on NK T cell; PBL was isolated from fresh blood samples, stained, and gated on 








Figure 2-17: Histograms for Integrin and Chemokine receptors on CD56 High NK cell.  
Flow cytometry was used to measure the expression of the above Integrin and Chemokine 
receptors on CD56 High NK cell; PBL was isolated from fresh blood samples, stained, and 







Figure 2-18: Histograms for Integrin and Chemokine receptors on NK cell.  
Flow cytometry was used to measure the expression of the above Integrin and Chemokine 
receptors on NK cell; PBL was isolated from fresh blood samples, stained, and gated on their 










3. Statistics:  
 
The data is mean ± standard error of the mean (SEM) and was analysed using a one-way 








































CHAPTER 3: STUDYING THE EFFECT OF AGE ON HUMAN 
ADIPONECTIN SERUM LEVEL AND ON THE SURFACE 
EXPRESSION OF ADIPONECTIN RECEPTORS AR1 AND AR2 ON 


















1. Introduction  
 
An imbalance or dysfunction of adipose tissue can play a part in obesity-induced chronic 
inflammation which subsequently leads to metabolic diseases like insulin resistance, type 2 
diabetes and cardiovascular disease. Adipose tissue can be considered to be an immune organ, 
and adipose tissue macrophages are the most significant source of inflammatory mediators, 
including adopkines, in adipose tissue. (Kadowaki and Yamauchi, 2005).  
      The adipokine, adiponectin, circulates as either a full-length form, or as a smaller globular 
fragment in human plasma (Cheng et al., 2012). In humans it was found by Lodish’s group 
that only a small fraction of circulating adiponectin is in the globular form. (Folco et al., 
2009). There is wide expression of adiponectin receptors, AR1 and AR2, in organs and in 
cells of the immune system, e.g. human peripheral monocytes, as well as in macrophages 
obtained from monocyte  (Nielsen and Jensen, 1997) (Spiegelman et al., 1993). In these cells 
adiponectin regulates inflammatory activity and plays a critical role in restricting their 
transformation into foam cells, which is a characteristic of atherosclerosis (Zhang et al., 1995) 
(Maeda et al., 2012). Adiponectin particularly stimulates the release of the anti-inflammatory 
cytokine IL-10 in human monocytes and macrophages (Maeda et al., 2012)  (Arita et al., 
2012) and reduces  the LPS-stimulated release of IL-6 in porcine macrophages (Shimomura et 
al., 1996). In addition, there is a decrease in adiponectin-induced secretion of IL-6 and IL-8 in 
monocytes from patients that have type 1 or type 2 diabetes (Spiegelman et al., 1993) 
(Okamoto et al., 2000). Importantly, plasma levels of adiponectin were considerably lower in 
obese/diabetic mice and in humans (Lawlor et al., 2005) (Mandal et al., 2011) (Hansson, 
2005). Adiponectin also reduced the tumour necrosis factor-α-induced expression of adhesion 
molecules on vascular endothelial cells (Eckel et al., 1992) (Skurk et al., 2005). These aspects 
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of adiponectin biology may have substantial consequences with respect to the atherosclerotic 
processes, because a critical role is performed by these cells in the pathogenesis of 
atherosclerosis (Steinberg et al., 1989). It is recognized that adiponectin levels are lower in 
patients who are suffering from type 2 diabetes, obesity and coronary artery disease (CAD) 
(Ross, 1993) (Kodama et al., 1990). However, it has been shown that adiponectin was 
associated with a negative outcome in patients suffering from CAD, which challenged the 
emerging concept of anti-inflammatory and protective role (Schnabel, 2008). This may 
indicate that the increase in adiponectin serum level is a form of counter-regulatory 
mechanism in order to resist pro-atherosclerotic processes but it fails due to the of burden and 
the severity of the atherosclerotic changes. The same concept could be used in case of obesity, 
even though AQ is released from adipocytes, obesity is associated with low level of AQ 
serum level as mentioned above.  
In several clinical studies, it has been found that hypoadiponectinemia (AQ less than 
4ug/ml) is related to insulin resistance and type 2 diabetes, and also to dyslipidemia, 
cardiovascular disease and hypertension (Dellinger et al., 2008). There is a decrease in plasma 
adiponectin levels in patients suffering from coronary artery disease, including myocardial 
infarction (Eckel et al., 1992). Levels of plasma adiponectin are also related to the severity  of 
atherosclerosis (Ouchi et al., 1999) (Kumada et al., 2003) (Otsuka et al., 2006). In addition, 
the level of circulating adiponectin had a significant and negative correlation with the risk of 
coronary artery disease in Caucasian men (Ai et al., 2011). Furthermore, when there was a 
low concentration of plasma adiponectin (below 4.0 μg/ml) it served as an independent risk 
factor for coronary artery disease in Japanese men after adjustment for other risk factors 
(Kumada et al., 2003) . It was also shown that hypoadiponectinemia is related to the 
complexity of coronary lesions in patients, who had stable coronary artery disease and those 
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who had acute coronary syndrome (Wang XY1, 2007). However, it is notable that in other 
studies, there is no relationship between plasma adiponectin levels and coronary artery disease 
(Kern et al., 2003) (Kumada et al., 2003) (Lawlor et al., 2013). It was also demonstrated that 
the levels of adiponectin did not determine the risk of coronary heart disease in British women 
(Laughlin et al., 2007).  
The biological basis for this difference is poorly understood, with some studies 
suggesting that estorgen influences AQ productions but this evidence is limited and 
contradictory. One study reported that menopausal women have higher AQ production than 
premenopausal women (Sieminska et al., 2005), but another study refutes this claim and 
shows that it has no effect (Cnop et al., 2003).    
Similarly, it was found that adiponectin levels were not related to coronary artery 
disease in American Indians in a case controlled study from Strong Heart Study (Lindsay et 
al., 2005). But a meta-analysis of seven studies showed that there was a weak but significant 
link between adiponectin levels and coronary heart disease (Sattar et al., 2006). 
The positive, protective effects of adiponectin in the vasculature are also well 
documented. It has been found that adiponectin affects endothelial activity in several ways. A 
clinical study showed that there was a significant relationship between the levels of plasma 
adiponectin and vaso-relaxation in reaction to reactive hyperaemia (Ohashi et al., 2009).  
Adiponectin regulates blood pressure of APN-KO mice through an eNOS-dependent system 
(Ohashi et al., 2009). When cultured endothelial cells are treated with adiponectin, there is 
greater differentiation with the development of capillary-like structures and migration, while 
there is a decrease in apoptosis upon  serum starvation, in part through AMP activated protein 
kinase (AMPK)- eNOS signalling pathways (Ouchi et al., 2004). In addition, adiponectin 
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increases revascularization in a mouse model of hind limb ischemia through an AMPK-
dependent system (Shibata et al., 2004). It was reported that adiponectin encourages  
angiogenic responses in vivo through its capacity to increase expression of cyclooxygenase-2 
(COX-2) (Ohashi et al., 2010).  
It seems that adiponectin also has an impact on the differentiation and migration of 
vascular smooth muscle cells, which are critical players in vascular remodelling. Adiponectin 
stops the expansion and spread of vascular smooth muscle cells stimulated by platelet derived 
growth factor-BB (PDGF-BB), platelet-derived growth factor-AA, and heparin binding 
epidermal growth factor (HB-EGF) by inhibiting  extracellular signal-regulated kinase (ERK) 
activation (Arita et al., 2012). Adiponectin binds to PDFG-BB, basic fibroblast growth factor 
(b-FGF) and HB-EGF and stops their proliferative functions in smooth muscle cells (Wang et 
al., 2005).  
It has been found in several studies that adiponectin regulates the activity and 
phenotypes of macrophages. The expression of class A scavenger receptor (SR-A) is reduced 
in human macrophages by adiponectin, which also curtails the conversion of macrophages 
into foam cells (Ouchi et al., 2001). The tissue inhibitor of metalloproteinase-1 is also 
increased by adiponectin upon expression of interleukin-10 (IL-10) in human macrophages 
(Kumada et al., 2004). This result suggests that adiponectin may impede foam cell formation 
and prevent plaque rupture in atherosclerotic lesions. Moreover, it stops the infiltration of 
CD4
+
 T lymphocytes in atherosclerotic lesions by decreasing the expression of T lymphocyte 
chemo-attractant in macrophages (e.g. MDC, I-309, PARC)(Okamoto et al., 2008). It is also 
apparent from recent findings that there is a link between the macrophage differentiation and 
chronic inflammatory states within adipose tissue (Lumeng et al., 2007). There are essentially 
two kinds of macrophages in adipose tissue, a classically activated macrophage (MI) and an 
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alternatively activated macrophage (M2). M1 macrophage polarization in rodent adipose 
tissue is a result of obesity, which plays a role in inflammatory reactions and tissue damage 
(Xu et al., 2003). It is indicated that M2 macrophage polarization also plays a part in wound 
repair and vascular security with anti-inflammatory features (Gordon, 2003). It has been 
found in various studies that adiponectin can encourage the phenotypes of macrophages to 
turn to the anti-inflammatory states. There is an increase in concentrations of M1-related 
genes expressed, such as interferon-γ in peritoneal macrophages (Okamoto et al., 2008) and 
stromal vascular fractions (SVFs) separated from APN-KO mice in comparison to wide-type 
mice (Ohashi et al., 2010). Consistent with the in vivo outcomes, when mouse peritoneal 
macrophages and SVF are treated with adiponectin, there is greater expression of M2 markers 
and lower expression of M1 markers (Ohashi et al., 2010). These results imply that 
adiponectin works to adjust the macrophage polarization from pro-inflammatory states to anti-
inflammatory phenotypes, which ultimately reduces chronic inflammation. 
2. Results 
 
In this chapter we wanted to investigate the implication of old age on the expression of 
AR1, AR2. This was done by measuring the surface expression of both receptors on PBMCs 
subsets using flow cytometry and by measuring the gene expression of the receptors on mixed 
PBMCs. In addition, we planned to measure the circulating levels of AQ by commercial kit. 
We were particularly interested in the B cell due to PEPITEM being released exclusively 
from B cells after they are stimulated by Adiponectin (AQ) (Chimen et al., 2015). 
To conduct this experiment, we recruited both young and old subjects, placing them 
into two different groups (n=6). The young subjects were aged between 20-35 years old and 
the old subjects aged between 60-75 years old. All subjects were matched for sex, ethnicity, 
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BMI, physical activities, illness, and statin drugs usage. See clinical parameters of the study 
on Table 3-1.  
To investigate the expression of the receptors of our panel, we used designated 
markers to differentiate PBL subsets. B-cells (CD19+), NK T cell (CD56+ CD3+), Memory 
(CD4+\CD8+ CD45RO+) T-cells, Naïve (CD4+\CD8+ CD45RO-) T cell, NK cells (CD56+ 
CD3-), and CD56 high NK cell (CD56high CD3-). It’s important to note that in Adiponectin 
measurement experiments, we used CD56+ PE antibody to identify CD3+ T cell population. 
This was necessary because in Integrin and Chemokine receptors chapters, CD56+ APC 
antibodies were utilised in order to identify CD3+ T cell population.  
In case of monocytes, we studied 3 populations: classical monocytes (CD14+CD16-), 
non-classical monocytes (CD14+CD16++) and intermediate monocytes (CD14++CD16+ 











 young subjects old subjects 
N 6 6 
AGE 25 67.3 
BMI 24.05 26.79 
Table 3-1: Clinical parameters of study subjects 
Data figures are represented as a median (n=6); subjects were divided into two groups: young 
and old, and subjects in both groups were matched for sex and ethnicity. BMI was higher in 
the old subjects. 
 
2.1. Surface expression of AR1, AR2 on PBMCs cell isolated from young or old 
controls. 
 
By accruing the percentage frequency and MFI for each subset, we were able to study 
the surface expression of AR1 and AR2. By measuring the positive cells of AR1 on PBL 
subsets (Figure 3-1), we did not see a significant difference in both groups. When we look at 
MFI graphs (Figure 3-2), we saw a significant increase of AR1 expression on B-cells in 
young subjects when compared to old subjects. In cases of NK cells and CD56 high NK cells 
did not show any significant disparities between the groups. In the case of T cell subsets, the 
expression of AR1 was very low or absent which was expected. In case of AR2, the MFI of B 
cells was significantly higher in young subjects compared to old ones. Similarly, the 
expression of AR2 on other T-cell subsets was very low, or absent (Figures 3-3, 3-4). 
Following this, we focussed on the surface expression of AR1 and AR2 in monocyte 
subsets, as mentioned above; we studied three distinct populations of monocyte: classical 
monocytes, non-classical monocytes, and intermediate monocytes. Consistent with the 
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literature, the percentage of frequency of AR1 and AR2 on monocyte subsets was very high in 
both groups (Figure 3-5 and 3-7). However MFI graphs of AR1 (Figure 3-6) show marginal 
differences between young and old subjects, no significant difference was noticed. On the 
other hand, we noticed a substantial difference in AR1 expression between classical and non-
classical monocytes within young subjects (Figure 3- 6). The same observation was seen in 












Figure 3-1:AR1 frequency on PBL subsets.  
Flow cytometry was used to measure the frequency of AR1; PBL was isolated from fresh 
blood samples, stained, and gated on their forward/side scatter profile. CD19 antibody was 
used to identify B-cells. CD3 and CD56 were used to identify the different population of NK 
Cells. AR1 expression was measured on the basis of the isotype control for each subset. Data 
is mean ± SEM (N=6), and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 






Figure 3-2:AR1 mean fluorescent intensity on PBL subsets 
Flow cytometry was used to measure the fluorescent intensity of AR1; PBL was isolated from 
fresh blood samples, stained, and gated on their forward/side scatter profile. CD19 antibody 
was used to identify B-cells. CD3 and CD56 were used to identify the different populations of 
NK cells. AR1 expression was measured on the basis of the isotype control for each subset. 
Data is mean ± SEM (N=6), and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 







Figure 3-3: AR2 frequency on PBL subsets 
Flow cytometry was used to measure the frequency of AR2; PBL was isolated from fresh 
blood samples, stained, and gated on their forward/side scatter profile. CD19 antibody was 
used to identify B-cells. CD3 and CD56 were used to identify the different populations of NK 
Cells. AR1 expression was measured on the basis of the isotype control for each subset. Data 
is mean ± SEM (N=6), and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 






Figure 3-4:AR2 mean fluorescent intensity on PBL subsets 
Flow cytometry was used to measure the fluorescent intensity of AR2; PBL was isolated from 
fresh blood samples, stained, and gated on their forward/side scatter profile. CD19 antibody 
was used to identify B-cells. CD3 and CD56 were used to identify the different populations of 
NK Cells. AR1 expression was measured on the basis of the isotype control for each subset. 
Data is mean ± SEM (N=6), and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 









Figure 3-5: AR1 frequency on monocytes subsets  
Flow cytometry was used to measure the frequency of AR1; monocytes were isolated from 
fresh blood samples, stained, and gated on their forward/side scatter profile. CD14 antibody 
was used to identify classical monocytes. CD16 and CCR2 antibodies were used to identify 
non-classical and intermediate monocytes. AR1 expression was measured on the basis of the 
isotype control for each subset. Data is mean ± SEM (N=6), and the differences between 
groups were determined by using an independent sample t test. The probability values of less 






Figure 3-6: AR1 mean fluorescent intensity on monocytes subsets  
Flow cytometry was used to measure the fluorescent intensity of AR1; monocytes were 
isolated from fresh blood samples, stained, and gated on their forward/side scatter profile. 
CD14 antibody was used to identify classical monocytes. CD16 and CCR2 antibodies were 
used to identify non-classical and intermediate monocytes. AR1 expression was measured on 
the basis of the isotype control for each subset. Data is mean ± SEM (N=6), and the 
differences between groups were determined by using an independent sample t test. The 
probability values of less than 0.05 were considered significant (N=6). (* = P ≤ 0.05, **= P ≤ 








     
Figure 3-7: AR2 frequency on monocyte subsets 
Flow cytometry was used to measure the frequency of AR1; monocytes was were isolated 
from fresh blood samples, stained, and gated on their forward/side scatter profile. CD14 
antibody was used to identify classical monocytes. CD16 and CCR2 antibodies were used to 
identify non-classical and intermediate monocytes. AR1 expression was measured on the 
basis of the isotype control for each subset. Data is mean ± SEM (N=6), and the differences 
between groups were determined by using an independent sample t test. The probability 
values of less than 0.05 were considered significant (N=6). (* = P ≤ 0.05, **= P ≤ 0.01, *** = 







Figure 3-8: AR2 mean fluorescent intensity on monocytes subsets  
Flow cytometry was used to measure the fluorescent intensity of AR2; monocytes were 
isolated from fresh blood samples, stained, and gated on their forward/side scatter profile. 
CD14 antibody was used to identify classical monocytes. CD16 and CCR2 antibodies were 
used to identify non-classical and intermediate monocytes. AR1 expression was measured on 
the basis of the isotype control for each subset. Data is mean ± SEM (N=6), and the 
differences between groups were determined by using an independent sample t test. The 
probability values of less than 0.05 were considered significant (N=6). (* = P ≤ 0.05, **= P ≤ 







2.2.  The levels of gene expression for AR1 and AR2 on PBMCs in young and old 
controls.  
 
To correlate surface expression of AR1 and AR2 with the gene expression of both 
receptors on the same young and old groups, we measured the gene expression on PBMCs. 
However, we found no significant difference in AR1 or AR2 gene expression between young 
and old subjects (Figure 3-9).  
 
Figure 3-9:AR1/2 gene expression on PBMCs in young and old subjects. 
PBMCs were isolated from fresh blood samples and gene expression was measured and 
quantified using qPCR. Data is mean ± SEM (N=6), and the differences between groups were 
determined by using an independent sample t test. The probability values of less than 0.05 









2.3.  The levels of adiponectin in young and old controls.  
 
Since AQ is an important factor in leukocytes trafficking and the PEPITEM pathway, it is 
very useful to measure the AQ serum level in both groups. Hence, we collected serum 
samples from the same young and old subjects and then used Quantikine ELISA Kits (R&D 
SYSTEMS). This assay revealed significant increase in AQ level in the serum of old subjects 
compared to that found in young subjects (Figure 3-10). 
 
Figure 3-10: Circulating AQ levels in young and old subjects.  
Circulating AQ levels were measured using ELISA kits and the numeric values were 
calculated using a standard curve, as described in the manufacturer’s protocol. Data is mean ± 
SEM (N=6), and the differences between groups were determined by using an independent 
sample t test. The probability values of less than 0.05 were considered significant (N=6). (* = 








We argue that old age has a negative correlation on the expression of Adiponectin 
receptors 1 and 2 (AR1, AR2) on B cell, which may contribute to the increased susceptibility 
of elderly people developing cardiovascular disease. It is well established that Adiponectin 
(AQ) has a protective function against cardiovascular diseases (Kato et al., 2006), therefore 
from the data we showed that the expression of Adiponectin receptors (ARs) decreases with 
old age. This may inhibit AQ protective action, and subsequently increases the chances of 
developing cardiovascular disease. Other findings demonstrated the distribution of 
adiponectin receptors on PBL. The literature has shown that the frequency of ARs on B cell is 
the highest among PBL; by  47% then NK cell with 21% (Pang and Narendran, 2008), 
however our data shows that NK cells express more ARs than B-cells. This variation could be 
due to technical issues, such as the fluorescence difference between analysers or due to 
employing a different protocol for sample preparation. Moreover, there are some variations in 
the protocol of creating antibodies, for example the incubation time, which could affect the 
intensity of the fluorescence.  
The immune-regulatory effect of Adiponectin is focused on myeloid-monocytic lineage 
cells (Tilg and Moschen, 2006). Therefore, the fact that B and NK cells express more 
adipoectin receptors suggests that those subsets have potential capabilities to regulate the 
immune and inflammatory systems.  
Regarding monocytes expression, our data is consistent with the literature that suggests 
that monocytes have the highest expression of ARs among PBMCs. There was no significant 
variation in the frequency or MFI of both receptors on the three subsets. It was expected that 
there would be a significant decrease of the expression ARs on monocytes subsets because of 
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the hypothesis which states that monocytes differentiate into M1 macrophages 
(proatherogenic) more than into anti-inflammatory M2 macrophages (Lovren et al., 2009). 
We postulated that due to the fact that older subjects have lower expression of ARs on B and 
NK cells, this could mean that they are less sensitive to Adiponectin. Based on the hypothesis 
of Lovren et al. that states that Adiponectin primes monocytes to differentiate into the anti-
inflammatory macrophages (M2), we expected low ARs expression on monocytes subsets.  
During the analysis, interesting differences between the expressions of AR1 and AR2 
were noticed on monocyte subsets within the groups, with non-classical monocytes higher in 
expression in both groups compared to classical monocytes. It is well known that classical 
monocytes are considered as scavenger cells (Ziegler-Heitbrock, 2015), whereas non-classical 
monocytes are regarded as pro-inflammatory monocytes. In fact, non-classical monocytes 
have been proven to be involved in the progression of atherosclerosis (Stansfield and Ingram, 
2015).  We could conclude from this that the increase of AR1 and AR2 expression on non-
classical monocytes in old subjects, compared to that on classical monocytes in the same 
group, could be an early indicator of inflammation.  
The results from AR1 and AR2 gene expression are not conclusive or significant due to 
variability within groups. From the literature we know that the surface expression of ARs on 
PBMCs are very sensitive to lifestyle because studies have shown that that aerobic exercises 
modulate the gene expression of AR1 and AR2 on PBMCs (Lee et al., 2015). Therefore, we 
can speculate that our young subjects may have been more physically active during their 
participation in the study and this may have confounded our observation. So, it could be 
suggested that the optimum level of AQ in healthy young subjects aged between 20 and 35 
years is 7.0 ± 0.7 μg/ml (Adamandia D. Kriketos, 2004), whereas the AQ level of old subjects 
was 8.9±4.2 μg/ml in a study done by Isobe et al. (2005) where there were  372 subjects aged 
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60.3± 12,5 years (Isobe et al., 2005). However, in our study the level is higher than this in 
healthy, older subjects. We speculate that the increase is a compensation mechanism to 
overcome the reduction in ARs that occurs on some leukocytes with age. This would 
maximise signalling through those receptors.  
4. Conclusion 
 
Old age has a negative correlation on the surface expression of AR1 and AR2 on PBL. 
This negative impact presented as a significant decrease on the surface expression on AR1 
and AR2 on B-cells in old subjects, no significant change was seen on monocytes however. 
AQ serum level is higher in old subjects when compared to young ones something which may 




















CHAPTER 4: STUDYING THE EFFECT OF AGE ON CHEMOKINE 















With the progress in age, cells of the smooth muscles and vascular endothelium become 
dysfunctional and complex functional and structural transformations are induced by aging 
which is an important factor for developing cardiovascular diseases (Herrera et al., 2010) 
(Lundberg and Crow, 1999). The pro-inflammatory proteins i.e. the adhesion molecules, 
actively take part in inflammation process and immune response, and are crucially involved in 
cell-matrix/cell-cell interactions (Zou et al., 2003). The majority of cardiovascular disorders 
such as coronary artery disease (Heinz et al., 2003) and peripheral arterial disease (Ridker et 
al., 1998), and other aging related commonly occurring conditions (Espinosa-Heidmann et al., 
2002), plasma levels of soluble adhesion molecules are used as risk factors and biomarkers, 
and are also used as indicators of disease prognosis and severity (Ridker et al., 1998).  
Limited research with inconsistent data is available for reporting the aging related 
alterations in soluble adhesion molecules expression. For example, an increase in soluble 
ICAM-1 and VCAM-1 in humans, caused by  old age, has been reported by the study of 
Miles et al. (Miles et al., 2001). It has been shown by the study of Morisaki et al. (Morisaki et 
al., 1997) that positive correlation with age is associated only with soluble VCAM-1, and not 
with soluble ICAM-1. However, a decrease in the levels of VCAM-1, ICAM-1 and E-
selection has been reported in another study (Nash et al., 1996).  
There is no doubt that there is a poor understanding of aging mechanisms at present, but 
the conjecture suggested that the responsibility of aging consequences is due to the oxidative 
stress hypothesis and according to it the distinctive dysfunctions of aged subjects and 
abnormality in cellular functions are attributed to an imbalance in cellular redox system (Yu, 
1996) (Harman, 1956). It was concluded by the authors that increase in oxidative stress is 
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responsible for altered expressions soluble adhesion molecules with advanced age (Herrera et 
al., 2010).  
It has been observed that cell trafficking is reduced towards T-cells in older mice for 
CD4
+
 T-cells (through down-regulation of CD31 which contributes in the activation and 
adhesion of T-cells)  (Turner and Orme, 2002) and for mononuclear cells of peripheral blood 
in older rats (Schmucker et al., 2002).  
1.1.  Integrins   
 
Integrins are a significant family of cell surface-adhesion receptors that are manifested in 
all metazoans. They are heterodimers of non-covalently linked α and β subunits (Harburger 
and Calderwood, 2009). It is important for them to have particular attachment to extracellular 
matrix (ECM) proteins, or in certain situations, to counter-receptors on adjacent cells, as it 
allows for cell adhesion and brings about embryonic development, tissue maintenance and 
repair, host defence and haemostasis (Harburger and Calderwood, 2009). The processes are 
dependent on the relationship of integrins to the intracellular cytoskeleton through the 
normally short integrin cytoplasmic tails; these relationships allow for the bi-directional 
movement of force over the plasma membrane (Calderwood et al., 2000) (Evans and 
Calderwood, 2007). Apart from their mechanical functions in respect of anchorage, integrins 
transfer chemical signals inside the cell (outside-in signalling), providing information 
regarding its location, domestic setting, adhesive state and adjacent matrix (Hynes, 2002) 
(Miranti and Brugge, 2002). Many cellular reactions are based on these signals, and include 
survival, migration and differentiation. Apart from outside-in signalling, integrins can manage 
their affinity for extracellular ligands. This is done by making conformational adjustments to 
the extracellular domains that take place as a reaction to signals that modify the integrin 
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cytoplasmic tails – a process known as inside-out signalling or activation (Calderwood et al., 
2000). The best-characterized methods for examining integrin activation are for platelet and 
leukocyte integrins; however, integrin activation is a broad phenomenon that is critical for 
several kinds of cells where it manages matrix remodelling, tissue generation, angiogenesis 
and cell migration (Evans and Calderwood, 2007).   
1.1.1. Integrin signalling 
 
It is important to manage integrin activity since it is unsuitable for integrin activation in 
blood platelets, as it may for example contribute to thrombosis (Hynes, 2002). It appears that 
the α subunit of integrins is more important for the extracellular ligand binding specificity as 
the smaller cytoplasmic tail of the β subunit is the area that interacts with regulatory proteins 
in the inside-out process (Hynes, 2002). When the integrins are in a state of rest, α and β 
cytoplasmic tails are close to each other which restricts the integrin in a low-affinity 
constitution. Conformational modifications are brought about following the dissociation of 
the two tails by signals inside the cell, which then activates the integrins (Luo et al., 2007).  
 Alpha-L 
Significant roles are performed by integrin αLβ2 (LFA-1; CD11aCD18) in leukocyte 
biology that comprises of leukocyte adhesion, movement, and immune synapse generation 
(Lu et al., 2001). Ligands of αLβ2 include the ICAMS and the junctional adhesion molecules 







The a4 integrin subunits take part in leukocyte cell-cell and cell-matrix interactions and 
migration (Elices et al., 1990). The ligands of these cells are domains 1 and 4 of vascular cell 
adhesion molecule-1 (VCAM-1, CD106) (Defougerolles and Springer, 1992).  
 Beta-1 
There is extensive distribution of the β1 integrins (very late antigen, VLA) within several 
T cell subsets (Kubes et al., 1995). It was asserted in the past, there was barely any expression 
of β1 integrins on neutrophils so there could be no functional implication (Neeley et al., 
1993). However, it has been indicated in a variety of recent reports that VLA-4 (α4β1), VLA-
5 (α5β1) and VLA-9, (α9β1) demonstrate an expression on human and rat neutrophils and 
contribute to both adhesion and migration (Kubes et al., 1995).  
 Beta-2 
There is high expression of β2 integrins (CD18) on neutrophils and other leukocytes and 
this is important for adhesion to endothelial cells, particularly of CD11b/ CD18 (αMβ2, Mac-
1, CR3), which is a flexible molecule that attaches to numerous different ligands like ICAM-1 
(van den Berg et al., 2001). However, the most significant integrins on T lymphocytes are 
α4β1 (VLA-4, CD49d/CD29) and αLβ2 (LFA-1, CD11a/CD18) which attach to VCAM-1 
(CD106) and ICAM-1 (CD54), respectively (Elices et al., 1990) (Makgoba et al., 1988). It is 
possible for α4 and β2 integrins to facilitate stable adhesion, leukocyte proliferation, and 
migration, while only α4 integrins can facilitate preliminary rolling interactions (Alon et al., 
1995). The ligand binding ability of α4β1 and αLβ2 integrins that are constitutively expressed 
on circulating leukocytes is low; however, at areas of emigration during inflammation or 
trafficking, these integrins are “activated”  in a chemokine regulated way (Chan et al., 2000).  
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1.2.  Chemokines  
 
Chemokines are chemotactic cytokines that activate particular G-protein-coupled 7-
transmembrane receptors (Figure 4-1). They have been classified into C, CC, CXC, and 
CX3C families based on the position of conserved cysteine residues. CX3CL1 is the only 
recognized CX3C chemokine. This is also called fractalkine (Zlotnik and Yoshie, 2000) and is 
expressed by the activated vascular endothelial cells (Bazan et al., 1997), neurons (Harrison et 
al., 1998), epithelial cells (Lucas et al., 2001), smooth muscle cells (Ludwig et al., 2002), 
dendritic cells (DCs) (Papadopoulos et al., 1999) and macrophages (Greaves et al., 2001). The 
only recognized CX3CL1 receptor, CX3CR1, has expression on T-cell and natural killer (NK) 
cell subsets (Imai et al., 1997), DC subsets, brain microglia (Harrison et al., 1998) and also on 
blood monocytes. Tight, integrin-independent adhesion of CX3CR1-expressing leukocytes is 
encouraged by CX3CL1. It has been found that human CX3CR1 gene polymorphisms are 
genetic risk factors for both coronary artery diseases and atherosclerosis (Moatti et al., 2001). 
It was also found that mice that were deficient in client CX3CR1 or CX3CL1 demonstrated 
relative resistance to atherosclerosis formation in the relevant murine disease models 
(Combadiere et al., 2003). However, there are still arguments on the mechanistic justifications 
for these phenotypes.  
 CXCR3 
There has been particular focus on the chemokine system, with concern given to its 
contribution to several biological processes (Bonacchi et al., 2001). CXCR3 has been found 
on various cells of hematopoietic family, including T and B lymphocytes, and natural killer 
cells (Luster, 1998). Various chronic inflammatory diseases have shown expression of the 
CXCR3-targeting chemokines, including ulcerative colitis (Cole et al., 1998) and 
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arthrosclerosis (Pupilli et al., 1999). There is limited information on the signal transduction 
pathways that CXCR3 activates and the way they are possibly linked to biological actions 
shown by its agonists.  
 CCR5 
CCR5 is a functional receptor for several inflammatory CC-chemokines and has 
expression on macrophages, migroglia, memory T cells and dendrite cells. It has been found 
that CCR5 regulates chemotaxis, proliferation and immune responses (Gosling et al., 1997). 
There are two subsets of CD4+ lymphocytes. Th1 lymphocytes produce interferon gamma 
(IFNg) and lymphotoxin, which encourage cell-mediated immunity to intracellular pathogens 
(Abbas et al., 1996). Th2 lymphocytes produce interleukins 4 and 5 (IL-4 and IL-5), and these 
play a part in allergy and humoral immunity to parasites (Abbas et al., 1996). It was found 
that there was expression of high concentrations of CCR5 in Th1; however, it was almost 
non-existent in Th2 lymphocytes. Furthermore, after T lymphocytes are recovered from the 
synovial fluid present in rheumatoid joints, demonstrate a Th1 phenotype, express CCR5 and 
CXCR3 in high concentrations and CCR3 in low concentrations (Baggiolini et al., 1997). This 
study provides further evidence that chemokine receptors are expressed on T lymphocytes on 
the basis of their state of activation and differentiation. Those chemokines that are often 
generated in inflammation do not bring about any response in naïve and memory T 
lymphocytes however. CCR1, CCR2, CCR5 and CXCR3 expression and chemotactic 
migration determines activation, especially with IL-2 (Wu et al., 1997).  
1.2.1. Chemokin receptors 
 
These are a subgroup of heterotrimeric GTP-coupled proteins (G-proteins), a large 
seven transmembrane domain receptor family (Murphy et al., 2000) (Figure 4-1).  
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Designation of chemokine receptors is based on the chemokine (s) mediators they couple 
(CC, CX3C, CXC, XC), followed by R for receptor and a digit or numeric denoting the 
discovery order (Moser et al., 2004). G-proteins of Gi-type are required by these receptors for 
signal transduction as described by experiment on toxin of Bordetella pertussis (Murphy et 
al., 2000, Suresh and Wanchu, 2006). Molecular responses of cells to chemokines are usually 
temporary in duration and rapid in onset, the cells regain retrieve responsiveness to a certain 
chemokine after a brief period of culturing in medium lack chemokine by a transient cellular 
desensitization phenomenon which is a negative control mechanism evoked signal 
transduction of chemokine receptors (Moser et al., 2004). Directed cell migration and 
polarized chemokine sensitivity are maintained along a chemokine gradient by persistent 
chemokine receptor redistribution on leucocyte surfaces induced by rapid internalization 
(Moser and Willimann, 2004). It is not mandatory that chemokine coupling proteins would 
elicit cell migration, as described by CXCR3-B (Lasagni et al., 2003). A high 
indiscrimination exists in chemokine selection by several chemokine receptors, and vice 
versa; one receptor, for example, can bind to more than one chemokines (Zlotnik and Yoshie, 
2000, Murphy, 2002, Moser et al., 2004) (Figure 4-2). Inflammation is also caused by such 
redundancy, in contrast to numerous monogamous chemokine systems having activity in 
homeostatic leucocyte migration and development process; certain natural chemokines having 
combinatorial agonistic-antagonistic ability, accentuating their importance as controllers of 
leucocyte navigation, have been reported to exist. For CCR3, the antagonists are CXCL11, 





Figure 4-1: Transmembrane domains of chemokine receptors 
Seven transmembrane domains tend the chemokine receptors to be imbedded into membrane. 
(1) NH2-terminus, which reacts with chemokine coupling pocket created by transmembrane 
domains of chemokine receptors, (2) N loop terminus, that enables starting receptor contact, 
and (3) matrix fixation site in COOH terminal α-helix or core structure, are the three 
functional sites of chemokines, Three intracellular loop sites and COOH terminus contribute 
in signal transduction mediated by G-protein whereas chemokine coupling is coordinated by 





Figure 4-2: Chemokine receptors and their ligands  (Proudfoot, 2002) 
Chemokines are classified into subclasses based on the spacing of the N-terminal cysteine 
residues. Blue colour indicates the receptors for the (or CXC) whereas the receptors for the 
(or CC) subclass in red. Green colour indicates and the receptors for the minor subclasses 








2.1. Characterisation of surface expression of adhesion molecules and chemokine 
receptors on fresh blood PBL, migrated PBL, and surface adherent cells.   
 
We began our experiment by comparing the expression levels of adhesion molecules and 
chemokine receptors on fresh blood PBL, migrated PBL, and surface adherent PBL. Our 
subjects were male Caucasians aged between 20-75 years of age. The PBL was isolated 
directly from fresh whole blood to measure the surface expression of certain adhesion 
molecules and chemokine receptors on circulating populations of lymphocytes. Our adhesion 
molecules and chemokine receptor panel included the receptors of αL, α4, β1, β2, PSGL-1, 
CCR5, CXCR3, and CX3CR1. From the same donors we isolated  PBL from transmigration 
assays which enabled us to study the effect of recruitment by EC on the expression of these 
molecules. During this part of the experiment, The PBL was briefly placed on stimulated EC 
for 7 minutes, and then surface adherent PBL (Phase bright PBL) were detached from EC 
using cold EDTA and re-suspended and kept ready for staining. The transmigrated PBL 
(phase dark PBL) were collected from EC by adding EDTA for a longer time and shaking the 
plate with the cells that were collected and kept for staining. To investigate the expression of 
these receptors on different lymphocyte populations we used a panel of cell specific markers; 
B cells (CD19+), NK T cell (CD56+ CD3+), Memory (CD4+\CD8+ CD45RO+) T cells, 
naïve (CD4+\CD8+ CD45RO-) T cells, NK cells (CD56+ CD3-), and CD56 high NK cells 
(CD56high CD3-). Interestingly we found that fresh blood PBL have a high expression of 
CCR5, CXCR3, and CX3CR1 receptors on all PBL subsets but the expression is lost after 
migration as seen on Figures 4-3, 4-4, and 4-5. We observed very clear and significant 
differences between circulating cells and cells recruited by EC. Interestingly, transmigration 
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was not a requirement for down regulation of these receptors, as even the surface adherent 
population has low expression.  
Furthermoe, we measured the expression of adhesion molecules β-1, β-2, α-L, α-4, PSGL-
1; however, we did not notice the same pattern of a sharp loss of the surface expression after 
adhesion and transmigration. Figure 4-6 shows some variation on the surface expression of 
Alpha-L integrin on NK T cells, CD56 High NK cells, and NK cells. In the case of Alpha-4 
integrin, as seen in figure 4-7, the surface expression did not change after adhesion and 
transmigration, except for some modest differences after transmigration on NK T cells, CD56 
High NK cells, and NK cells. Regarding the surface expression of β1 integrin in figure 4-8, 
the graph shows expression of β1 is unchanged after transmigration on all subsets. Similar 
patterns of surface expression after transmigration were seen in the case of β2 and PSGL-1 in 
all PBL subsets except B cells as seen on figure 4-9 and 4-10.  Following this, we pooled the 
data for surface adherent and migrated PBL and compared their surface expression with 
circulating PBL, the surface expression of β2 on N-CD4, N-CD8. We found that M-CD4 
increased significantly the after transmigration (Figure 4-14), the expression of the remaining 









Figure 4-3: MFI of CCR5 receptor on different subsets of PBL isolated from healthy 
donors (20-75 years old).  
Flow cytometry was used to measure the MFI of CCR5 receptor; PBL was isolated from fresh 
blood samples, stained with same panel of antibodies, and gated on their forward/side scatter 
profile. Surface adherent PBL is collected from transmigration assay where PBL are added on 
DMEC and incubated for 7 minutes at 37°C. Then, using Phosphate-buffered saline (PBS) 
surface adherent The PBL was collected gently using pipette. Finally, The PBL was stained 
with same panel. Regarding migrated PBL, they are PBL collected from transmigration assay 
where PBL are added on DMEC and incubated for 7 minutes at 37°C. Then, TrypLE was 
used as cell-dissociation enzymes that make transmigrated PBL floating. Finaly, The PBL 
was collected and stained with same panel of antibodies. Direct conjugated antibodies were 
used for staining. CCR5 receptor expression was measured on the basis of the isotype control 
for each subset. Data is mean ± SEM (N=12) and were analysed using one way Anova, with a 
Bonferroni post hoc test. The probability values of less than 0.05 were considered significant 








Figure 4-4: MFI of CXCR3 receptor on different subsets of PBL isolated from healthy 
donors (20-75 years old).  
Flow cytometry was used to measure the MFI of CXCR3 receptor; PBL was isolated from 
fresh blood samples, stained with same panel of antibodies, and gated on their forward/side 
scatter profile. Surface adherent PBL is collected from transmigration assay where PBL are 
added on DMEC and incubated for 7 minutes at 37°C. Then, using Phosphate-buffered saline 
(PBS) surface adherent The PBL was collected gently using pipette. Finally, The PBL was 
stained with same panel. Regarding migrated PBL, they are PBL collected from 
transmigration assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. 
Then, TrypLE was used as cell-dissociation enzymes that make transmigrated PBL floating. 
The PBL was collected and stained with same panel of antibodies. Direct conjugated 
antibodies were used for staining. CXCR3 receptor expression was measured on the basis of 
the isotype control for each subset. Data is mean ± SEM (N=12) and were analysed using one 
way Anova, with a Bonferroni post hoc test. The probability values of less than 0.05 were 






Figure 4-5: MFI of CX3CR1 receptor on different subsets of PBL isolated from healthy 
donors (20-75 years old).  
Flow cytometry was used to measure the MFI of CX3CR1 receptor; PBL was isolated from 
fresh blood samples, stained with same panel of antibodies, and gated on their forward/side 
scatter profile. Surface adherent PBL is collected from transmigration assay where PBL are 
added on DMEC and incubated for 7 minutes at 37°C. Then, using Phosphate-buffered saline 
(PBS) surface adherent The PBL was collected gently using pipette. Finally, the PBL was 
stained with same panel. Regarding migrated PBL, they are PBL collected from 
transmigration assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. 
Then, TrypLE was used as cell-dissociation enzymes that make transmigrated PBL floating. 
The PBL was collected and stained with same panel of antibodies. Direct conjugated 
antibodies were used for staining. CX3CR1 receptor expression was measured on the basis of 
the isotype control for each subset. Data is mean ± SEM (N=12) and were analysed using one 
way Anova, with a Bonferroni post hoc test. The probability values of less than 0.05 were 







Figure 4-6: MFI of Alpha-L receptor on different subsets of PBL isolated from healthy 
donors (20-75 years old).  
Flow cytometry was used to measure the MFI of Alpha-L receptor; PBL was isolated from 
fresh blood samples, stained with same panel of antibodies, and gated on their forward/side 
scatter profile. Surface adherent PBL is collected from transmigration assay where PBL are 
added on DMEC and incubated for 7 minutes at 37°C. Then, using Phosphate-buffered saline 
(PBS) surface adherent The PBL was collected gently using pipette. Finally, the PBL was 
stained with same panel. Regarding migrated PBL, they are PBL collected from 
transmigration assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. 
Then, TrypLE was used as cell-dissociation enzymes that make transmigrated PBL floating. 
The PBL was collected and stained with same panel of antibodies. Direct conjugated 
antibodies were used for staining. Alpha-L receptor expression was measured on the basis of 
the isotype control for each subset. Data is mean ± SEM (N=12) and were analysed using one 
way Anova, with a Bonferroni post hoc test. The probability values of less than 0.05 were 





Figure 4-7: MFI of Alpha-4 receptor on different subsets of PBL isolated from healthy 
donors (20-75 years old).  
Flow cytometry was used to measure the MFI of Alpha-4 receptor; PBL was isolated from 
fresh blood samples, stained with same panel of antibodies, and gated on their forward/side 
scatter profile. Surface adherent PBL is collected from transmigration assay where PBL are 
added on DMEC and incubated for 7 minutes at 37°C. Then, using Phosphate-buffered saline 
(PBS) surface adherent The PBL was collected gently using pipette. Finally, the PBL was 
stained with same panel. Regarding migrated PBL, they are PBL collected from 
transmigration assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. 
Then, TrypLE was used as cell-dissociation enzymes that make transmigrated PBL floating. 
The PBL was collected and stained with same panel of antibodies. Direct conjugated 
antibodies were used for staining. Alpha-4 receptor expression was measured on the basis of 
the isotype control for each subset. Data is mean ± SEM (N=12) and were analysed using one 
way Anova, with a Bonferroni post hoc test. The probability values of less than 0.05 were 





Figure 4-8: MFI of Beta-1 receptor on different subsets of PBL isolated from healthy 
donors (20-75 years old).  
Flow cytometry was used to measure the MFI of Beta-1 receptor; PBL was isolated from 
fresh blood samples, stained with same panel of antibodies, and gated on their forward/side 
scatter profile. Surface adherent PBL is collected from transmigration assay where PBL are 
added on DMEC and incubated for 7 minutes at 37°C. Then, using Phosphate-buffered saline 
(PBS) surface adherent The PBL was collected gently using pipette. Finally, the PBL was 
stained with same panel. Regarding migrated PBL, they are PBL collected from 
transmigration assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. 
Then, TrypLE was used as cell-dissociation enzymes that make transmigrated PBL floating. 
The PBL was collected and stained with same panel of antibodies. Direct conjugated 
antibodies were used for staining. Beta-1 receptor expression was measured on the basis of 
the isotype control for each subset. Data is mean ± SEM (N=12) and were analysed using one 
way Anova, with a Bonferroni post hoc test. The probability values of less than 0.05 were 







Figure 4-9: MFI of Beta-2 receptor on different subsets of PBL isolated from healthy 
donors (20-75 years old).  
Flow cytometry was used to measure the MFI of Beta-2 receptor; PBL was isolated from 
fresh blood samples, stained with same panel of antibodies, and gated on their forward/side 
scatter profile. Surface adherent PBL is collected from transmigration assay where PBL are 
added on DMEC and incubated for 7 minutes at 37°C. Then, using Phosphate-buffered saline 
(PBS) surface adherent The PBL was collected gently using pipette. Finally, The PBL was 
stained with same panel. Regarding migrated PBL, they are PBL collected from 
transmigration assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. 
Then, TrypLE was used as cell-dissociation enzymes that make transmigrated PBL floating. 
The PBL was collected and stained with same panel of antibodies. Direct conjugated 
antibodies were used for staining. Beta-2 receptor expression was measured on the basis of 
the isotype control for each subset. Data is mean ± SEM (N=12) and were analysed using one 
way Anova, with a Bonferroni post hoc test. The probability values of less than 0.05 were 





Figure 4-10: MFI of PSGL-1 receptor on different subsets of PBL isolated from healthy 
donors (20-75 years old).  
Flow cytometry was used to measure the MFI of PSGL-1 receptor; PBL was isolated from 
fresh blood samples, stained with same panel of antibodies, and gated on their forward/side 
scatter profile. Surface adherent PBL is collected from transmigration assay where PBL are 
added on DMEC and incubated for 7 minutes at 37°C. Then, using Phosphate-buffered saline 
(PBS) surface adherent The PBL was collected gently using pipette. Finally, The PBL was 
stained with same panel. Regarding migrated PBL, they are PBL collected from 
transmigration assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. 
Then, TrypLE was used as cell-dissociation enzymes that make transmigrated PBL floating. 
The PBL was collected and stained with same panel of antibodies. Direct conjugated 
antibodies were used for staining. PSGL-1 receptor expression was measured on the basis of 
the isotype control for each subset. Data is mean ± SEM (N=12) and were analysed using one 
way Anova, with a Bonferroni post hoc test. The probability values of less than 0.05 were 




Figure 4-11: MFI of Alpha-L receptor on different subsets of PBL isolated from healthy 
donors (20-75 years old).  
Flow cytometry was used to measure the MFI Alphal-L; PBL was isolated from fresh blood 
samples, stained, and gated on their forward/side scatter profile. EC- recruited is the pool data 
for surface adherent PBL and migrated PBL. Direct conjugated antibodies were used for 
staining. Alphal-L expression was measured on the basis of the isotype control for each 
subset. Data is mean ± SEM (N=6) and the differences between groups were determined by 
using an independent sample t test. The probability values of less than 0.05 were considered 







Figure 4-12:  MFI of Alpha-4 receptor on different subsets of PBL isolated from healthy 
donors (20-75 years old).  
Flow cytometry was used to measure the MFI Alphal-4; PBL was isolated from fresh blood 
samples, stained, and gated on their forward/side scatter profile. EC- recruited is the pool data 
for surface adherent PBL and migrated PBL. Direct conjugated antibodies were used for 
staining. Alphal-4 expression was measured on the basis of the isotype control for each 
subset. Data is mean ± SEM (N=6) and the differences between groups were determined by 
using an independent sample t test. The probability values of less than 0.05 were considered 









Figure 4-13:  MFI of Beta-1 receptor on different subsets of PBL isolated from healthy 
donors (20-75 years old).  
Flow cytometry was used to measure the MFI Beta-1; PBL was isolated from fresh blood 
samples, stained, and gated on their forward/side scatter profile. EC- recruited is the pool data 
for surface adherent PBL and migrated PBL. Direct conjugated antibodies were used for 
staining. Beta-1 expression was measured on the basis of the isotype control for each subset. 
Data is mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 







Figure 4-14: MFI of Beta-2 receptor on different subsets of PBL isolated from healthy 
donors (20-75 years old).  
Flow cytometry was used to measure the MFI Beta-2; PBL was isolated from fresh blood 
samples, stained, and gated on their forward/side scatter profile. EC- recruited is the pool data 
for surface adherent PBL and migrated PBL. Direct conjugated antibodies were used for 
staining. Beta-2 expression was measured on the basis of the isotype control for each subset. 
Data is mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 







Figure 4-15: MFI of PSGL-1 receptor on different subsets of PBL isolated from healthy 
donors (20-75 years old).  
Flow cytometry was used to measure the MFI PSGL-1; PBL was isolated from fresh blood 
samples, stained, and gated on their forward/side scatter profile. EC- recruited is the pool data 
for surface adherent PBL and migrated PBL. Direct conjugated antibodies were used for 
staining. PSGL-1 expression was measured on the basis of the isotype control for each subset. 
Data is mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 











2.2.  The effect of age on adhesion molecule and chemokine receptors expression on 
fresh blood PBL 
 
2.2.1. Surface expression of Adhesion molecules receptors on fresh blood PBL 
from young or old controls 
 
The above data was of donors who were unstratified on the basis of age. Here, we did 
a more detailed analysis by recruiting young and old subjects; the young group were aged 
between 20-35 years of age, whereas old group participants were between 60-75 years of age. 
The clinical parameters of the study subjects are described below in table 1. Both groups were 
matched for sex, ethnicity, and body mass index (BMI) and were also healthy to the best of 
our knowledge. We measured the surface expression of the same set of adhesion molecules 
and chemokine receptors on the same PBL subsets used above. In the first instance we 
compared expression levels in circulating blood.   
 young subjects old subjects 
N 6 6 
AGE 26.33 66.66 
BMI 24.1 28.9 
Table 4-1: Clinical parameters of study subjects: Data is represented as a median (n=6); 
subjects were divided into two groups: young and old, and subjects in both groups were 
matched for sex and ethnicity. BMI was higher in the old subjects. 
 
The data showed there was an increase in the expression of Alpha-L and Alpha-4 
receptors in old subjects compared to young ones (Figure 4-16, 4-17), although this was 
dependent upon the lymphocyte subset and was not consistent between markers. The 
increases were particularly marked and statistically significant on CD56 high NK cells and 
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NK cells for both receptors. The expression of alpha-4 also increased significantly on naïve T 
cells. Regarding Beta-1 and Beta-2 receptors expression, (Figures 4-18 and 4-19) indicate 
different patterns of expression. Generally, with the exception of CD56 high NK cells and NK 
cells these receptors did not vary with age. Concerning PGGL-1, Figure 4-20 shows a 
decrease in the expression of PSGL-1 in old subjects when compared to young ones across 
nearly all lymphocyte populations with the exception of B cells which showed very low levels 
of expression nonetheless. 
With regard to the surface expression of both adhesion molecules and chemokines 
receptors on surface adherent PBL, we did not deem it necessary to mention the difference 
from the results for transmigrated PBL as these were essentially the same as the expression 
patterns on migrated cells and this data is included in the appendix.  Here, we have shown 
MFI as a measure of expression. The percentage of positive cells for each receptor measured 











Figure 4-16: MFI of Alpha-L receptor on different subsets of PBL isolated from healthy 
donors.  
Flow cytometry was used to measure the MFI of Alpha-L receptor on fresh blood PBL 
subsets; Fresh blood was collected from young or old subjects. Young subjects aged from 20-
35 whereas old subjects aged 60-75 years old.  Subjects were matched for sex, ethnicity, and 
BMI, Statin usage. PBL was isolated from fresh blood samples, stained, and gated on their 
forward/side scatter profile. Direct conjugated antibodies were used for staining. Alpha L 
expression was measured on the basis of the isotype control for each subset. Data is mean ± 
SEM (N=6) and the differences between groups were determined by using an independent 
sample t test. The probability values of less than 0.05 were considered significant (* = P ≤ 





Figure 4-17: MFI of Alpha-4 receptor on different subsets of PBL isolated from healthy 
donors.  
Flow cytometry was used to measure the MFI of Alpha-4 receptor on fresh blood PBL 
subsets; Fresh blood was collected from young or old subjects. Young subjects aged from 20-
35 whereas old subjects aged 60-75 years old.  Subjects were matched for sex, ethnicity, and 
BMI, Statin usage. PBL was isolated from fresh blood samples, stained, and gated on their 
forward/side scatter profile. Direct conjugated antibodies were used for staining. Alpha-4 
expression was measured on the basis of the isotype control for each subset. Data is mean ± 
SEM (N=6) and the differences between groups were determined by using an independent 
sample t test. The probability values of less than 0.05 were considered significant (* = P ≤ 








Figure 4-18: MFI of Beta-1 receptor on different subsets of PBL isolated from healthy 
donors.  
Flow cytometry was used to measure the MFI of Beta-1 receptor on fresh blood PBL subsets; 
Fresh blood was collected from young or old subjects. Young subjects aged from 20-35 
whereas old subjects aged 60-75 years old.  Subjects were matched for sex, ethnicity, and 
BMI, Statin usage. PBL was isolated from fresh blood samples, stained, and gated on their 
forward/side scatter profile. Direct conjugated antibodies were used for staining. Alpha L 
expression was measured on the basis of the isotype control for each subset. Data is mean ± 
SEM (N=6) and the differences between groups were determined by using an independent 
sample t test. The probability values of less than 0.05 were considered significant (* = P ≤ 









Figure 4-19: MFI of Beta-2 receptor on different subsets of PBL isolated from healthy 
donors.  
Flow cytometry was used to measure the MFI of Beta-2 receptor on fresh blood PBL subsets; 
Fresh blood was collected from young or old subjects. Young subjects aged from 20-35 
whereas old subjects aged 60-75 years old.  Subjects were matched for sex, ethnicity, and 
BMI, Statin usage. PBL was isolated from fresh blood samples, stained, and gated on their 
forward/side scatter profile. Direct conjugated antibodies were used for staining. Alpha-2 
expression was measured on the basis of the isotype control for each subset. Data is mean ± 
SEM (N=6) and the differences between groups were determined by using an independent 
sample t test. The probability values of less than 0.05 were considered significant (* = P ≤ 








Figure 4-20: MFI of PSGL-1 receptor on different subsets of PBL isolated from healthy 
donors.  
Flow cytometry was used to measure the MFI of PSGL-1 receptor on fresh blood PBL 
subsets; Fresh blood was collected from young or old subjects. Young subjects aged from 20-
35 whereas old subjects aged 60-75 years old.  Subjects were matched for sex, ethnicity, and 
BMI, Statin usage. PBL was isolated from fresh blood samples, stained, and gated on their 
forward/side scatter profile. Direct conjugated antibodies were used for staining. PSGL-1 
expression was measured on the basis of the isotype control for each subset. Data is mean ± 
SEM (N=6) and the differences between groups were determined by using an independent 
sample t test. The probability values of less than 0.05 were considered significant (* = P ≤ 








2.2.2.  Surface expression of chemokine receptors on fresh blood PBL from 
young or old controls 
 
With relation to the chemokine receptors surface expression, Figures 4-21, 4-22, 4-23 
showed the expression of chemokine receptors on PBL subsets in both young and old groups. 
Figure 4-21 shows an increase in the expression of CCR5 receptors in the older group when 
compared with the younger group, and this increase is significant on all subsets except 
memory CD8+ T cells and NK T cells. Figure 4-22 shows that old subjects have a higher 
surface expression of CXCR3 when compared to young subjects on all subsets except 
MCD8+ T cells. CX3CR1 receptors are highly expressed on all PBL subsets in old subjects 
compared to young subjects. It is also worth mentioning that in the case of CCR5 the increase 










Figure 4-21: MFI of CCR5 receptor on different subsets of PBL isolated from healthy 
donors.  
Flow cytometry was used to measure the MFI of CCR5 receptor on fresh blood PBL subsets; 
Fresh blood was collected from young or old subjects. Young subjects aged from 20-35 
whereas old subjects aged 60-75 years old.  Subjects were matched for sex, ethnicity, and 
BMI, Statin usage. PBL was isolated from fresh blood samples, stained, and gated on their 
forward/side scatter profile. Direct conjugated antibodies were used for staining. CCR5 
receptor expression was measured on the basis of the isotype control for each subset. Data is 
mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 




Figure 4-22: MFI of CXCR3 receptor on different subsets of PBL isolated from healthy 
donors.  
Flow cytometry was used to measure the MFI of CXCR3 receptor on fresh blood PBL 
subsets; Fresh blood was collected from young or old subjects. Young subjects aged from 20-
35 whereas old subjects aged 60-75 years old.  Subjects were matched for sex, ethnicity, and 
BMI, Statin usage. PBL was isolated from fresh blood samples, stained, and gated on their 
forward/side scatter profile. Direct conjugated antibodies were used for staining. CXCR3  
receptor expression was measured on the basis of the isotype control for each subset. Data is 
mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 









Figure 4-23: MFI of CX3CR1 receptor on different subsets of PBL isolated from healthy 
donors.  
Flow cytometry was used to measure the MFI of CX3CR1 receptor on fresh blood PBL 
subsets; Fresh blood was collected from young or old subjects. Young subjects aged from 20-
35 whereas old subjects aged 60-75 years old.  Subjects were matched for sex, ethnicity, and 
BMI, Statin usage. PBL was isolated from fresh blood samples, stained, and gated on their 
forward/side scatter profile. Direct conjugated antibodies were used for staining. CX3CR1 
receptor expression was measured on the basis of the isotype control for each subset. Data is 
mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 








2.3.  The effect of age on adhesion molecule and chemokine receptors expression on 
migrated PBL 
 
2.3.1. Surface expression of adhesion molecules on migrated PBL from young or 
old controls 
 
Our aim in this section was to investigate the effect of the process of leukocyte adhesion 
and transmigration on the same set of adhesion molecules and chemokine receptors on PBL 
subsets. Here the PBL was not freshly isolated from the donor and stained, but were collected 
after in vitro transmigration assay across cytokine stimulated DMEC.  
After transmigration, it appears that the surface expression of Alpha-L receptors has was 
dramatically different in young and old donors with the exception of B cells and CD8+ 
memory T cells (Figure 4-24).. Interestingly figure 4-25 shows a slightly higher level in the 
surface expression of Alpha-4 receptors on the B cells and CD8 T cells of the older subjects in 
comparison to the younger subjects.  It seems, therefore, that age might have some minor 
effects on activation dependent changes of Alpha-4 and Alpha-L expression on some 
lymphocyte subsets Similarly to Alpha-4, there was a difference in the surface expression of 
Beta-1 receptors on N CD4+ T cells, N CD8+ T and on M CD4+ T cells as illustrated on 
figure 4-26. The Beta-2 receptors in figure 4-27 show a higher level of expression in younger 
subjects in comparison to the older subjects. However in the case of PSGL-1, in figure 4-28 
shows marginal variations of expression. These experiments show there may be some 
differential in the activation dependent regulation of chemokine receptors and adhesion 
receptors with age. An analysis of this by calculating the percentage difference between blood 
borne and EC activated lymphocytes shows no difference on the surface expression as seen on 




Figure 4-24: MFI of Alpha-L receptor on different subsets of migrated PBL isolated 
from healthy donors.  
Flow cytometry was used to measure the MFI of Alpha L receptor on migrated PBL; Fresh 
blood was collected from young or old subjects. Young subjects aged from 20-35 whereas old 
subjects aged 60-75 years old.  Subjects were matched for sex, ethnicity, Statin drug usage 
and BMI. PBL collected from transmigration assay where PBL are added on DMEC and 
incubated for 7 minutes at 37°C. Then, TrypLE was used as cell-dissociation enzymes that 
make transmigrated PBL floating. The PBL was collected and stained with same panel of 
antibodies. PBL was stained, and gated on their forward/side scatter profile. Direct conjugated 
antibodies were used for staining. Alpha -L expression was measured on the basis of the 
isotype control for each subset. Data is mean ± SEM (N=6) and the differences between 
groups were determined by using an independent sample t test. The probability values of less 





Figure 4-25: MFI of Alpha-4 receptor on different subsets of migrated PBL isolated 
from healthy donors.  
Flow cytometry was used to measure the MFI of Alpha -4 receptor on migrated PBL; Fresh 
blood was collected from young or old subjects. Young subjects aged from 20-35 whereas old 
subjects aged 60-75 years old.  Subjects were matched for sex, ethnicity, Statin drug usage 
and BMI. PBL collected from transmigration assay where PBL are added on DMEC and 
incubated for 7 minutes at 37°C. Then, TrypLE was used as cell-dissociation enzymes that 
make transmigrated PBL floating. The PBL was collected and stained with same panel of 
antibodies. PBL was stained, and gated on their forward/side scatter profile. Direct conjugated 
antibodies were used for staining. Alpha -4 expression was measured on the basis of the 
isotype control for each subset. Data is mean ± SEM (N=6) and the differences between 
groups were determined by using an independent sample t test. The probability values of less 








Figure 4-26: MFI of Beta-1 receptor on different subsets of migrated PBL isolated from 
healthy donors.  
Flow cytometry was used to measure the MFI of Beta-1 receptor on migrated PBL; Fresh 
blood was collected from young or old subjects. Young subjects aged from 20-35 whereas old 
subjects aged 60-75 years old.  Subjects were matched for sex, ethnicity, Statin drug usage 
and BMI. PBL collected from transmigration assay where PBL are added on DMEC and 
incubated for 7 minutes at 37°C. Then, TrypLE was used as cell-dissociation enzymes that 
make transmigrated PBL floating. The PBL was collected and stained with same panel of 
antibodies. PBL was stained, and gated on their forward/side scatter profile. Direct conjugated 
antibodies were used for staining. Beta-1 expression was measured on the basis of the isotype 
control for each subset. Data is mean ± SEM (N=6) and the differences between groups were 
determined by using an independent sample t test. The probability values of less than 0.05 







Figure 4-27: MFI of Beta-2 receptor on different subsets of migrated PBL isolated from 
healthy donors.  
Flow cytometry was used to measure the MFI of Beta-2 receptor on migrated PBL; Fresh 
blood was collected from young or old subjects. Young subjects aged from 20-35 whereas old 
subjects aged 60-75 years old.  Subjects were matched for sex, ethnicity, Statin drug usage 
and BMI. PBL collected from transmigration assay where PBL are added on DMEC and 
incubated for 7 minutes at 37°C. Then, TrypLE was used as cell-dissociation enzymes that 
make transmigrated PBL floating. The PBL was collected and stained with same panel of 
antibodies. PBL was stained, and gated on their forward/side scatter profile. Direct conjugated 
antibodies were used for staining. Beta-2 expression was measured on the basis of the isotype 
control for each subset. Data is mean ± SEM (N=6) and the differences between groups were 
determined by using an independent sample t test. The probability values of less than 0.05 






Figure 4-28: MFI of PSGL-1 receptor on different subsets of migrated PBL isolated 
from healthy donors.  
Flow cytometry was used to measure the MFI of PSGL-1 receptor on migrated PBL; Fresh 
blood was collected from young or old subjects. Young subjects aged from 20-35 whereas old 
subjects aged 60-75 years old.  Subjects were matched for sex, ethnicity, Statin drug usage 
and BMI. PBL collected from transmigration assay where PBL are added on DMEC and 
incubated for 7 minutes at 37°C. Then, TrypLE was used as cell-dissociation enzymes that 
make transmigrated PBL floating. The PBL was collected and stained with same panel of 
antibodies. PBL was stained, and gated on their forward/side scatter profile. Direct conjugated 
antibodies were used for staining. PSGL-1 expression was measured on the basis of the 
isotype control for each subset. Data is mean ± SEM (N=6) and the differences between 
groups were determined by using an independent sample t test. The probability values of less 






Figure 4-29: Circulating PBL vs Endothelium recruited (EC-recruited) PBL in young 
subjects.  
Flow cytometry was used to measure the percentage of circulating PBL and EC-recruited 
PBL; Fresh blood was collected from young subjects. Young subjects aged from 20-35.  
Subjects were matched age, sex, ethnicity, and BMI. EC- recruited is the pool data for surface 
adherent PBL and migrated PBL. PBL was isolated, stained, and gated on their forward/side 
scatter profile. Data is mean ± SEM (N=6) and the differences between groups were 
determined by using an independent sample t test. The probability values of less than 0.05 









Figure 4-30: Circulating PBL vs Endothelium recruited (EC-recruited) PBL in old 
subjects.  
 
Flow cytometry was used to measure the percentage of circulating PBL and EC-recruited 
PBL; Fresh blood was collected from old subjects. Old subjects aged from 60-75.  Subjects 
were matched age, sex, ethnicity, and BMI. EC- recruited is the pool data for surface adherent 
PBL and migrated PBL. PBL was isolated, stained, and gated on their forward/side scatter 
profile. Data is mean ± SEM (N=6) and the differences between groups were determined by 
using an independent sample t test. The probability values of less than 0.05 were considered 









2.3.2. Surface expression of chemokine receptors expression on migrated PBL 
from young or old controls 
 
In the first analysis of the chapter (2.1) we observed a marked and highly significant 
down regulation of all chemokine receptors assayed upon activation by EC. Here we could 
see no significant differences in the levels of chemokine receptors down regulation with age. 
Thus both cohorts of donors effectively lost surface expression of CCR5, CXCR3, and 











Figure 4-31: MFI of CCR5 receptor on different subsets of migrated PBL isolated from 
healthy donors.  
Flow cytometry was used to measure the MFI of CCR5 receptor on migrated PBL; Fresh 
blood was collected from young or old subjects. Young subjects aged from 20-35 whereas old 
subjects aged 60-75 years old.  Subjects were matched for sex, ethnicity, Statin drug usage 
and BMI. PBL collected from transmigration assay where PBL are added on DMEC and 
incubated for 7 minutes at 37°C. Then, TrypLE was used as cell-dissociation enzymes that 
make transmigrated PBL floating. The PBL was collected and stained with same panel of 
antibodies. PBL was stained, and gated on their forward/side scatter profile. Direct conjugated 
antibodies were used for staining. CCR5 receptor expression was measured on the basis of the 
isotype control for each subset. Data is mean ± SEM (N=6) and the differences between 
groups were determined by using an independent sample t test. The probability values of less 









Figure 4-32: MFI of CXCR3 receptor on different subsets of migrated PBL isolated 
from healthy donors.  
Flow cytometry was used to measure the MFI of CXCR3 receptor on migrated PBL; Fresh 
blood was collected from young or old subjects. Young subjects aged from 20-35 whereas old 
subjects aged 60-75 years old.  Subjects were matched for sex, ethnicity, Statin drug usage 
and BMI. PBL collected from transmigration assay where PBL are added on DMEC and 
incubated for 7 minutes at 37°C. Then, TrypLE was used as cell-dissociation enzymes that 
make transmigrated PBL floating. The PBL was collected and stained with same panel of 
antibodies. PBL was stained, and gated on their forward/side scatter profile. Direct conjugated 
antibodies were used for staining. CXCR3 receptor expression was measured on the basis of 
the isotype control for each subset. Data is mean ± SEM (N=6) and the differences between 
groups were determined by using an independent sample t test. The probability values of less 






Figure 4-33: MFI of CX3CR1 receptor on different subsets of migrated PBL isolated 
from healthy donors.  
Flow cytometry was used to measure the MFI of CX3CR1 receptor on migrated PBL; Fresh 
blood was collected from young or old subjects. Young subjects aged from 20-35 whereas old 
subjects aged 60-75 years old.  Subjects were matched for sex, ethnicity, Statin drug usage 
and BMI. PBL collected from transmigration assay where PBL are added on DMEC and 
incubated for 7 minutes at 37°C. Then, TrypLE was used as cell-dissociation enzymes that 
make transmigrated PBL floating. The PBL was collected and stained with same panel of 
antibodies. PBL was stained, and gated on their forward/side scatter profile. Direct conjugated 
antibodies were used for staining. CX3CR1 receptor expression was measured on the basis of 
the isotype control for each subset. Data is mean ± SEM (N=6) and the differences between 
groups were determined by using an independent sample t test. The probability values of less 







2.4.  Enrichment ration of surface adherent and migrated PBL from young and old 
controls:  
 
The effects of ageing and activation on the levels of adhesion receptors and chemokine 
receptors expression are complex and vary widely between lymphocyte subs sets. We wanted 
to see if they had any functional consequences. To do this we analysed the enrichment ratio of 
surface adherent and transmigrated PBL. Thus, we divided the number of surface adherent 
cells or transmigrated cells in each subset by the total number of cells of that subset added to 
the assay. Figure 4-34 and 35 show that there is no clear and obvious difference in the ratios 









Figure 4-34: Enrichment ratio of migrated PBL in static condition:  
The enrichment ratio for each subset from each group has been calculated. Fresh blood was 
collected from young or old subjects. Young subjects aged from 20-35 whereas old subjects 
aged 60-75 years old. Subjects were matched sex, ethnicity, and BMI. PBL collected from 
transmigration assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. 
Then, TrypLE was used as cell-dissociation enzymes that make transmigrated PBL floating. 
The number of transmigrated cells in each subset was divided by the total number of cells of 
that subset added to the assay. Data is mean ± SEM (N=6) and the differences between groups 
were determined by using an independent sample t test. The probability values of less than 































































































Figure 4-35:  Enrichment ratio of surface adherent PBL in static condition:  
The enrichment ratio for each subset from each group has been calculated. Fresh blood was 
collected from young or old subjects. Young subjects aged from 20-35 whereas old subjects 
aged 60-75 years old. Subjects were matched sex, ethnicity, and BMI. PBL collected from 
transmigration assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. 
Then, TrypLE was used as cell-dissociation enzymes that make transmigrated PBL floating. 
The number of surface adherent cells in each subset was divided by the total number of cells 
of that subset added to the assay. Data is mean ± SEM (N=6) and the differences between 
groups were determined by using an independent sample t test. The probability values of less 










We studied the effect of old age on the surface expression of eight adhesion molecules and 
three chemokine receptors. Firstly, we looked at the expression on freshly isolated PBL. 
Then, using static adhesion assay, we looked at the expression on PBL which had 
transmigrated through stimulated EC and on PBL that had firmly adhered to the EC surface. 
We did this experiment to investigate the effect of the transmigration process on the 
expression of integrins and chemokine receptors on PBL. As mentioned above, the 
mechanism which involves leukocytes capturing and rolling is well understood, but the 
mechanisms involved in leukocyte transmigration through the endothelium is still unclear. 
Our data showed a loss of the expression of chemokines CCR5, CXCR3, and CX3CR1 
receptors upon activation by EC.  This result is consistent with the data which had been 
established in our lab previously (Ahmed et al., 2011). Ahmed et al suggested that the 
chemokine signal is a short lived signal which is required during leukocyte trafficking to 
activate β1 and β2 intergrins which subsequently activate the release of Prostaglandin D2 
(PGD2). At this point PGD2 takes over and induces the transmigration process (Ahmed et al., 
2011). The current understanding of lymphocyte trafficking suggests that chemokine 
signalling is delivered to promote integrin mediated adhesion which is followed by actin 
cytoskeleton reorganization which enables the lymphocytes to spread and transmigrate. So it 
seems that chemokine signalling is essential for integrin activation and stabilization of 
lymphocytes, but that this signal needs to be stopped in order for PGD2 to facilitate the 
transmigration processes. Certainly, our data showed the loss of chemokine signalling very 
soon after activation on the EC surface and on both surface adherent and migrated cells.  
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One way in which chemokine receptors are down-regulated is internalization. It is well 
established that the control of internalization and recycling is a multistep step process and also 
that it is a complicated one. Usually it starts with receptor-ligand interactions followed by 
down-regulation of certain receptors.  Thus, after chemokine- ligand binding, a 
transmembrane signal transduced via G protein-coupled receptors (GPCRs) promotes 
chemokine receptors uptake into endocytic vesicles, effectively deactivating the receptors. 
This explanation is supported by the findings by Ubogu et al (2006) who looked at the 
expression of CCR5 on monocytes and CD3+ T cells following CCL5 -driven transmigration 
through the blood brain barrier (BBB). The authors concluded that there was a noticeable 
down-regulation of CCR5 after transmigration (Ubogu et al., 2006). It should be noted that 
the migration through the BBB and through endothelium in other vascular beds is different 
due to the physiological and functional characteristics of these barriers. However, these 
author’s findings are in agreement with ours; showing down regulation of CCR5 after 
activation at the EC surface. An interesting aspect of our observations is the down regulation 
of a number of chemokine receptors (CXCR3, CCR5 and CXC3R1) even though lymphocyte 
activation in this model is largely driven through signalling through CXCR3 (Personal 
communication with Dr. McGettrick). This activation of one receptor is sufficient to drive 
internalisation of multiple surface receptors. 
After studying the chemokine receptor expression, we investigated the expression of 
adhesion molecules receptors after transmigration. In contrast to the down regulation of 
chemokine receptors we did not notice any dramatic regulation of adhesion molecules. This 
result was expected since those adhesion molecules receptors are needed in order to maintain 
and stabilize the adhesion; otherwise, lymphocytes would detach from EC. Our results concur 
with the data collected by Hourihan et al (1993) who reported that the expression of adhesion 
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molecules on lymphocytes is slightly altered apparently to increase the adhesiveness between 
lymphocyte and EC, (Hourihan et al., 1993). We also noticed an increase in the surface 
expression of Beta-1, Beta-2, Alpha-L, and Alpha-L receptors on a small number of subsets 
after transmigration which was an interesting observation. As we know from the literature that 
integrins modulate leukocyte crawling during adhesion cascade, but also that the integrin 
signal must then be attenuated in order to allow the transmigration process to start. Then, after 
the transmigration process is completed, the same signal is strengthened again to firmly 
adhere the leukocytes to EC (Barreiro and Sanchez-Madrid, 2009). So, we assume that the 
increase we noticed in integrin receptors expression reflects the strength of the integrin signal 
that is needed to keep PBL adhered to the EC.  
  Secondly, we looked at the effect of old age on the expression of adhesion molecules 
and chemokine receptors. The known slow deterioration of the immune system with age is 
called immunosenescence. Research has shown that every component of the immune system 
is negatively affected by age which in turn leads to functional impairment (Globerson and 
Effros, 2000). Many elucidations of the  aging process support the hypothesis of oxidative 
stress which contributes to this increasing cellular dysfunction due to imbalances in the 
cellular redox mechanism (Zou et al., 2003). We noticed an increased expression only in 
Alpha-L and Alpha-4. This increase was significantly high on two subsets: CD56 high NK 
cell and NK cells. From the perspective of the existing literature, data regarding  the effect of 
age on the expression of adhesion molecules and integrins receptors is conflicting. It has been 
suggested that there is an increase of adhesion molecules with age (Purschwitz et al., 2001) 
but data was challenged by another study by Nash et al which showed a decreased level of 
expression with age (Nash et al., 1996). Our data suggests a level of increase of expression 
with age only with Alpha-L and Alpha-4.  
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Regarding the Beta subunits of integrins molecules, we did not notice a significant 
change in the expression of β1 and β2 receptors, as mentioned above. In the case of the 
expression of PSGL-1, we found a decreased expression in the older age group. PSGL-1 is the 
most widespread P-selectin ligand on leukocytes and regulates leukocytes rolling. Current 
literature has shown that an over-expression of PSGL-1 is usually associated with diseases 
(Zarbock et al., 2009). For example, over expression of PSGL-1 has been noticed in patients 
with chronic obstructive pulmonary disease (COPD) (Schumacher et al., 2005). Moreover, it 
has also been reported in patients with MS (Engelhardt, 2009). These diseases are examples 
of the inflammatory response when it is over exuberant. The loss of PSGL-1 with age may 
indicate a deficiency in leukocyte recruitment which would be consistent with the increased 
incidence of opportunistic infections that are associated with age.  
Regarding chemokine receptors expression on fresh blood PBL, we documented that 
there is a noticeably higher expression of CCR5 and CX3CR1 receptors on some PBL subsets 
of older subjects. This increase in chemokine receptors expression in circulation could be an 
indication of uncontrolled inflammation which leads to higher susceptibility to inflammatory 
disease. In fact many reports have suggested an increase in the level of chemokine receptors 
and cytokines in circulation with age (Hu et al., 2004). Moreover mice studies have also 
shown that aged mice have higher expressions of chemokine receptors (Yung and Mo, 2003).  
In the case of the expression on migrated PBL and surface adherent PBL, we found 
that there is no old age associated observable difference in the expression of adhesion 
molecules?, but at the same time we revealed a dramatic down regulation of chemokines 
CCR5, CXCR3, and CX3CR1 in both groups.  
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Finally we wanted to look at the ability of PBL subsets to bind to endothelial, measured 
by an enrichment study. We did not notice clear and obvious differences in the ratios of the 
subsets that are recruited in old and younger donors which could be a result of technical 
problems because previous work in our? lab showed a significant enrichment ratio (personal 
communication with Dr. Myriam Chimen and Professor Ed Rainger). 
4. Conclusion 
 
From our data, we conclude that the chemokine receptors of CCR5, CXCR3, and 
CX3CR1 are down regulated during the transmigration process on the majority of PBL 
subsets. So it seems that chemokine signalling is essential for integrin activation and 
stabilization of lymphocytes, but that this signal needs to be stopped in order for PGD2 to 
facilitate transmigration processes. Further clarifying the regulation process which facilitates 
this may help in the development of antagonists for treating conditions involving chronic 
inflammation such as atherosclerosis or neuro-inflammation such as MS. Finally, the age 
related differences in the expression of adhesion molecules and integrins could be an 

















CHAPTER 5: STUDYING THE BEHAVIOUR OF PEPITEM AND 

















A novel peptide has been discovered in our lab. It is the Peptide inhibitor of trans-
endothelial migration called PEPITEM and inhibits T cell trafficking by a multistep 
mechanism (Chimen et al., 2015). The work in our lab shows that PEPITEM is released 
exclusively from B cells after they are stimulated by Adiponectin (AQ). After that PEPITEM 
binds to EC by Cadherin-15; this binding stimulates the release of a bioactive lipid mediator 
called sphingosine-1-phosphate. Since T cells express receptors for sphingosine-1-phosphate 
(S1PR1 and S1PR4), the release of S1P from EC inhibits T cell trafficking as it is well-
established that S1P is a key player in T cell trafficking. The finding is suggestive of high 
levels of S1P in circulation, where it has very high binding affinity for albumin and high 
density lipoprotein (HDL), and is considered to be the stem of S1P role in pathogenesis of 
atherosclerosis (Maceyka et al., 2012). There is a large variety of cells in which S1P has 
multiple effects which are pivotal to atherosclerosis development such as: activation of NF-
κB pathway resulting in pro inflammatory cytokines production, vascular tone, smooth 
muscle cell proliferation, and migration and attachment of monocytes (Daum et al., 2009).  
Sphingosine-1-phosphate (S1P) has an inhibitory and stimulatory effect on atherosclerosis 
because of the pleiotropic effect of sphingosine-1-phosphate (S1P) on  macrophages, SMCs 
and ECs which are the principle cells in atherosclerosis development (Wang et al., 2010). 
Macrophages/monocytes express the two major S1P receptor types, S1PR1 and S1PR2 
(Hughes et al., 2008). It has been illustrated by current studies that S1PR1 receptor 
stimulation by S1P containing HDL and S1P induces anti-inflammatory phenotypes, 
including the inhibition of pro inflammatory cytokine production in ECs and macrophages, 
and leucocyte adhesion (Hughes et al., 2008, Whetzel et al., 2006). Development of 
159 
 
atherosclerosis is inhibited in apolipoprotein E-deficient mice and by a phosphorylation 
product of FTY-720 which is considered as an agonist with high affinity for S1PR3, S1PR4, 
S1PR5, S1PR1 but not S1PR2 (Nofer et al., 2006) (Keul et al., 2007). Marked inhibition of 
atherosclerosis has been demonstrated in compound mutant mice deprived of S1PR2 and 
apoE (S1pr2-/-Apoe-/-mice) (Wang et al., 2010).  
After a long debate regarding the physiological significance of S1P binding to plasma 
albumin versus its transport in HDL, it has been suggested that S1P may be pro-atherogenic 
when localized in blood bound to albumin and anti-atherogenic when transported in HDL 
(SamarM. Hammad, 2012) (Alewijnse and Peters, 2008) (Okajima, 2002). It is most 
significant to note that in patients having coronary artery disease, S1P distribution between 
protein fraction of blood and plasma lipoprotein tends to be altered significantly (Sattler et al., 
2010).  
SIP and S1PR1, the main SIP receptors that are expressed on lymphocytes, are significant 
regulators of lymphocyte trafficking (Im et al., 2000). The migration of mature thymocytes 
from the thymus into blood and of T and B cells from the lymph nodes (LN) into the efferent 
lymph depends on signalling of the SIP1 receptor by SIP (Ikeda et al., 2004). A key role is 
performed by the circulation of T cells between blood and secondary lymphoid organs (SLO) 
regarding the development of the adaptive immune response. Naïve T cells develop in the 
thymus, and they migrate into the systematic circulation and re-circulate between blood and 
SLO looking for antigens  (Means and Brown, 2009). After antigen encounters in SLO, T 
cells obtain effector functions and then home to areas of inflammation to organize an 
immune-regulated reaction (Graeler et al., 2003). According to the existing evidence, with 
respect to antigen-specific activation within the LN, S1P1 receptors on T cells are rapidly 
down-regulated. Consequently, such cells show a lack of response to the egress signal created 
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by the prevailing SIP positive concentration gradient between lymphoid tissues and 
circulatory fluids and therefore stay in the LN (Wendler and Rivkees, 2006). Following their 
expansion and differentiation, effector T cells carry out up-regulation of SIPR1 expression 
and, as a reaction to the SIP gradient, progress through the sinus-lining endothelium into 
lymphatic sinuses, and then within the efferent lymph into the blood via the thoracic duct 
(Yatomi et al., 1997). SIP may also offer a further regulatory method for lymphocyte egress 
from the LN by signalling at the S1P1 receptors on sinus-lining endothelial cells (Okamoto et 
al., 1999). Selective SIP1 agonists, however, can restrict the transendothelial migration of T 
cells over the lymphatic endothelial barrier in the LN, without modifying cell motility 
(Kohama et al., 1998).  
2. Results 
 
 In this chapter we wanted to test the action of PEPITEM on PBL isolated from 
atherosclerosis patients. It is well known that atherosclerosis is characterised by prolonged 
PBL trafficking, so we designed an in vitro static adhesion assay, where isolated the PBL was 
put on stimulated EC and after a few minutes, PBL migration behaviour was studied. Based 
on previous studies our hypothesis was that if we treated PBL with PEPITEM, we would see 
a lower number of transmigrated PBL. Also, we wanted to measure the surface expression of 
AR1 and AR2 on B cells which are responsible for releasing PEPITEM in to the extracellular 
environment. In addition to the surface expression, we measured the gene expression of AR1 
and AR2 on PBMCs. Finally, we measured the serum level of AQ. Changes in any of these 




To conduct this experiment, we recruited Atherosclerosis patients (Athero patients) 
and healthy subjects and put them into two different groups (n=6). All subjects were matched 
for age, sex, ethnicity, BMI, illness, and Statin usage. See clinical parameters of the study on 
Table 4. These Subjects are healthy and not taking any medications which might affect our 
results.  
 Control subjects Atherosclerosis patients 
N 6 6 
AGE 68 70 
BMI 31 29 
Table 5-1: Clinical parameters of study subjects 
Data is represented as median (n=6); subjects were divided into two groups: control and 
atherosclerosis patients and subjects in both groups were matched for age, sex and ethnicity, 
BMI, Statin use.  
 
2.1.  In vitro static transmigration assay 
 
First, we looked at the effect of PEPITEM on the total levels of PBL adhesion. Figure (5-
1) shows that PEPITEM did not affect the levels of adhesion of PBL form either diseased or 
healthy donors. This is in agreement with our previous observations. Thereafter the effect of 
PEPITEM and AQ treatment on the migration of PBL was observed. Figure (5-2) shows that 
there was no effect of treatment on PBL isolated from atherosclerosis patients. However,  the 
treatment of PBL from healthy donors with AQ and PEPITEM inhibited the transmigration of 
PBL significantly, in line with our previously published responses to these agents. This is an 
extremely surprising and interesting observation because in other patient cohorts (e.g. Type-1 
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diabetics and rheumatoid arthritis patients) loss of the response to adiponectin can be rescued 
by addition of exogenous PEPITEM. However, in atherosclerosis patients this is not the case.  
2.2. Surface expression of AR1, AR2 on B cell isolated from atherosclerosis patients 
 
Briefly, a flow cytometry assay was used to investigate the surface expression of AR1 
and AR2 on B cells. PBL was freshly isolated from subjects and processed to isolate PBL 
from whole blood. Subsequently, PBL was stained with specific antibodies to identify 
each cell subset. Our analysis shows that the number of AR1 positive B cells was 
unchanged in patients (Figure 5-3). In addition there was no significant change in the MFI 
of positive cells comparing donor cohorts (Figure 5-4). There was a significant increase in 
the frequency of B cells positive for AR2 (Figure 5-5), although there was not an increase 
in the MFI of these positive cells (Figure 5-6).  
2.3. Levels of gene expression of AR1and AR2 in patients with atherosclerosis in 
healthy controls.  
 
PBMCs were isolated from blood and RNA was extracted to study the gene expression of 
AR1 and AR2 in PBMCs. Figure (5-7) shows the gene expression of AR1 and AR2 on both 
groups. The graph shows that gene expression for both receptors was unchanged in PBMCs 
isolated from atherosclerosis patients when compared to the control group. 
2.4. Levels of adiponectin in patients with atherosclerosis and in healthy controls. 
 
Serum isolated from atherosclerosis patients or healthy controls was assayed for levels of 
adiponectin using a commercial ELISA. Figure (5-8) shows that adiponectin levels in patients 
are significantly lower than in healthy controls. Indeed, patients are considered 
hypoadiponectinaemic when levels fall below 4g/ml. 
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2.5.  Surface expression of S1PR1 and SIPR4 on whole PBL subset: 
  
 To establish protocol, blood was taken from random donors and PBL’s were isolated and 
stained by direct conjugated antibodies to measure SIPR1 and SIPR4 on PBL subsets. Since 
SIPRs are expressed both on the surface and internally, we measured the expression 
accordingly both on the surface and internally. Our analysis shows that the receptors were 
widely expressed inside lymphocyte subsets. However, only circulating B cells and some NK 
subsets showed any marked expression of S1PR1on their surface, while S1PR4 was largely 
absent from the surface of circulating lymphocytes. (Figures 5-9, 5-10, 5-11, and 5-12).  
2.6. PBL binding on ICAM-SIPR1/4 expression:  
 
As the PBL of patients with atherosclerosis were refractory to the effects of PEPITEM, 
but had normal levels of AR1 and AR2 on their B cells, we hypothesised that an alternative 
defect was inhibiting responses to the pathway. We wondered if patient T cells were unable to 
respond to S1P. One way this might occur is by an inability of their T cells to express S1P 
receptors on the surface in response to inflammatory stimulation. We have previously assayed 
for this expression by inducing S1P receptor expression on T cells bound to ICAM-1 and 
stimulated by chemokines. Here we used a 16 well plate coated with ICAM-1 to bind 
lymphocytes, these were then activated by CXCL10 to induce the up-regulation of SIPR1 and 
SIPR4. Incubated, the PBL was collected by rough pipetting with cold PBS in FACS tube and 
then stained for flow cytometry. Unfortunately we were unable to demonstrate S1P receptor 
mobilisation using this assay, even in the T cell of healthy control donors. Furthermore, the 




Figure 5-1: Total adhesion of PBL from atherosclerosis patients or age match control.  
Static transmigration assay was used to calculate the total adhesion of PBL isolated from 
atherosclerosis patients and control subjects. Subjects were aged from 60-75 years old and 
they were matched for sex, ethnicity,  BMI, and Statin usage. DMEC were cultured in culture 
medium, and then stimulated with TNF-α/IFN-γ for 24 hours. First, PBL was either treated by 
Pepitem, scramble peptide, or AQ. Second, PBL was added to EC and the total adhesion was 
calculated. Data is mean ± SEM (N=6) and were analysed using one way Anova, with a 
Bonferroni post hoc test. The probability values of less than 0.05 were considered significant 







Figure 5-2: Transmigration percentage of PBL from atherosclerosis patients or age 
match control. 
Static transmigration assay was used to calculate the percentage of transmigration of PBL 
isolated from atherosclerosis patients and control subjects. Subjects were aged from 60-75 
years old and they were matched for sex, ethnicity,  BMI, and Statin usage. DMEC were 
cultured in culture medium, and then stimulated with TNF-α/IFN-γ for 24 hours. First, PBL 
was either treated by Pepitem, scramble peptide, or AQ. Second, PBL was added to EC and 
the percentage of transmigration was calculated. Data is mean ± SEM (N=6) and were 
analysed using one way Anova, with a Bonferroni post hoc test. The probability values of less 
than 0.05 were considered significant (* = P ≤ 0.05, **= P ≤ 0.01, *** = P ≤ 0.001). The 
effect of PEPITEM and AQ treatment on the migration of PBL was then considered. This 
figure shows that there was no effect of treatment on PBL isolated from atherosclerosis 
patients. However,   the treatment of PBL from healthy donors with AQ and PEPITEM 
inhibited the transmigration of PBL significantly, in line with our previously published 
responses to these agents. This is an extremely surprising and interesting observation because 
in other patient cohorts (e.g. Type-1 diabetics and rheumatoid arthritis patients) loss of the 
response to adiponectin can be rescued by addition of exogenous PEPITEM. However, in 






Figure 5-3: ARs frequency on B cells from atherosclerosis patients or age match control.  
Flow cytometry was used to measure the frequency of AR1 and AR2; PBL was isolated from 
atherosclerosis patients or age match control. . Subjects were aged from 60-75 years old and 
they were matched for sex, ethnicity,  BMI, and Statin usage. Fresh blood samples, stained, 
then gated on their forward/side scatter profile. CD19 antibody was used to identify B cells. 
ARs receptors expression was measured on the basis of the isotype control for each subset. 
Data is mean ± SEM (N=6) and the differences between groups were determined by using an? 
independent sample t test. The probability values of less than 0.05 were considered significant 










Figure 5-4: ARs frequency on B cells from atherosclerosis patients or age match control.  
Flow cytometry was used to measure the MFI of AR1 and AR2; PBL was isolated from 
atherosclerosis patients or age match control. . Subjects were aged from 60-75 years old and 
they were matched for sex, ethnicity,  BMI, and Statin usage. Fresh blood samples were 
stained, then gated on their forward/side scatter profile. CD19 antibody was used to identify B 
cells. ARs receptors expression was measured on the basis of the isotype control for each 
subset. Data is mean ± SEM (N=6) and the differences between groups were determined by 
using an independent sample t test. The probability values of less than 0.05 were considered 










Figure 5-5: AR1/2 gene expression on PBMCs from atherosclerosis patients or age 
match control.  
qPCR was used to measure the gene expression of AR1/2 on PBMCs from atherosclerosis 
patients or age match control. Subjects were aged from 60-75 years old and they were 
matched for sex, ethnicity,  BMI, and Statin usage. PBMCs were isolated from fresh blood 
samples and gene expression was measured and quantified using qPCR. Data is mean ± SEM 
(N=6) and the differences between groups were determined by using an independent sample t 
test. The probability values of less than 0.05 were considered significant (* = P ≤ 0.05, **= P 











Figure 5-6: Circulating AQ levels in atherosclerosis patients or age match control.  
The ELISA technique was used to measure the Circulating levels of Adiponectin in 
atherosclerosis patients or age match control. Subjects were aged from 60-75 years old and 
they were matched for sex, ethnicity,  BMI, and Statin usage. ELISA kit and the numeric 
values were calculated using a standard curve as described by the manufacture protocol.  Data 
is mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 










Figure 5-7: Surface expression of SIPR1 on fresh PBL subsets from random healthy 
donors. 
Flow cytometry was used to measure the frequency of SIPR1 receptor on fresh blood PBL; 
blood was collected from random donors and PBL surface staining figures represent the 
surface expression of the receptors whereas PBL- intracellular staining represents the 
intracellular expression of receptors. Data is mean ± SEM (N=6). Since the experiment did 









Figure 5-8: Surface expression of SIPR1 on fresh PBL subsets from random healthy 
donors. 
Flow cytometry was used to measure the MFI of SIPR1 receptor on fresh blood PBL; blood 
was collected from random donors and PBL surface staining figures represent the surface 
expression of the receptors whereas PBL- intracellular staining represents the intracellular 
expression of receptors. Data is mean ± SEM (N=6). Since the experiment did not work as 









Figure 5-9: Surface expression of SIPR4 on PBL subsets from random healthy donors. 
Flow cytometry was used to measure the frequency of SIPR4 receptor on fresh blood PBL; 
blood was collected from random donors and PBL surface staining figures represent the 
surface expression of the receptors whereas PBL- intracellular staining represents the 
intracellular expression of receptors. Data is mean ± SEM (N=6). Since the experiment did 









Figure 5-10: Surface expression of SIPR4 on PBL subsets from random healthy donors. 
 Flow cytometry was used to measure the MFI of SIP4 receptor on fresh blood PBL; blood 
was collected from random donors and PBL surface staining figures represent the surface 
expression of the receptors whereas PBL- intracellular staining represents the intracellular 
expression of receptors. Data is mean ± SEM (N=6). Since the experiment did not work as 










Figure 5-11: The frequency of SIPR1 receptor on migrated PBL of random healthy 
donors using ICAM surface. 
Static adhesion assay was used to measure the frequency of the up-regulation SIPR1 on the 
surface of PBL after binding to I-CAM. PBL-0 represents PBL without any treatment. PBL-
IP10 represents PBL treatment with IP10.  Data is mean ± SEM (N=6) and the differences 
between groups were determined by using an independent sample t test. The probability 
values of less than 0.05 were considered significant (* = P ≤ 0.05, **= P ≤ 0.01, *** = P ≤ 











Figure 5-12: The MFI of SIPR1 receptor on migrated PBL of random healthy donors 
using ICAM surface.  
Static adhesion assay was used to measure MFI of the up-regulation SIPR1 on the surface of 
PBL after binding to I-CAM. PBL-0 represents PBL without any treatment; PBL-IP10 
represents PBL treatment with IP10. Data is mean ± SEM (N=6) and the differences between 
groups were determined by using an independent sample t test. The probability values of less 
than 0.05 were considered significant (* = P ≤ 0.05, **= P ≤ 0.01, *** = P ≤ 0.001). Since the 











Figure 5-13: The frequency of SIPR4 receptor on migrated PBL of random healthy 
donors using ICAM surface. 
Static adhesion assay was used to measure the frequency of the up-regulation SIPR4 on the 
surface of PBL after binding to I-CAM. PBL-0 represents PBL without any treatment; PBL-
IP10 represents PBL treatment with IP10.  Data is mean ± SEM (N=6) and the differences 
between groups were determined by using an independent sample t test. The probability 
values of less than 0.05 were considered significant (* = P ≤ 0.05, **= P ≤ 0.01, *** = P ≤ 












Figure 5-14: The MFI of SIPR4 receptor on migrated PBL of random healthy donors 
using ICAM surface. 
Static adhesion assay was used to measure the frequency of the up-regulation SIPR4 on the 
surface of PBL after binding to I-CAM. PBL-0 represents PBL without any treatment, PBL-
IP10 represents PBL treatment with IP10.  Data is mean ± SEM (N=6) and the differences 
between groups were determined by using an independent sample t test. The probability 
values of less than 0.05 were considered significant (* = P ≤ 0.05, **= P ≤ 0.01, *** = P ≤ 













In this chapter we discuss the effect on migration of treating PBL which have been 
isolated from atherosclerosis patients (Athero patients) with PEPITEM or AQ. Firstly, when  
looking at the total adhesion of PBL; we noticed no significant change in the number of PBL 
adhering to the endothelium when these were isolated from patients with atherosclerosis.. 
Studies on mouse atherosclerotic aortas have shown that lymphocyte  adhesion is affected by 
lesion topology and  depends of VCAM-1 expression on the atherosclerotic lesions (Moller et 
al., 2005). Moreover, studies using targeted mutations to E or P selectins or adhesion 
molecules such as ICAM-1, chemokines such as MCP-1 and their receptors, suggested that 
leukocyte recruitment in the case of atherosclerosis is mediated by their actions (Rosenfeld, 
2002).  
Furthermore, we planned to investigate the effect of the treatment of PBL isolated from 
atherosclerosis patients with PEPITEM and AQ. Interestingly, PBL isolated from 
atherosclosis patients did not show any sign of inhibition of transmigration after treatment, 
whereas PBL isolated from healthy controls showed a significant inhibition of transmigration 
after treatment with either agent. Previous work in our lab studied the effect of PEPITEM and 
AQ treatment on PBL isolated from patients with type 1diabetes (T1D). The behaviour of 
PBL in response to AQ was lost in these patients. The molecular basis of this deficiency was 
loss of ARs on B cells, leading to loss of PEPITEM release in response to AQ stimulation.  
Importantly, regulation of T cell trafficking could be restored with exogenous PEPITEM. 
(Chimen et al., 2015). Interesting, exactly the same defect was evident in patients with 
rheumatoid arthritis. Thus in both T1D and RA, T cell migration was defective on the same 
basis, and it is therefore  extremely interesting that in atherosclerosis, although there is a loss 
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of response to AQ, this cannot be rescued with PEPITEM and does not appear to be due to the 
same changes observed in T1D or RA. 
Thus, in our study, PEPITEM and AQ did not have any obvious effect on the migration of 
PBL which may suggest that the signal downstream of PEPITEM release from B cells was 
likely to have been lost or impaired. As mentioned above, PEPITEM works by binding to 
cadherin-15 on EC which activates the synthesis and the release of SIP. Following this, SIP 
binds to its receptors SIPR1 and SIPR4 on T cells? to inhibit T cell transmigration.  We 
subsequently hypothesized that SIP production or the signalling from S1PR might be 
defective.   
We therefore focused our work on SIP and SIP receptors. As a result, we aimed to 
develop an assay enabling us to measure the up-regulation of SIPR1 and SIPR4 on PBL 
surfaces? which would enable us to measure their expression on atherosclerosis patients’ 
PBL. The first step was characterising SIPR1 and SIPR4 expression on PBL, since these 
receptors are expressed internally and externally,  expressions were measured in both pools. 
SIP receptors are widely expressed internally but show only very limited expression 
externally; meaning we wanted to develop an assay to stimulate the surface expression of the 
receptors which would allow us to measure this expression on atherosclerosis patients and 
then compare that to the healthy control. For that reason, we wanted PBL to bind to ICAM-1 
and anticipated that this binding in association with stimulation with chemokine CXCL10, 
would increase SIPR1 and SIPR4 on the surface. Indeed, we have reported positive results 
from this assay previously. Unfortunately only very low surface expression was achieved. It is 
possible that SIPRs were up-regulated, but because of the high SIP concentration in the 
medium (in the serum), the surface expression was down-regulated very quickly (Ikeda et al., 
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2004). So, another assay needed to be developed to enable us to measure SIPRs’ expression 
on the surface.  
For flow cytometry analysis, we measured the expression of AR1 and AR2 on B cells 
because PEPITEM is produced from this source. We actually saw no change of these 
receptors on the B cells from atherosclerosis patients when compared to healthy donors. A 
higher expression of AR1 and AR2 is usually associated with healthy individuals and loss of  
the receptors has been reported in diseases such as RA and T1D (Kadowaki et al., 2006). Here 
however, the expression of AR1 and AR2 on B cells did not change in either groups. Clearly 
the pathogenesis of these diseases varies markedly, but it is interesting that the PEPITEM 
system, although deregulated in all 3 diseases, does not demonstrate the same molecular basis 
of deficiency.  
We also looked at the gene expression of AR1 and AR2 on PBMCs as this has been 
shown to be a sensitive marker for changes in disease. The gene expression in the 
atherosclerosis group compared to the healthy group was unchanged. Moreover, previous 
studies from unpublished work by Dr. Helen McGettrick in our lab showed the same pattern 
of the gene expression of AR1 and AR2 in arthritis patients.  
Most interestingly AQ serum levels in atherosclerosis patients are significantly lower 
compared to the healthy control. As mentioned above existing literature has concluded 
that any AQ serum level less than 4 µg/ ml can indicate hypoadiponectinemia. Our data 
shows AQ serum levels as 4.4 µg/ ml which is very close to the cut-off value for 
hypoadiponectinemia whereas AQ serum levels in the healthy group is 11.1 µg/ ml. This 
value is consistent with other data which shows hypoadiponectinemia is associated with 
T1D and atherosclerosis (Weyer et al., 2001).   
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It’s worth mentioning however, that there are some studies which show a decrease in 
the surface expression of AR1 and AR2 in T1D. Kollias et al measured the expression of 
AR1 and AR2 on monocytes from a patient with coronary artery disease and  reported a 
decrease of the surface expression (Kollias et al., 2011). So, there is no general consensus 
about the gene or surface expression of AR1 and AR2 in case of diseases.  Additionally 

















4. Conclusion  
 
Since PEPITEM is a novel peptide discovered in our lab; this is the first time to our 
knowledge, that the effect of PEPITEM and AQ on PBL isolated from Atherosclerosis 
patients has been reported. We  demonstrated for the first time that the AQ-pepitem 
pathway is impaired in these patients. In addition, we have reported that the surface 
expression and the gene expression of AR1 and AR2 is unchanged in atherosclerosis 
patients Furthermore, in contrast to genetic analysis and flow cytometry analysis, the AQ 























CHAPTER 6: STUDYING THE EFFECT OF ATHEROSCLEROSIS 
















The recruitment of inflammatory cells present in blood and their subsequent migration in a 
transendothelial manner is one of the initial steps in the progression of atherosclerosis. The 
cellular adhesion molecules which are involved in regulating this function are upregulated by 
inflammatory substances acting on the vascular endothelium, and on circulating leukocytes 
the importance of adhesion molecules in the development of atherosclerosis and plaque 
stability, however, has been demonstrated through a number of evidential studies. On 
atherosclerotic plaques, VCAM-1, ICAM-1 and E-selectin have been consistently observed 
(Blankenbrg et al., 2003). Studies provide proof soluble versions of these molecules, e.g. 
sICAM-1 sVCAM-1 in the blood is associated with high risk of developing cardiovascular 
disease or can be found in CAD patients (Blankenbrg et al., 2003).  
1.1.  Adhesion molecules and Integrins  
 
Adhesion molecules are expressed with distinct patterns. For example L-selectin is 
constitutively expressed most leukocytes, P-selectin is found in granule stores in endothelium 
and in platelets and can be rapidly (minutes) mobilised on the surface of the cell after 
activation (Smith, 2008). E-selectin and VCAM-1 are transcriptionally unregulated upon 
endothelial cell activation by cytokines and other inflammatory agonists (Olofsson et al., 
1994). The processes supporting  down-regulation of  these molecules are essential to 
terminate inflammatory processes; it is vital for them to be removed from the surface of the 
cell after the activation otherwise inflammation can become a chronic process (Blankenbrg et 
al., 2003). Selectin molecules and VCAM-1 are eliminated from the cell surface after 
activation of the cell though the process of internalisation and lysosomal targeting (P- and E-
selectin) or by shedding by proteolytic cleavage (Blankenbrg et al., 2003). It is this processes 
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that produces soluble forms of the adhesion molecules, which can be measured in the blood 
(Hafezi-Moghadam et al., 2001). P-selectin glycoprotein ligand (PSGL-1) is the most 
important ligand for P-selectin because it has more affinity to P selectins on myeloid cells 
(Borges et al., 1997). It is displayed on the  leukocyte surface, specifically on microvillous 
tips (Sako et al., 1994).  
Integrin molecules are hetrodimeric proteins made of α chain and β chain. There is 
complexity in their patterns of association with many α and β chains demonstrating 
promiscuity in their associating partners. For example, β1 integrin, may be linked to any of 12 
α chains (Blankenbrg et al., 2003). The function of integrins is regulated by their confirmation 
state which can be regulated by cellular activation. Their nature in resting cells is mostly non-
adhesive, due to the low affinity interactions that occur with ligands. As a result of variations in 
their confirmation which is directly associated with the activation of these cells, this affinity 
increases.. This process of regulated integrin activity is based on inside-out signalling to these 
receptors (Blankenbrg et al., 2003).  
Intergins are also capable of providing outside-in signals following ligand binding (Faull 
and Ginsberg, 1996). The important aspect here, are the leukocyte integrins that support 
leukocyte trafficking. Beta-2 integrins are exclusively displayed only in white blood cells and 
they are particularly important for the trafficking of these cells  (Rodriguez et al., 1996).  
During this process they can interact with endothelial counter receptors such as ICAM-1 as 
well as matrix proteins in the vessel wall and the tissue, which allow leukocytes to migrate in 
these environments (Lynam et al., 1998). Soluble adhesion molecules may have utility  as 
biomarkers for CAD (Gearing and Newman, 1993). The soluble forms increase in the 
circulation in association with a number of cardiovascular risk factors, such as smoking 
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(Blann et al., 1997), hypercholesterolemia  and/or hypertriglyceridemia. (Hackman et al., 
1996) (Lupattelli et al., 2000).  
Soluble ICAM-1 and soluble VCAM-1 and proatherogenic lipid profiles are considered 
markers for CVD (Ridker et al., 2000). Statin therapy was discovered to decrease the soluble 
adhesion molecules soluble ICAM-1 and soluble P-selectin (Blann et al., 2001). Soluble 
adhesion molecules have also been proposed to be biohumoral markers for disease severity in  
atherosclerosis (Blann and McCollum, 1994), and carotid intima-media thickness correlates to 
the levels of sVCAM-1 and sICAM-1(Rohde et al., 1998).   
1.2.  Chemokines and Atherosclerosis 
 
In atherosclerosis chemokines are involved in the recruitment of leukocytes into 
atherosclerotic plaques (Burke-Gaffney et al., 2002). These are a super family of proteins 
which are structurally associated with a molecular weight of 8-10 kDa. (Baggiolini et al., 
1997). Based on the distance between the first two of four conserved cysteine residues, the 40 
or more chemokines so far identified can be categorized into four groups (Burke-Gaffney et 
al., 2002). The CC, CXC, CX3C, XC chemokines. It has been observed that chemokines 
stimulate leukocyte activation  through seven transmembrane domain G protein-coupled cell-
surface receptors present on target cells (Braunersreuther et al., 2007).  The chemokine 
receptor is responsible for regulating the chemokine’s biological functions.  There is 
promiscuity in the ligand receptor interactions of chemokines with for example several 
chemokines forming bonds with one receptor, or one receptor binding more than one 
chemokine ligand (Burke-Gaffney et al., 2002). In atherosclerosis, the major roles of 
chemokines is to regulate leukocyte extravasation (Reape et al., 1999) and studies in mice 
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with genetic deletion of chemokines or their receptors show reduced burden of atherosclerotic 
disease (Wan et al., 2013) .   
There are no antichemokine therapeutic interventions currently accessible to treat 
atherosclerosis. Despite this, in clinical use a number of agents, such as the lipid-lowering 
statins and insulin-sensitizer glitazones, regulate the appearance of chemokines and these 
present potential in development of drugs (Ray et al., 2006).  
2. Results 
2.1.  Surface expression of adhesion molecule receptors on PBL from patients with 
atherosclerosis or age matched controls 
 
The aim of this chapter was to compare the surface expression of adhesion molecules and 
chemokine receptors on the PBL of atherosclerosis patients and compare this to age-matched 
healthy control subjects. We used the same two cohorts we had recruited in the previous 
chapter (Chapter 5). Here we have shown MFI as measure of expression. The percentage of 
positive cells for each receptor measured can also be found in the appendix section. We did 
not include the data of the surface expression of both adhesion molecules and chemokine 
receptors on surface adherent PBL, as it was not deemed necessary to mention the difference 
from the results for transmigrated PBL as these were essentially the same as the expression 
patterns on migrated cells. This data is not included in the appendix section to avoid 
distracting the reader and to follow the guidelines of the thesis word limit.  
The surface expression of Alpha-L receptors was generally the same between cohorts, 
however there was a significantly lower expression on naïve CD8 T cells in patients. There 
was also a marked reduction in expression on some NK populations in patients (Figure 6-1). 
Figure (6-2) shows Alpha-4 receptor surface expression; the expression was significantly 
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higher on NK cells in healthy subjects, whereas the expression on other subsets was similar. 
The surface expression of Beta-receptor family (Beta-1 and Beta-2) was significantly higher 
in some PBL subsets in atherosclerosis patients (Figure 6-3, 6-4). The same trend of increase 
expression in atherosclerosis patients was seen in the case of PSGL-1 receptors on some 
subsets (figure 6-5). In general these significant increases in some PBL subsets indicates an 
increase in the expression of capture receptors such as PSGL-1 and a shift in integrin from 
alpha4/B1 to a beta-2 dominated expression, although this was most consistently marked in 












Figure 6-1: MFI of Alpha-L receptor on different subsets of PBL isolated from 
atherosclerosis patients or age match control.  
Flow cytometry was used to measure the MFI of Alpha-L receptors? on fresh blood PBL 
subsets. Fresh blood was collected from atherosclerosis patients or age match control subjects 
aged from 60-75. Subjects were matched for age, sex, ethnicity, BMI, and Statin usage. PBL 
was isolated from fresh blood samples, stained, and gated on their forward/side scatter profile. 
Direct conjugated antibodies were used for staining. Alpha L expression was measured on the 
basis of the isotype control for each subset. Data is mean ± SEM (N=6) and the differences 
between groups were determined by using an independent sample t test. The probability 










Figure 6-2: MFI of Alpha-4 receptor on different subsets of PBL isolated from 
atherosclerosis patients or age match control.  
Flow cytometry was used to measure the MFI of Alpha-4 receptor on fresh blood PBL 
subsets. Fresh blood was collected from atherosclerosis patients or age match control subjects 
aged from 60-75. Subjects were matched for age, sex, ethnicity, BMI, and Statin usage. PBL 
was isolated from fresh blood samples, stained, and gated on their forward/side scatter profile. 
Direct conjugated antibodies were used for staining. Alpha-4 receptor expression was 
measured on the basis of the isotype control for each subset. Data is mean ± SEM (N=6) and 
the differences between groups were determined by using an independent sample t test. The 
probability values of less than 0.05 were considered significant (* = P ≤ 0.05, **= P ≤ 0.01, 










Figure 6-3: MFI of Beta-1 receptor on different subsets of PBL isolated from 
atherosclerosis patients or age match control.  
Flow cytometry was used to measure the MFI of Beta-1 receptor on fresh blood PBL subsets. 
Fresh blood was collected fromatherosclerosis patients or age match control subjects aged 
from 60-75. Subjects were matched for age, sex, ethnicity, BMI, and Statin usage. PBL was 
isolated from fresh blood samples, stained, and gated on their forward/side scatter profile. 
Direct conjugated antibodies were used for staining. Beta-1 receptor expression was measured 
on the basis of the isotype control for each subset. Data is mean ± SEM (N=6) and the 
differences between groups were determined by using an independent sample t test. The 
probability values of less than 0.05 were considered significant (* = P ≤ 0.05, **= P ≤ 0.01, 








Figure 6-4: MFI of Beta-2 receptor on different subsets of PBL isolated from 
atherosclerosis patients or age match control.  
Flow cytometry was used to measure the MFI of Beta-2 receptor on fresh blood PBL subsets; 
Fresh blood was collected from  atherosclerosis patients or age match control subjects aged 
from 60-75. Subjects were matched for age, sex, ethnicity, BMI, and Statin usage. PBL was 
isolated from fresh blood samples, stained, and gated on their forward/side scatter profile. 
Direct conjugated antibodies were used for staining. Beta-2 receptor expression was measured 
on the basis of the isotype control for each subset. Data is mean ± SEM (N=6) and the 
differences between groups were determined by using an independent an sample t test. The 
probability values of less than 0.05 were considered significant (* = P ≤ 0.05, **= P ≤ 0.01, 










Figure 6-5: MFI of PSGL-1 receptor on different subsets of PBL isolated from 
atherosclerosis patients or age match control.  
Flow cytometry was used to measure the MFI of PSGL-1 receptor on fresh blood PBL 
subsets. Fresh blood was collected from  atherosclerosis patients or age match control subjects 
aged from 60-75. Subjects were matched for age, sex, ethnicity, BMI, and Statin usage. PBL 
was isolated from fresh blood samples, stained, and gated on their forward/side scatter profile. 
Direct conjugated antibodies were used for staining. PSGL-1 receptor expression was 
measured on the basis of the isotype control for each subset. Data is mean ± SEM (N=6) and 
the differences between groups were determined by using an independent sample t test. The 
probability values of less than 0.05 were considered significant (* = P ≤ 0.05, **= P ≤ 0.01, 








2.2.  Surface expression of chemokine receptors on fresh PBL from atherosclerosis 
patients or age matched controls.  
 
 In this section we looked at chemokine receptors expression on PBL subsets. We put 
them into a separate section because in the literature they are classified as a distinct family, 
and their activation, down-regulation and role in leukocyte trafficking is different from that of 
adhesion molecules.  We used the same PBL subsets markers we had used for adhesion 
molecules; we observed that there was a large degree of variation within populations of 
donors for both CCR5 and CXCR3 receptors. However, there was a strong trend for lower 
expression of these receptors in patients and this was significant for some subsets. Again 
changes in NK cell populations seemed most consistent (Figure 6-6, 6-7). Surprisingly, the 
expression of fractalkine receptor (CX3CR1) showed a reciprocal response and was in general 







Figure 6-6: MFI of CCR5 receptor on different subsets of PBL isolated from 
atherosclerosis patients or age match control.  
Flow cytometry was used to measure the MFI of CCR5 receptor on fresh blood PBL subsets. 
Fresh blood was collected from  atherosclerosis patients or age match control subjects aged 
from 60-75. Subjects were matched for age, sex, ethnicity, BMI, and Statin usage. PBL was 
isolated from fresh blood samples, stained, and gated on their forward/side scatter profile. 
Direct conjugated antibodies were used for staining. CCR5 receptor expression was measured 
on the basis of the isotype control for each subset. Data is mean ± SEM (N=6) and the 
differences between groups were determined by using an independent sample t test. The 
probability values of less than 0.05 were considered significant (* = P ≤ 0.05, **= P ≤ 0.01, 











Figure 6-7: MFI of CXCR3 receptor on different subsets of PBL isolated from 
atherosclerosis patients or age match control.  
Flow cytometry was used to measure the MFI of CXCR3 receptor on fresh blood PBL 
subsets. Fresh blood was collected from atherosclerosis patients or age match control subjects 
aged from 60-75. Subjects were matched for age, sex, ethnicity, BMI, and Statin usage. PBL 
was isolated from fresh blood samples, stained, and gated on their forward/side scatter profile. 
Direct conjugated antibodies were used for staining. CXCR3 receptor expression was 
measured on the basis of the isotype control for each subset. Data is mean ± SEM (N=6) and 
the differences between groups were determined by using an independent an sample t test. 
The probability values of less than 0.05 were considered significant (* = P ≤ 0.05, **= P ≤ 










Figure 6-8: MFI of CX3CR1 receptor on different subsets of PBL isolated from 
atherosclerosis patients or age match control.  
Flow cytometry was used to measure the MFI of CX3CR1 receptor on fresh blood PBL 
subsets. Fresh blood was collected from atherosclerosis patients or age match control subjects 
aged from 60-75. Subjects were matched for age, sex, ethnicity, BMI, and Statin usage. PBL 
was isolated from fresh blood samples, stained, and gated on their forward/side scatter profile. 
Direct conjugated antibodies were used for staining. CX3CR1 receptor expression was 
measured on the basis of the isotype control for each subset. Data is mean ± SEM (N=6) and 
the differences between groups were determined by using an independent an sample t test. 
The probability values of less than 0.05 were considered significant (* = P ≤ 0.05, **= P ≤ 








2.3. Surface expression of adhesion molecules receptors on migrated PBL from 
patients atherosclerosis or age matched controls 
 
The following graphs show the expression of the same set of adhesion molecules on PBL 
that were collected after in vitro transmigration assay (see Chapter 2 for a detailed protocol). 
The data analysis shows that the expression of Alpha-L receptors on PBL subsets after 
transmigration is higher in atherosclerosis patients compared to the healthy controls (figure 6-
9). However, the same pattern was not seen in the case of Alpha-4 receptors; in fact the 
surface expression was almost equal and there was only a small variation on some subsets 
(figures 6-10). Both the Beta receptors family (Beta-1 and Beta-2) and PSGL-1 surface 







Figure 6-9: MFI of Alpha-L receptor on different subsets of migrated PBL isolated from 
atherosclerosis patients or age match control.  
Flow cytometry was used to measure the MFI of Alpha L receptors. Fresh blood was 
collected from atherosclerosis patients or age match control subjects aged from 60-75. 
Subjects were matched for age, sex, ethnicity, BMI, and Statin usage. PBL collected from 
transmigration assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. 
TrypLE was subsequently used as cell-dissociation enzymes that make transmigrated PBL 
floating. The PBL was collected and stained with same antibodies panel. PBL was stained, 
and gated on their forward/side scatter profile. Direct conjugated antibodies were used for 
staining.  The Alpha L receptor expression was measured on the basis of the isotype control 
for each subset. Data is mean ± SEM (N=6) and the differences between groups were 
determined by using an independent sample t test. The probability values of less than 0.05 









Figure 6-10: MFI of Alpha-4 receptor on different subsets of migrated PBL isolated 
from atherosclerosis patients or age match control.  
Flow cytometry was used to measure the MFI of Alpha-4 receptors. Fresh blood was 
collected from atherosclerosis patients or age match control subjects aged from 60-75. 
Subjects were matched for age, sex, ethnicity, BMI, and Statin usage. PBL collected from 
transmigration assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. 
TrypLE was subsequently used as cell-dissociation enzymes that make transmigrated PBL 
floating. The PBL was collected and stained with same antibodies panel. PBL was stained, 
and gated on their forward/side scatter profile. Direct conjugated antibodies were used for 
staining.  The Alpha-4 receptor expression was measured on the basis of the isotype control 
for each subset. Data is mean ± SEM (N=6) and the differences between groups were 
determined by using an independent sample t test. The probability values of less than 0.05 








Figure 6-11: MFI of Beta-1 receptor on different subsets of migrated PBL isolated from 
atherosclerosis patients or age match control.  
Flow cytometry was used to measure the MFI of Beta-1 receptors. Fresh blood was collected 
from atherosclerosis patients or age match control subjects aged from 60-75. Subjects were 
matched for age, sex, ethnicity, BMI, and Statin usage. PBL collected from transmigration 
assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. TrypLE was 
subsequently used as cell-dissociation enzymes that make transmigrated PBL floating. The 
PBL was collected and stained with same antibodies panel. PBL was stained, and gated on 
their forward/side scatter profile. Direct conjugated antibodies were used for staining.  The 
Beta-1 receptor expression was measured on the basis of the isotype control for each subset. 
Data is mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 









Figure 6-12: MFI of Beta-2 receptor on different subsets of migrated PBL isolated from 
atherosclerosis patients or age match control.  
Flow cytometry was used to measure the MFI of Beta-2 receptors. Fresh blood was collected 
from atherosclerosis patients or age match control subjects aged from 60-75. Subjects were 
matched for age, sex, ethnicity, BMI, and Statin usage. PBL collected from transmigration 
assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. TrypLE was 
subsequently used as cell-dissociation enzymes that make transmigrated PBL floating. The 
PBL was collected and stained with same antibodies panel. PBL was stained, and gated on 
their forward/side scatter profile. Direct conjugated antibodies were used for staining.  The 
Beta-2 receptor expression was measured on the basis of the isotype control for each subset. 
Data is mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 









Figure 6-13:  MFI of PSGL-1 receptor on different subsets of migrated PBL isolated 
from atherosclerosis patients or age match control.  
Flow cytometry was used to measure the MFI of PSGL-1 receptors. Fresh blood was 
collected from atherosclerosis patients or age match control subjects aged from 60-75. 
Subjects were matched for age, sex, ethnicity, BMI, and Statin usage. PBL collected from 
transmigration assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. 
TrypLE was subsequently used as cell-dissociation enzymes that make transmigrated PBL 
floating. The PBL was collected and stained with same antibodies panel. PBL was stained, 
and gated on their forward/side scatter profile. Direct conjugated antibodies were used for 
staining.  The PSGL-1 receptor expression was measured on the basis of the isotype control 
for each subset. Data is mean ± SEM (N=6) and the differences between groups were 
determined by using an independent sample t test. The probability values of less than 0.05 








2.4.  Surface expression of chemokine receptors on migrated PBL from 
atherosclerosis patients or age matched controls 
 
As mentioned above, this section provided a discussion regarding  chemokine receptors 
expression on PBL subsets. We hypothesized that Atherosclerosis patients have higher 
expressions of chemokin receptors than healthy controls. They were put  into separate 
sections because the literature classifies them as a distinct family and their activation, down-
regulation, and role in leukocyte trafficking is different from that of adhesion molecules. Our 
analysis shows a dramatic down-regulation of the surface expression of CCR5, CXCR3, 
CX3CR1 receptors after transmigration when compared to that in fresh blood PBL.  This did 









Figure 6-14:  MFI of CCR5 receptor on different subsets of migrated PBL isolated from 
atherosclerosis patients or age match control.  
Flow cytometry was used to measure the MFI of CCR5 receptors. Fresh blood was collected 
from atherosclerosis patients or age match control subjects aged from 60-75. Subjects were 
matched for age, sex, ethnicity, BMI, and Statin usage. PBL collected from transmigration 
assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. TrypLE was 
subsequently used as cell-dissociation enzymes that make transmigrated PBL floating. Finally  
The PBL was collected and stained with the same antibodies panel. PBL was stained, and 
gated on their forward/side scatter profile. Direct conjugated antibodies were used for 
staining.  The CCR5 receptor expression was measured on the basis of the isotype control for 
each subset. Data is mean ± SEM (N=6) and the differences between groups were determined 
by using an independent sample t test. The probability values of less than 0.05 were 









Figure 6-15: MFI of CXCR3 receptor on different subsets of migrated PBL isolated 
from atherosclerosis patients or age match control.  
Flow cytometry was used to measure the MFI of CXCR3 receptors. Fresh blood was collected 
from atherosclerosis patients or age match control subjects aged from 60-75. Subjects were 
matched for age, sex, ethnicity, BMI, and Statin usage. PBL collected from transmigration 
assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. TrypLE was 
subsequently used as cell-dissociation enzymes that make transmigrated PBL floating. Finally  
The PBL was collected and stained with the same antibodies panel. PBL was stained, and 
gated on their forward/side scatter profile. Direct conjugated antibodies were used for 
staining.  The CXCR3 receptor expression was measured on the basis of the isotype control 
for each subset. Data is mean ± SEM (N=6) and the differences between groups were 
determined by using an independent sample t test. The probability values of less than 0.05 









Figure 6-16: MFI of CX3CR1 receptor on different subsets of migrated PBL isolated 
from atherosclerosis patients or age match control.  
Flow cytometry was used to measure the MFI of CX3CR1 receptors. Fresh blood was 
collected from atherosclerosis patients or age match control subjects aged from 60-75. 
Subjects were matched for age, sex, ethnicity, BMI, and Statin usage. PBL collected from 
transmigration assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. 
TrypLE was subsequently used as cell-dissociation enzymes that make transmigrated PBL 
floating. Finally  The PBL was collected and stained with the same antibodies panel. PBL was 
stained, and gated on their forward/side scatter profile. Direct conjugated antibodies were 
used for staining.  CX3CR1 receptor expression was measured on the basis of the isotype 
control for each subset. Data is mean ± SEM (N=6) and the differences between groups were 
determined by using an independent sample t test. The probability values of less than 0.05 








2.5.  Enrichment ratio of surface adherent and transmigrated PBL from 
atherosclerosis patients or age matched controls. 
 
Here, we aimed to measure the response of PBL subsets to the cytokines. In our static 
adhesion assay, we stimulated EC with TNF-α and INF-ɤ, and then PBL was added to adhere. 
We wanted to investigate the response of these PBL to cytokines and also their ability to bind 
to EC. We made this measurement by dividing either the number of surface adherent cells or 
transmigrated cells by the total number of added cells. Figures 6-17 and 6-18 show the 
enrichment ration of PBL subsets between atherosclerosis patients and healthy control 
subjects. The figures reveal no clear and obvious difference in the ratios of the subsets that are 






Figure 6-17: Enrichment ratio of migrated PBL from atherosclerosis patients or age 
match control in static condition:  
The enrichment ratio for each subset from each group has been calculated. Fresh blood was 
collected from atherosclerosis patients or age match control subjects aged from 60-75. 
Subjects were matched for age, sex, ethnicity, BMI, and Statin usage. PBL collected from 
transmigration assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. 
TrypLE was subsequently used as cell-dissociation enzymes that make transmigrated PBL 
floating. The number of transmigrated cells in each subset was divided by the total number of 
cells of that subset added to the assay. Data is mean ± SEM (N=6) and the differences 
between groups were determined by using an independent sample t test. The probability 
values of less than 0.05 were considered significant (* = P ≤ 0.05, **= P ≤ 0.01, *** = P ≤ 
0.001).The transmigrated cells in each subset was divided by the total number of cells of that 
subset added to the assay. Data is mean ± SEM (N=6) and the differences between groups 
were determined by using an independent sample t test. The probability values of less than 








Figure 6-18: Enrichment ratio of Surface adherent PBL from atherosclerosis patients or 
age match control in static condition:  
The enrichment ratio for each subset from each group has been calculated. Fresh blood was 
collected from atherosclerosis patients or age match control subjects aged from 60-75. 
Subjects were matched for age, sex, ethnicity, BMI, and Statin usage. PBL collected from 
transmigration assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. 
TrypLE was subsequently used as cell-dissociation enzymes that make transmigrated PBL 
floating. The number of transmigrated cells in each subset was divided by the total number of 
cells of that subset added to the assay. Data is mean ± SEM (N=6) and the differences 
between groups were determined by using an independent sample t test. The probability 
values of less than 0.05 were considered significant (* = P ≤ 0.05, **= P ≤ 0.01, *** = P ≤ 
0.001).The number of surface adherent PBL in each subset was divided by the total number of 
cells of that subset added to the assay. Data is mean ± SEM (N=6) and the differences 
between groups were determined by an using an independent sample t test. The probability 










In this section, we discuss the results of our investigations of the effect of atherosclerosis 
on the surface expression of adhesion molecules and chemokines receptors. Our panel of 
receptors was chosen because it represented the classical receptors that are responsible for T 
cell trafficking and therefore might lead to the progression of atherosclerosis. Our hypothesis 
was that after patients develop atherosclerosis, the process of T cell trafficking becomes 
prolonged, and that this might be caused by an increased expression of adhesion molecules. 
Our data shows that Alpha-L receptor surface expression was highly expressed on some PBL 
subsets in healthy subjects when compared to atherosclerosis patients.  In the case of alpha-4 
receptor surface expression, it was found to be higher on healthy subjects, but only on NK 
cells. As mentioned above, the majority of the integrins involved in leukocytes trafficking are 
β2 and α4, and usually α and β members bind together to form one main receptor, such as 
LFA-1, which consists of αLβ2. It is also worth mentioning that α4β1 is called VLA-4 
(Galkina and Ley, 2007). The fact that alpha-L receptor expression was low in the 
atherosclerosis patients is also interesting. We speculate that the reason for this anomaly is 
because once the manifestation of atherosclerosis is recognized by the immune system, it 
adapts by down regulating the expression of adhesion molecules. Another reason could relate 
to the medications used by the patients; studies have shown for instance, that Statins reduce 
the expression of some adhesion molecules (Rezaie-Majd et al., 2003), and all of these 
patients will be well served with such drugs.   
The increased expression of Beta-1, Beta-2, and PSGL-1 receptors surface expression on 
some PBL subsets in atherosclerosis patients was not very surprising; the involvement of the 
Beta integrins family is well established. In fact, Beta-1/Alpha-5 is known to mediate the 
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inflammation in the early stages of atherosclerosis (Yurdagul et al., 2014). One of the main 
characteristics of PSGL-1 is its interaction with the selectins (Schumacher et al., 2005). 
PSGL-1 plays a key role in monocyte recruitment in atherosclerosis; in fact, it is considered to 
be the favoured ligand of leukocytes P and E section (An et al., 2008). Additionally, it has 
been shown that PSGL-1 regulated selective T cell recruitment to an atherosclerosis site (An 
et al., 2008). Its increase here, therefore, was interesting in the atherosclerosis patients.  
Chemokines receptor expression was significantly higher on some PBL subsets in healthy   
subjects than in atherosclerosis patients. The expression of chemokines receptors is regulated 
by internalization and shedding mechanisms, which is controlled by levels of ligand in the 
environment.  This data contradicts another study, however, which showed that inflammatory 
Ly-6Chi monocytes highly express certain chemokines such as CCR2 and CX3CR1 when 
compared to healthy ones (An et al., 2008). Furthermore another study by Burke-Gaffney et al 
concluded that in inflammatory conditions, the interaction between leukocytes and EC leads 
to amplification of chemokines release (Burke-Gaffney et al., 2002). On the other hand, a 
study on menopausal women revealed that menopausal women have higher expressions of 
certain pro-inflammatory serum markers (Sivro et al., 2013). Moreover, animal studies have 
shown an increase in chemokine expression on T cell subsets (Chen et al., 2003).  
Migrated PBL data on the expression of adhesion molecules was not conclusive; their 
levels of expression on most PBL subsets in both groups were almost equal, except for Alpha-
L receptors which were highly expressed in atherosclerosis patients when compared to 
healthy controls. In terms of chemokines receptors surface expression, as we have seen above, 
their expression declined sharply, which indicates they had been down regulated.  
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Similarly to the enrichment data in chapter 4, we did not notice any difference in the ratios 
of the subsets that are recruited in at atherosclerosis patients and age matched controls which 
could be a result of technical problem.  
4. Conclusion 
 
Some PBL subsets which were freshly isolated from atherosclerosis patients highly 
express Beta-1, Beta-2, and PSGL-1 receptors, whereas their surface expression of Alpha-L 
and Alpha-4 receptors is low when compared to healthy subjects. Moreover, chemokines 
surface expression on freshly isolated PBL subsets is low compared to healthy controls. In the 
case of migrated and surface adherent PBL subsets, no conclusive difference in surface 
expression of adhesion molecules between atherosclerosis patients and healthy control  was 
noticed. Finally, both groups recorded down-regulated chemokine receptors after the 




































1. General discussion 
 
The main goal for this thesis was to study the PEPITEM pathway and its dysregulation in 
atherosclerosis patients. We showed for the first time that the PEPITEM pathway is impaired 
in atherosclerosis patients, evidenced by the lack of the inhibitory effect of PEPITEM on PBL 
isolated from patients. In addition, we showed the lack of AQ inhibitory effect on PBL from 
the same patients. These data suggest a missing link along the PEPITEM pathway which 
needs more investigation. Previous published work from our lab shows that the treatment of 
PBL isolated from T1D patients by PEPITEM and AQ, rescues the PEPITEM pathway and 
restores its effect which is seen by the inhibition of T cell migration in static adhesion assay 
(Chimen et al., 2015). So in this instance we tried to focus on the pathological changes 
between both diseases atherosclerosis and T1D. The literature shows that atherosclerosis 
starts in very early ages and some studies have also reported signs of sub-endothelium 
changes in the right coronary artery (Tabas et al., 2007). This fact suggests that the 
endothelium injury which initiates atherosclerosis has been progressing for a long period of 
time without prevention in contrast to T1D which can be predicated by a blood test. We now 
suggest that this chronic and long-term progression of endothelium lesion formation might 
make it advisable to increase the stock concentration of PEPITEM and AQ when treating PBL 
in the adhesion assay. In this experiment we used the same concentration of PEPITEM and 
AQ which has been used for the T1D study, so we also suspect that increasing the dose might 
restore the inhibitory effect of the PEPITEM pathway.  
Adiponectin is very important in respect of the PEPITEM pathway because of its binding 
to its receptors (AR1 and AR2) on B cells which is essential for PEPITEM production. 
However, we demonstrated that both AR1 and AR2 surface and gene expression were 
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unchanged in atherosclerosis patients, and that neither PEPITEM nor AQ inhibit T cell 
transmigration. At the same time we found a significant decrease in AQ serum levels in 
atherosclerosis patients. It appeared that the unchanged surface expression and the gene 
expression of AR1 and AR2 could be a compensation mechanism from the immune system to 
resist any down regulation of AR1 and AR2 surface expression. The AQ serum level supports 
this speculation  since the serum level is decreased in atherosclerosis patients; meaning that 
the vasculature protective mechanism of AQ is impaired. When we looked at AQ serum levels 
on older subjects we found out a significant increase in AQ serum levels which we believe is 
the compensation mechanism which intervenes again to maintain AQ vasculature protective 
function.  
Another suggestion is to explore the other components of the pathway. S1P receptors 
expression is a potential target for further investigation but the lack of SIP serum level 
measurement kit makes it difficult to study the whole pathway. Worse still, the rapid 
internalization of S1P receptors prevents us from measuring the expression of S1PR1 and 
S1PR4 on the PBL surface. On account of our assay, we know that AQ, PEPITEM, and CHD-
15 are present in the system but due to these technical issues we were unable to investigate 
SIP and SIPRs behaviour. It is worth mentioning that CHD-15 is expressed on the 
endothelium we used (DMEC), this information is confirmed by the manufacturer’s certificate 
and previous work in our lab.  
In addition to the percentage of transmigration, we showed that the adhesive properties of 
PBL in atherosclerosis patients are similar to that in healthy subjects. These findings are in 
contrast with another study which showed the high expression of adhesion molecules VCAM-
1 using an in vitro assay, with the authors reporting a higher expression of VCAM-1 on EC 
when stimulated by TNF-α, interleukin-1 and lipopolysaccharide (Carlos and Harlan, 1994). 
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Even though it is well known that β-2 is an important adhesion molecule on PBL surface 
helping to orchestrate its adhesion to EC, we did not notice a significant increase in 
atherosclerosis patients PBL adhesive behaviour. We showed an increase in β-2 surface 
expression on some PBL subsets isolated from atherosclerosis patients. Since β-2 interaction 
is mediated by ICAM-1 on EC, this increase in β-2 on the PBL surface is highly likely to be 
accompanied by an increase on EC expression of ICAM-1. A result of this should be an 
increase in the percentage of PBL total adhesion on EC which is something we were  unable 
to  demonstrate.  
Furthermore, we looked at the impact of old age on the adhesive properties of PBL. 
There is a well-established relationship between old age and the development of 
atherosclerosis. We hypothesized that older subjects may more highly express adhesion 
molecules on their peripheral PBL than younger subjects, and we expected this high 
expression to be wide and consistent on all PBL subsets.  Our data, however, did not support 
this hypothesis. We therefore considered the affinity and activation state of the adhesion 
molecule receptors. Research has shown an increase in the number of infiltrating leukocytes 
to inflamed tissue when there is prolonged expression of chemokine receptors (Scholten et al., 
2012). Also, the authors of this study showed that there is a redundancy in the chemokine 
system because of the fact that a single receptor has multiple binding sites which might lead 
to differential signalling. This means that the outcome of signalling pathway probably 
depends not only on ligand-receptor interaction but also on the activation state of the 
receptors and the presence of signalling proteins. 
  Transmigrated PBL showed down-regulation of chemokine receptors CCR5, CXCR3, 
and CX3CR1. To the best of our knowledge in this thesis we revealed for the first time that 
surface adherent PBL down-regulate chemokine receptors as well, just like transmigrated 
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PBL. This temporarily down-regulation is necessarily for integrin activation which as a result 
completes the leukocyte adhesion cascade.  
In the case of adhesion molecules receptors after transmigration, we did not see the 
same down-regulation which was expected, as these molecules keep PBL adhered to the EC. 
Moreover, we showed that the process of down-regulation of chemokine receptors during 
transmigration does not change with age or with atherosclerosis.  
In respect of the impact of old age on the surface expression of chemokine receptors 
on PBL subsets, we showed a significant increase in the expression on peripheral PBL subsets 
of older subjects compared with that of atherosclerosis patients. This was not anticipated 
because atherosclerosis is associated with an increase of surface expression of chemokine 
receptors (Blankenberg et al., 2003). Chemokine receptors have been implicated in many 
chronic diseases including atherosclerosis, allergy, and malaria (Murdoch and Finn, 2000).  
This increase could be a sign of the beginning of EC stimulation because the 
expression of chemokine receptors or chemokines by EC recruits inflammatory cells 
(Braunersreuther et al., 2007). In addition to leukocyte recruitment, chemokines play a role in 
platelets activation, something which is considered pro-inflammatory because it secretes 
inflammatory mediators, one of which is chemokine platelet factor-4. Furthermore, platelets 
release another chemokine called RANTES which is known to recruit monocytes (Li et al., 
1996) (Davenpeck et al., 2000). In our studies we have shown an increase in the expression of 
both CCR5 and CXCR3 receptors, and the literature has also previously revealed an 
association between atherosclerosis and the expression of  both of these receptors (Warnock et 
al., 1998).  Polymorphism studies have also shown reductions of early MI macrophages when 
the CCR5 gene is depleted (Hughes and Pfaff, 1998). Our data suggests possible therapeutic 
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uses of chemokine receptors to cure atherosclerosis. Interestingly TAK-799 (which is 
considered both a CCR5 and CXCR3 antagonist) has revealed a reduction in disease burden 


















2. Further experiments 
 
Further investigation in some areas is clearly required.  
 As mentioned above atherosclerosis is more complicated than other chronic diseases, 
using higher PEPITEM concentration with atherosclerosis patients in static adhesion 
assay could restore PEPITEM function.  
 One of the limitations of our experiments is that we measured AR1 and AR2 gene 
expression on PBMCs not B cells. The fact that monocyte subsets highly express ARs 
(see chapter 1), make our data very general, so measuring ARs gene expression on B-
cells using magnetic beads would provide us with accurate and specific results 
regarding the role of B-cellse in PEPITEM releases.  
 Although we used static adhesion assay in this thesis, it would be very interesting to 
see what difference could be seen when using flow adhesion assay instead of static. 
Flow adhesion assay enables us to reconstruct leucocyte recruitment cascade in the 
presence of shear stress which is important in EC adhesion molecules expression.  
 Another future experiment which would help us understand the dysfunction in 
PEPITEM-Adiponectin pathway in atherosclerosis patients is to measure the surface 
expression of SIPR1 and SIPR4 on transmigrated PBL. We think that SIPRs are not 
up-regulated in transmigrated PBL which prevents the inhibitory effect of PEPITEM 
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Chapter 4: Studying the effect of age on Chemokine and Integrin recptors expression on 
PBL subsets. 
 Characterisation of surface expression of adhesion molecules and chemokine 
receptors on fresh blood PBL, migrated PBL, and surface adherent cells.   
First we started by comparing the difference in the expression of adhesion molecules and 
integrins on fresh blood PBL, migrated PBL, and surface adherent PBL. Migrated PBL and 
surface adherent PBL are the PBL after migration assay where PBL placed on stimulated EC. 
After that, Number of migrated PBL and surface adherent PBL was calculated and finally the 
expression of integrins and adhesion molecules have been analysed to see which molecules 







Figure  0-1: Frequency of CCR5 receptor on different subsets of PBL isolated from 
healthy donors (20-75 years old).  
Flow cytometry was used to measure the frequency of CCR5 receptor; PBL was isolated from 
fresh blood samples, stained with same panel of antibodies, and gated on their forward/side 
scatter profile. Surface adherent PBL is collected from transmigration assay where PBL are 
added on DMEC and incubated for 7 minutes at 37°C. Then, using Phosphate-buffered saline 
(PBS) surface adherent The PBL was collected gently using pipette. Finally, The PBL was 
stained with same panel. Regarding migrated PBL, they are PBL collected from 
transmigration assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. 
Then, TrypLE was used as cell-dissociation enzymes that make transmigrated PBL floating. 
The PBL was collected and stained with same panel of antibodies. Direct conjugated 
antibodies were used for staining. CCR5 receptor expression was measured on the basis of the 
isotype control for each subset. Data is mean ± SEM (N=12) and were analysed using one 
way Anova, with a Bonferroni post hoc test. The probability values of less than 0.05 were 




















































































Figure  0-2: Frequency of CXCR3 receptor on different subsets of PBL isolated from 
healthy donors (20-75 years old).  
Flow cytometry was used to measure the frequency of CXCR3receptor; PBL was isolated 
from fresh blood samples, stained with same panel of antibodies, and gated on their 
forward/side scatter profile. Surface adherent PBL is collected from transmigration assay 
where PBL are added on DMEC and incubated for 7 minutes at 37°C. Then, using Phosphate-
buffered saline (PBS) surface adherent The PBL was collected gently using pipette. Finally, 
The PBL was stained with same panel. Regarding migrated PBL, they are PBL collected from 
transmigration assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. 
Then, TrypLE was used as cell-dissociation enzymes that make transmigrated PBL floating. 
The PBL was collected and stained with same panel of antibodies. Direct conjugated 
antibodies were used for staining. CXCR3 receptor expression was measured on the basis of 
the isotype control for each subset. Data is mean ± SEM (N=12) and were analysed using one 
way Anova, with a Bonferroni post hoc test. The probability values of less than 0.05 were 
























































































Figure  0-3: Frequency of CX3CR1 receptor on different subsets of PBL isolated from 
healthy donors (20-75 years old).  
Flow cytometry was used to measure the frequency of CX3CR1 receptor; PBL was isolated 
from fresh blood samples, stained with same panel of antibodies, and gated on their 
forward/side scatter profile. Surface adherent PBL is collected from transmigration assay 
where PBL are added on DMEC and incubated for 7 minutes at 37°C. Then, using Phosphate-
buffered saline (PBS) surface adherent The PBL was collected gently using pipette. Finally, 
The PBL was stained with same panel. Regarding migrated PBL, they are PBL collected from 
transmigration assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. 
Then, TrypLE was used as cell-dissociation enzymes that make transmigrated PBL floating. 
The PBL was collected and stained with same panel of antibodies. Direct conjugated 
antibodies were used for staining. CX3CR1 receptor expression was measured on the basis of 
the isotype control for each subset. Data is mean ± SEM (N=12) and were analysed using one 
way Anova, with a Bonferroni post hoc test. The probability values of less than 0.05 were 





































































































































































Figure  0-4:  Frequency of Alpha-L receptor on different subsets of PBL isolated from 
healthy donors (20-75 years old).  
Flow cytometry was used to measure the frequency of Alpha-L receptor; PBL was isolated 
from fresh blood samples, stained with same panel of antibodies, and gated on their 
forward/side scatter profile. Surface adherent PBL is collected from transmigration assay 
where PBL are added on DMEC and incubated for 7 minutes at 37°C. Then, using Phosphate-
buffered saline (PBS) surface adherent The PBL was collected gently using pipette. Finally, 
The PBL was stained with same panel. Regarding migrated PBL, they are PBL collected from 
transmigration assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. 
Then, TrypLE was used as cell-dissociation enzymes that make transmigrated PBL floating. 
The PBL was collected and stained with same panel of antibodies. Direct conjugated 
antibodies were used for staining. Alpha-L receptor expression was measured on the basis of 
the isotype control for each subset. Data is mean ± SEM (N=12) and were analysed using one 
way Anova, with a Bonferroni post hoc test. The probability values of less than 0.05 were 














































































Figure  0-5:  Frequency of Alpha-4 receptor on different subsets of PBL isolated from 
healthy donors (20-75 years old).  
Flow cytometry was used to measure the frequency of Alpha-4 receptor; PBL was isolated 
from fresh blood samples, stained with same panel of antibodies, and gated on their 
forward/side scatter profile. Surface adherent PBL is collected from transmigration assay 
where PBL are added on DMEC and incubated for 7 minutes at 37°C. Then, using Phosphate-
buffered saline (PBS) surface adherent The PBL was collected gently using pipette. Finally, 
The PBL was stained with same panel. Regarding migrated PBL, they are PBL collected from 
transmigration assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. 
Then, TrypLE was used as cell-dissociation enzymes that make transmigrated PBL floating. 
The PBL was collected and stained with same panel of antibodies. Direct conjugated 
antibodies were used for staining. Alpha-4 receptor expression was measured on the basis of 
the isotype control for each subset. Data is mean ± SEM (N=12) and were analysed using one 
way Anova, with a Bonferroni post hoc test. The probability values of less than 0.05 were 



















































































Figure  0-6: Frequency of Beta-1 receptor on different subsets of PBL isolated from 
healthy donors (20-75 years old).  
Flow cytometry was used to measure the frequency of Beta-1 receptor; PBL was isolated 
from fresh blood samples, stained with same panel of antibodies, and gated on their 
forward/side scatter profile. Surface adherent PBL is collected from transmigration assay 
where PBL are added on DMEC and incubated for 7 minutes at 37°C. Then, using Phosphate-
buffered saline (PBS) surface adherent The PBL was collected gently using pipette. Finally, 
The PBL was stained with same panel. Regarding migrated PBL, they are PBL collected from 
transmigration assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. 
Then, TrypLE was used as cell-dissociation enzymes that make transmigrated PBL floating. 
The PBL was collected and stained with same panel of antibodies. Direct conjugated 
antibodies were used for staining. Beta-1 receptor expression was measured on the basis of 
the isotype control for each subset. Data is mean ± SEM (N=12) and were analysed using one 
way Anova, with a Bonferroni post hoc test. The probability values of less than 0.05 were 




















































































Figure  0-7:  Frequency of Beta-2 receptor on different subsets of PBL isolated from 
healthy donors (20-75 years old).  
Flow cytometry was used to measure the frequency of Beta-2 receptor; PBL was isolated 
from fresh blood samples, stained with same panel of antibodies, and gated on their 
forward/side scatter profile. Surface adherent PBL is collected from transmigration assay 
where PBL are added on DMEC and incubated for 7 minutes at 37°C. Then, using Phosphate-
buffered saline (PBS) surface adherent The PBL was collected gently using pipette. Finally, 
The PBL was stained with same panel. Regarding migrated PBL, they are PBL collected from 
transmigration assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. 
Then, TrypLE was used as cell-dissociation enzymes that make transmigrated PBL floating. 
The PBL was collected and stained with same panel of antibodies. Direct conjugated 
antibodies were used for staining. Beta-2 receptor expression was measured on the basis of 
the isotype control for each subset. Data is mean ± SEM (N=12) and were analysed using one 
way Anova, with a Bonferroni post hoc test. The probability values of less than 0.05 were 





















































































Figure  0-8: Frequency of PSGL-1 receptor on different subsets of PBL isolated from 
healthy donors (20-75 years old).  
Flow cytometry was used to measure the frequency of PSGL-1 receptor; PBL was isolated 
from fresh blood samples, stained with same panel of antibodies, and gated on their 
forward/side scatter profile. Surface adherent PBL is collected from transmigration assay 
where PBL are added on DMEC and incubated for 7 minutes at 37°C. Then, using Phosphate-
buffered saline (PBS) surface adherent The PBL was collected gently using pipette. Finally, 
The PBL was stained with same panel. Regarding migrated PBL, they are PBL collected from 
transmigration assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. 
Then, TrypLE was used as cell-dissociation enzymes that make transmigrated PBL floating. 
The PBL was collected and stained with same panel of antibodies. Direct conjugated 
antibodies were used for staining. PSGL-1 receptor expression was measured on the basis of 
the isotype control for each subset. Data is mean ± SEM (N=12) and were analysed using one 
way Anova, with a Bonferroni post hoc test. The probability values of less than 0.05 were 







 Surface expression of adhesion molecule receptors on fresh blood PBL from 

















































































Figure  0-9: Frequency of Alpha-L receptor on different subsets of PBL isolated from 
healthy donors.  
Flow cytometry was used to measure the frequency of Alpha-L receptor on fresh blood PBL 
subsets; Fresh blood was collected from young or old subjects. Young subjects aged from 20-
35 whereas old subjects aged 60-75 years old.  Subjects were matched for sex, ethnicity, and 
BMI, Statin usage. PBL was isolated from fresh blood samples, stained, and gated on their 
forward/side scatter profile. Direct conjugated antibodies were used for staining. Alpha L 
receptor expression was measured on the basis of the isotype control for each subset. Data is 
mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 





Figure  0-10: Frequency of Alpha-4 receptor on different subsets of PBL isolated from 
healthy donors.  
Flow cytometry was used to measure the frequency of Alpha-4 receptor on fresh blood PBL 
subsets; Fresh blood was collected from young or old subjects. Young subjects aged from 20-
35 whereas old subjects aged 60-75 years old.  Subjects were matched for sex, ethnicity, and 
BMI, Statin usage. PBL was isolated from fresh blood samples, stained, and gated on their 
forward/side scatter profile. Direct conjugated antibodies were used for staining. Alpha 4 
receptor expressions was measured on the basis of the isotype control for each subset. Data is 
mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 




















































































Figure  0-11: Frequency of Beta-1 receptor on different subsets of PBL isolated from 
healthy donors.  
Flow cytometry was used to measure the frequency of Beta-1 receptor on fresh blood PBL 
subsets; Fresh blood was collected from young or old subjects. Young subjects aged from 20-
35 whereas old subjects aged 60-75 years old.  Subjects were matched for sex, ethnicity, and 
BMI, Statin usage. PBL was isolated from fresh blood samples, stained, and gated on their 
forward/side scatter profile. Direct conjugated antibodies were used for staining. Beta-1 
receptor expressions were measured on the basis of the isotype control for each subset. Data is 
mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 



















































































Figure  0-12: Frequency of Beta-2 receptor on different subsets of PBL isolated from 
healthy donors.  
Flow cytometry was used to measure the frequency of Beta-2 receptor on fresh blood PBL 
subsets; Fresh blood was collected from young or old subjects. Young subjects aged from 20-
35 whereas old subjects aged 60-75 years old.  Subjects were matched for sex, ethnicity, and 
BMI, Statin usage. PBL was isolated from fresh blood samples, stained, and gated on their 
forward/side scatter profile. Direct conjugated antibodies were used for staining. Beta-2 
receptor expressions were measured on the basis of the isotype control for each subset. Data is 
mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 

















































































Figure  0-13: Frequency of PSGL-1 receptor on different subsets of PBL isolated from 
healthy donors.  
Flow cytometry was used to measure the frequency of PSGL-1 receptor on fresh blood PBL 
subsets; Fresh blood was collected from young or old subjects. Young subjects aged from 20-
35 whereas old subjects aged 60-75 years old.  Subjects were matched for sex, ethnicity, and 
BMI, Statin usage. PBL was isolated from fresh blood samples, stained, and gated on their 
forward/side scatter profile. Direct conjugated antibodies were used for staining. PSGL-1 
receptor expressions were measured on the basis of the isotype control for each subset. Data is 
mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 









































































































































































Figure  0-14: Frequency of CCR5 receptor on different subsets of PBL isolated from 
healthy donors.  
Flow cytometry was used to measure the frequency of CCR5 receptor on fresh blood PBL 
subsets; Fresh blood was collected from young or old subjects. Young subjects aged from 20-
35 whereas old subjects aged 60-75 years old.  Subjects were matched for sex, ethnicity, and 
BMI, Statin usage. PBL was isolated from fresh blood samples, stained, and gated on their 
forward/side scatter profile. Direct conjugated antibodies were used for staining. CCR5 
receptor expressions were measured on the basis of the isotype control for each subset. Data is 
mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 


















































































Figure  0-15: Frequency of CXCR3 receptor on different subsets of PBL isolated from 
healthy donors.  
Flow cytometry was used to measure the frequency of CXCR3 receptor on fresh blood PBL 
subsets; Fresh blood was collected from young or old subjects. Young subjects aged from 20-
35 whereas old subjects aged 60-75 years old.  Subjects were matched for sex, ethnicity, and 
BMI, Statin usage. PBL was isolated from fresh blood samples, stained, and gated on their 
forward/side scatter profile. Direct conjugated antibodies were used for staining. CXCR3 
receptor expressions were measured on the basis of the isotype control for each subset. Data is 
mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 

























































































Figure  0-16: Frequency of CX3CR1 receptor on different subsets of PBL isolated from 
healthy donors.  
Flow cytometry was used to measure the frequency of CX3CR1 receptor on fresh blood PBL 
subsets; Fresh blood was collected from young or old subjects. Young subjects aged from 20-
35 whereas old subjects aged 60-75 years old.  Subjects were matched for sex, ethnicity, and 
BMI, Statin usage. PBL was isolated from fresh blood samples, stained, and gated on their 
forward/side scatter profile. Direct conjugated antibodies were used for staining. CX3CR1 
receptor expressions were measured on the basis of the isotype control for each subset. Data is 
mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 








 Surface expression of adhesion molecule receptors on migrated PBL from young 
or old controls:  
 
Figure  0-17: Frequency of Alpha-L receptor on different subsets of PBL isolated from 
healthy donors.  
Flow cytometry was used to measure the frequency of Alpha-L; Fresh blood was collected 
from young or old subjects. Young subjects aged from 20-35 whereas old subjects aged 60-75 
years old.  Subjects were matched sex, ethnicity, and BMI. PBL collected from transmigration 
assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. Then, TrypLE 
was used as cell-dissociation enzymes that make transmigrated PBL floating. The PBL was 
collected and stained withe same antibodies panel. PBL was stained, and gated on their 
forward/side scatter profile. Direct conjugated antibodies were used for staining. Alpha-L 
receptor expression was measured on the basis of the isotype control for each subset. Data is 
mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 

















































































Figure  0-18: Frequency of Alpha-4 receptor on different subsets of PBL isolated from 
healthy donors.  
Flow cytometry was used to measure the frequency of Alpha-4; Fresh blood was collected 
from young or old subjects. Young subjects aged from 20-35 whereas old subjects aged 60-75 
years old.  Subjects were matched sex, ethnicity, and BMI. PBL collected from transmigration 
assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. Then, TrypLE 
was used as cell-dissociation enzymes that make transmigrated PBL floating. The PBL was 
collected and stained withe same antibodies panel. PBL was stained, and gated on their 
forward/side scatter profile. Direct conjugated antibodies were used for staining. Alpha-4 
receptor expression was measured on the basis of the isotype control for each subset. Data is 
mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 



















































































Figure 19: Frequency of Beta-1 receptor on different subsets of PBL isolated from 
healthy donors.  
Flow cytometry was used to measure the frequency of Beta-1; Fresh blood was collected from 
young or old subjects. Young subjects aged from 20-35 whereas old subjects aged 60-75 
years old.  Subjects were matched sex, ethnicity, and BMI. PBL collected from transmigration 
assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. Then, TrypLE 
was used as cell-dissociation enzymes that make transmigrated PBL floating. The PBL was 
collected and stained withe same antibodies panel. PBL was stained, and gated on their 
forward/side scatter profile. Direct conjugated antibodies were used for staining. Beta-1 
receptor expression was measured on the basis of the isotype control for each subset. Data is 
mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 


















































































Figure  0-19: Frequency of Beta-2 receptor on different subsets of PBL isolated from 
healthy donors.  
Flow cytometry was used to measure the frequency of Beta-2; Fresh blood was collected from 
young or old subjects. Young subjects aged from 20-35 whereas old subjects aged 60-75 
years old.  Subjects were matched sex, ethnicity, and BMI. PBL collected from transmigration 
assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. Then, TrypLE 
was used as cell-dissociation enzymes that make transmigrated PBL floating. The PBL was 
collected and stained withe same antibodies panel. PBL was stained, and gated on their 
forward/side scatter profile. Direct conjugated antibodies were used for staining.Beta-2 
receptor expression was measured on the basis of the isotype control for each subset. Data is 
mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 


















































































Figure  0-20: Frequency of PSGL-1 receptor on different subsets of PBL isolated from 
healthy donors.  
Flow cytometry was used to measure the frequency of PSGL-1; Fresh blood was collected 
from young or old subjects. Young subjects aged from 20-35 whereas old subjects aged 60-75 
years old.  Subjects were matched sex, ethnicity, and BMI. PBL collected from transmigration 
assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. Then, TrypLE 
was used as cell-dissociation enzymes that make transmigrated PBL floating. The PBL was 
collected and stained withe same antibodies panel. PBL was stained, and gated on their 
forward/side scatter profile. Direct conjugated antibodies were used for staining. PSGL-1 
receptor expression was measured on the basis of the isotype control for each subset. Data is 
mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 



















































































 Surface expression of chemokine receptors on migrated PBL from young or old 
controls:  
 
Figure  0-21: Frequency of CCR5 receptor on different subsets of migrated PBL isolated 
from healthy donors.  
Flow cytometry was used to measure the frequency of CCR5; Fresh blood was collected from 
young or old subjects. Young subjects aged from 20-35 whereas old subjects aged 60-75 
years old.  Subjects were matched sex, ethnicity, and BMI. PBL collected from transmigration 
assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. Then, TrypLE 
was used as cell-dissociation enzymes that make transmigrated PBL floating. The PBL was 
collected and stained withe same antibodies panel. PBL was stained, and gated on their 
forward/side scatter profile. Direct conjugated antibodies were used for staining. CCR5 
receptor expression was measured on the basis of the isotype control for each subset. Data is 
mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 






































































































































































Figure  0-22: Frequency of CXCR3 receptor on different subsets of migrated PBL 
isolated from healthy donors.  
Flow cytometry was used to measure the frequency of CXCR3; Fresh blood was collected 
from young or old subjects. Young subjects aged from 20-35 whereas old subjects aged 60-75 
years old.  Subjects were matched sex, ethnicity, and BMI. PBL collected from transmigration 
assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. Then, TrypLE 
was used as cell-dissociation enzymes that make transmigrated PBL floating. The PBL was 
collected and stained withe same antibodies panel. PBL was stained, and gated on their 
forward/side scatter profile. Direct conjugated antibodies were used for staining. CXCR3 
receptor expression was measured on the basis of the isotype control for each subset. Data is 
mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 







Figure  0-23: Frequency of CX3CR1 receptor on different subsets of migrated PBL 
isolated from healthy donors.  
Flow cytometry was used to measure the frequency of CX3CR1; Fresh blood was collected 
from young or old subjects. Young subjects aged from 20-35 whereas old subjects aged 60-75 
years old.  Subjects were matched sex, ethnicity, and BMI. PBL collected from transmigration 
assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. Then, TrypLE 
was used as cell-dissociation enzymes that make transmigrated PBL floating. The PBL was 
collected and stained withe same antibodies panel. PBL was stained, and gated on their 
forward/side scatter profile. Direct conjugated antibodies were used for staining. CX3CR1 
receptor expression was measured on the basis of the isotype control for each subset. Data is 
mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 






















































































 Surface expression of adhesion molecule receptors on surface adherent PBL from 
young or old controls:  
 
Figure  0-24: Frequency of Alpha-L receptor on different subsets of PBL isolated from 
healthy donors.  
Flow cytometry was used to measure the frequency of Alpha-L; Fresh blood was collected 
from young or old subjects. Young subjects aged from 20-35 whereas old subjects aged 60-75 
years old.  Subjects were matched sex, ethnicity, and BMI. PBL collected from transmigration 
assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. Then, Then, 
using Phosphate-buffered saline (PBS) surface adherent The PBL was collected gently using 
pipette. The PBL was collected and stained withe same antibodies panel. PBL was stained, 
and gated on their forward/side scatter profile. Direct conjugated antibodies were used for 
staining. Alpha-L receptor expression was measured on the basis of the isotype control for 
each subset. Data is mean ± SEM (N=6) and the differences between groups were determined 
by using an independent sample t test. The probability values of less than 0.05 were 


















































































Figure  0-25: Frequency of Alpha-4 receptor on different subsets of PBL isolated from 
healthy donors.  
Flow cytometry was used to measure the frequency of Alpha-4; Fresh blood was collected 
from young or old subjects. Young subjects aged from 20-35 whereas old subjects aged 60-75 
years old.  Subjects were matched sex, ethnicity, and BMI. PBL collected from transmigration 
assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. Then, using 
Phosphate-buffered saline (PBS) surface adherent The PBL was collected gently using 
pipette. The PBL was collected and stained withe same antibodies panel. PBL was stained, 
and gated on their forward/side scatter profile. Direct conjugated antibodies were used for 
staining. Alpha-4 receptor expression was measured on the basis of the isotype control for 
each subset. Data is mean ± SEM (N=6) and the differences between groups were determined 
by using an independent sample t test. The probability values of less than 0.05 were 




















































































Figure  0-26: Frequency of Beta-1 receptor on different subsets of PBL isolated from 
healthy donors.  
Flow cytometry was used to measure the frequency of Beta-1; Fresh blood was collected from 
young or old subjects. Young subjects aged from 20-35 whereas old subjects aged 60-75 
years old.  Subjects were matched sex, ethnicity, and BMI. PBL collected from transmigration 
assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. Then, Then, 
using Phosphate-buffered saline (PBS) surface adherent The PBL was collected gently using 
pipette. The PBL was collected and stained withe same antibodies panel. PBL was stained, 
and gated on their forward/side scatter profile. Direct conjugated antibodies were used for 
staining. Beta-1  receptor expression was measured on the basis of the isotype control for each 
subset. Data is mean ± SEM (N=6) and the differences between groups were determined by 
using an independent sample t test. The probability values of less than 0.05 were considered 



















































































Figure 28:  Frequency of Beta-2 receptor on different subsets of PBL isolated from 
healthy donors.  
Flow cytometry was used to measure the frequency of Beta-2; Fresh blood was collected from 
young or old subjects. Young subjects aged from 20-35 whereas old subjects aged 60-75 
years old.  Subjects were matched sex, ethnicity, and BMI. PBL collected from transmigration 
assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. Then, Then, 
using Phosphate-buffered saline (PBS) surface adherent The PBL was collected gently using 
pipette. The PBL was collected and stained withe same antibodies panel. PBL was stained, 
and gated on their forward/side scatter profile. Direct conjugated antibodies were used for 
staining. Beta-2 receptor expression was measured on the basis of the isotype control for each 
subset. Data is mean ± SEM (N=6) and the differences between groups were determined by 
using an independent sample t test. The probability values of less than 0.05 were considered 



















































































Figure  0-27:  Frequency of PSGL-1 receptor on different subsets of PBL isolated from 
healthy donors.  
Flow cytometry was used to measure the frequency of PSGL-1; Fresh blood was collected 
from young or old subjects. Young subjects aged from 20-35 whereas old subjects aged 60-75 
years old.  Subjects were matched sex, ethnicity, and BMI. PBL collected from transmigration 
assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. Then, Then, 
using Phosphate-buffered saline (PBS) surface adherent The PBL was collected gently using 
pipette. The PBL was collected and stained withe same antibodies panel. PBL was stained, 
and gated on their forward/side scatter profile. Direct conjugated antibodies were used for 
staining. PSGL-1 receptor expression was measured on the basis of the isotype control for 
each subset. Data is mean ± SEM (N=6) and the differences between groups were determined 
by using an independent sample t test. The probability values of less than 0.05 were 


















































































 Surface expression of chemokine receptors on surface adherent PBL from young 
or old controls:  
 
Figure  0-28:  Frequency of CCR5 receptor on different subsets of PBL isolated from 
healthy donors.  
Flow cytometry was used to measure the frequency of CCR5 receptor; Fresh blood was 
collected from young or old subjects. Young subjects aged from 20-35 whereas old subjects 
aged 60-75 years old.  Subjects were matched sex, ethnicity, and BMI. PBL collected from 
transmigration assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. 
Then, Then, using Phosphate-buffered saline (PBS) surface adherent The PBL was collected 
gently using pipette. The PBL was collected and stained withe same antibodies panel. PBL 
was stained, and gated on their forward/side scatter profile. Direct conjugated antibodies were 
used for staining. CCR5 receptor expression was measured on the basis of the isotype control 
for each subset. Data is mean ± SEM (N=6) and the differences between groups were 
determined by using an independent sample t test. The probability values of less than 0.05 




















































































Figure  0-29:  Frequency of CXCR3 receptor on different subsets of PBL isolated from 
healthy donors.  
Flow cytometry was used to measure the frequency of CXCR3; Fresh blood was collected 
from young or old subjects. Young subjects aged from 20-35 whereas old subjects aged 60-75 
years old.  Subjects were matched sex, ethnicity, and BMI. PBL collected from transmigration 
assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. Then, Then, 
using Phosphate-buffered saline (PBS) surface adherent The PBL was collected gently using 
pipette. The PBL was collected and stained withe same antibodies panel. PBL was stained, 
and gated on their forward/side scatter profile. Direct conjugated antibodies were used for 
staining. CXCR3 receptor expression was measured on the basis of the isotype control for 
each subset. Data is mean ± SEM (N=6) and the differences between groups were determined 
by using an independent sample t test. The probability values of less than 0.05 were 




































































































































































Figure 32: Frequency of CX3CR1 receptor on different subsets of PBL isolated from 
healthy donors.  
Flow cytometry was used to measure the frequency of CX3CR1; Fresh blood was collected 
from young or old subjects. Young subjects aged from 20-35 whereas old subjects aged 60-75 
years old.  Subjects were matched sex, ethnicity, and BMI. PBL collected from transmigration 
assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. Then, Then, 
using Phosphate-buffered saline (PBS) surface adherent The PBL was collected gently using 
pipette. The PBL was collected and stained withe same antibodies panel. PBL was stained, 
and gated on their forward/side scatter profile. Direct conjugated antibodies were used for 
staining. CX3CR1 receptor expression was measured on the basis of the isotype control for 
each subset. Data is mean ± SEM (N=6) and the differences between groups were determined 
by using an independent sample t test. The probability values of less than 0.05 were 






 Surface expression (MFI) of adhesion molecules on surface adherent PBL from 
young or old controls:  
 
Figure  0-30:  MFI of Alpha-L receptor on different subsets of PBL isolated from healthy 
donors.  
Flow cytometry was used to measure the MFI of Alpha-L; Fresh blood was collected from 
young or old subjects. Young subjects aged from 20-35 whereas old subjects aged 60-75 
years old.  Subjects were matched sex, ethnicity, and BMI. PBL collected from transmigration 
assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. Then, Then, 
using Phosphate-buffered saline (PBS) surface adherent The PBL was collected gently using 
pipette. The PBL was collected and stained withe same antibodies panel. PBL was stained, 
and gated on their forward/side scatter profile. Direct conjugated antibodies were used for 
staining. Alpha-L receptor expression was measured on the basis of the isotype control for 
each subset. Data is mean ± SEM (N=6) and the differences between groups were determined 
by using an independent sample t test. The probability values of less than 0.05 were 













































































Figure  0-31:  MFI of Alpha-4 receptor on different subsets of PBL isolated from healthy 
donors.  
Flow cytometry was used to measure the MFI of Alpha-4; Fresh blood was collected from 
young or old subjects. Young subjects aged from 20-35 whereas old subjects aged 60-75 
years old.  Subjects were matched sex, ethnicity, and BMI. PBL collected from transmigration 
assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. Then, using 
Phosphate-buffered saline (PBS) surface adherent The PBL was collected gently using 
pipette. The PBL was collected and stained withe same antibodies panel. PBL was stained, 
and gated on their forward/side scatter profile. Direct conjugated antibodies were used for 
staining. Alpha-4 receptor expression was measured on the basis of the isotype control for 
each subset. Data is mean ± SEM (N=6) and the differences between groups were determined 
by using an independent sample t test. The probability values of less than 0.05 were 
















































































Figure  0-32:  MFI of Beta-1 receptor on different subsets of PBL isolated from healthy 
donors.  
Flow cytometry was used to measure the MFI of Beta-1; Fresh blood was collected from 
young or old subjects. Young subjects aged from 20-35 whereas old subjects aged 60-75 
years old.  Subjects were matched sex, ethnicity, and BMI. PBL collected from transmigration 
assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. Then, Then, 
using Phosphate-buffered saline (PBS) surface adherent The PBL was collected gently using 
pipette. The PBL was collected and stained withe same antibodies panel. PBL was stained, 
and gated on their forward/side scatter profile. Direct conjugated antibodies were used for 
staining. Beta-1  receptor expression was measured on the basis of the isotype control for each 
subset. Data is mean ± SEM (N=6) and the differences between groups were determined by 
using an independent sample t test. The probability values of less than 0.05 were considered 















































































Figure  0-33: MFI of Beta-2 receptor on different subsets of PBL isolated from healthy 
donors.  
Flow cytometry was used to measure the MFI of Beta-2; Fresh blood was collected from 
young or old subjects. Young subjects aged from 20-35 whereas old subjects aged 60-75 
years old.  Subjects were matched sex, ethnicity, and BMI. PBL collected from transmigration 
assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. Then, Then, 
using Phosphate-buffered saline (PBS) surface adherent The PBL was collected gently using 
pipette. The PBL was collected and stained withe same antibodies panel. PBL was stained, 
and gated on their forward/side scatter profile. Direct conjugated antibodies were used for 
staining. Beta-1  receptor expression was measured on the basis of the isotype control for each 
subset. Data is mean ± SEM (N=6) and the differences between groups were determined by 
using an independent sample t test. The probability values of less than 0.05 were considered 














































































Figure  0-34:  MFI of PSGL-1 receptor on different subsets of PBL isolated from healthy 
donors.  
Flow cytometry was used to measure the MFI of PSGL-1; Fresh blood was collected from 
young or old subjects. Young subjects aged from 20-35 whereas old subjects aged 60-75 
years old.  Subjects were matched sex, ethnicity, and BMI. PBL collected from transmigration 
assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. Then, Then, 
using Phosphate-buffered saline (PBS) surface adherent The PBL was collected gently using 
pipette. The PBL was collected and stained withe same antibodies panel. PBL was stained, 
and gated on their forward/side scatter profile. Direct conjugated antibodies were used for 
staining. PSGL-1 receptor expression was measured on the basis of the isotype control for 
each subset. Data is mean ± SEM (N=6) and the differences between groups were determined 
by using an independent sample t test. The probability values of less than 0.05 were 












































































 Surface expression (MFI) of chemokine receptors on surface adherent PBL from 








































































Figure  0-35: MFI CCR5 receptor on different subsets of PBL isolated from healthy 
donors.  
Flow cytometry was used to measure the MFI of CCR5 receptor; Fresh blood was collected 
from young or old subjects. Young subjects aged from 20-35 whereas old subjects aged 60-75 
years old.  Subjects were matched sex, ethnicity, and BMI. PBL collected from transmigration 
assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. Then, Then, 
using Phosphate-buffered saline (PBS) surface adherent The PBL was collected gently using 
pipette. The PBL was collected and stained withe same antibodies panel. PBL was stained, 
and gated on their forward/side scatter profile. Direct conjugated antibodies were used for 
staining. CCR5 receptor expression was measured on the basis of the isotype control for each 
subset. Data is mean ± SEM (N=6) and the differences between groups were determined by 
using an independent sample t test. The probability values of less than 0.05 were considered 










































































Figure  0-36: MFI of CXCR3 receptor on different subsets of PBL isolated from healthy 
donors.  
Flow cytometry was used to measure the MFI of CXCR3; Fresh blood was collected from 
young or old subjects. Young subjects aged from 20-35 whereas old subjects aged 60-75 
years old.  Subjects were matched sex, ethnicity, and BMI. PBL collected from transmigration 
assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. Then, Then, 
using Phosphate-buffered saline (PBS) surface adherent The PBL was collected gently using 
pipette. The PBL was collected and stained withe same antibodies panel. PBL was stained, 
and gated on their forward/side scatter profile. Direct conjugated antibodies were used for 
staining. CXCR3 receptor expression was measured on the basis of the isotype control for 
each subset. Data is mean ± SEM (N=6) and the differences between groups were determined 
by using an independent sample t test. The probability values of less than 0.05 were 
















































































Figure  0-37:  MFI of CX3CR1 receptor on different subsets of PBL isolated from healthy 
donors.  
Flow cytometry was used to measure the MFI of CX3CR1; Fresh blood was collected from 
young or old subjects. Young subjects aged from 20-35 whereas old subjects aged 60-75 
years old.  Subjects were matched sex, ethnicity, and BMI. PBL collected from transmigration 
assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. Then, Then, 
using Phosphate-buffered saline (PBS) surface adherent The PBL was collected gently using 
pipette. The PBL was collected and stained withe same antibodies panel. PBL was stained, 
and gated on their forward/side scatter profile. Direct conjugated antibodies were used for 
staining. CX3CR1 receptor expression was measured on the basis of the isotype control for 
each subset. Data is mean ± SEM (N=6) and the differences between groups were determined 
by using an independent sample t test. The probability values of less than 0.05 were 






CHAPTER 6: STUDYING THE EFFECT OF ATHEROSCLEROSIS ON 
CHEMOKINE AND INTEGRIN RECEPTORS EXPRESSION ON PBL SUBSETS:  
 
 surface expression of adhesion molecules receptors on PBL from patients with 
















































































Figure 41: Frquency of Alpha-L receptor on different subsets of PBL isolated from 
atherosclerosis patients or age match control.  
Flow cytometry was used to measure the MFI of Alpha-L receptor on fresh blood PBL 
subsets; Fresh blood was collected from from atherosclerosis patients or age match control 
subjects. Young subjects aged from 60-75. Subjects were matched for age, sex, ethnicity, 
BMI, and Statin usage. PBL was isolated from fresh blood samples, stained, and gated on 
their forward/side scatter profile. Direct conjugated antibodies were used for staining. CXCR3 
receptor expression was measured on the basis of the isotype control for each subset. Data is 
mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 


















































































Figure 42: Frequency of Alpha-4 receptor on different subsets of PBL isolated from 
atherosclerosis patients or age match control.  
Flow cytometry was used to measure the MFI of Alpha-4 receptor on fresh blood PBL 
subsets; Fresh blood was collected from from atherosclerosis patients or age match control 
subjects. Young subjects aged from 60-75. Subjects were matched for age, sex, ethnicity, 
BMI, and Statin usage. PBL was isolated from fresh blood samples, stained, and gated on 
their forward/side scatter profile. Direct conjugated antibodies were used for staining. Alpha-4 
receptor expression was measured on the basis of the isotype control for each subset. Data is 
mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 

















































































Figure 43: Frequency of Beta-1 receptor on different subsets of PBL isolated from 
atherosclerosis patients or age match control.  
Flow cytometry was used to measure the frequency of Beta-1 receptor on fresh blood PBL 
subsets; Fresh blood was collected from from atherosclerosis patients or age match control 
subjects. Young subjects aged from 60-75. Subjects were matched for age, sex, ethnicity, 
BMI, and Statin usage. PBL was isolated from fresh blood samples, stained, and gated on 
their forward/side scatter profile. Direct conjugated antibodies were used for staining. Beta-1 
receptor expression was measured on the basis of the isotype control for each subset. Data is 
mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 






















































































Figure 44: Frequency of Beta-2 receptor on different subsets of PBL isolated from 
atherosclerosis patients or age match control.  
Flow cytometry was used to measure the frequency of Beta-2 receptor on fresh blood PBL 
subsets; Fresh blood was collected from from atherosclerosis patients or age match control 
subjects. Young subjects aged from 60-75. Subjects were matched for age, sex, ethnicity, 
BMI, and Statin usage. PBL was isolated from fresh blood samples, stained, and gated on 
their forward/side scatter profile. Direct conjugated antibodies were used for staining. Beta-2 
receptor expression was measured on the basis of the isotype control for each subset. Data is 
mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 






















































































Figure 45: Frequency of PSGL-1 receptor on different subsets of PBL isolated from 
atherosclerosis patients or age match control.  
Flow cytometry was used to measure the frequency of PSGL-1 receptor on fresh blood PBL 
subsets; Fresh blood was collected from from atherosclerosis patients or age match control 
subjects. Young subjects aged from 60-75. Subjects were matched for age, sex, ethnicity, 
BMI, and Statin usage. PBL was isolated from fresh blood samples, stained, and gated on 
their forward/side scatter profile. Direct conjugated antibodies were used for staining. PSGL-1 
receptor expression was measured on the basis of the isotype control for each subset. Data is 
mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 








 Surface expression of chemokine receptors on migrated PBL from patients 














































































Figure 46: Frequency of CCR5 receptor on different subsets of migrated PBL isolated 
from atherosclerosis patients or age match control.  
Flow cytometry was used to measure the Frequency of CCR5 receptors; Fresh blood was 
collected from atherosclerosis patients or age match control subjects. Subjects aged from 60-
75. Subjects were matched for age, sex, ethnicity, BMI, and Statin usage. PBL collected from 
transmigration assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. 
Then, TrypLE was used as cell-dissociation enzymes that make transmigrated PBL floating. 
The PBL was collected and stained with same antibodies panel. PBL was stained, and gated 
on their forward/side scatter profile. Direct conjugated antibodies were used for staining.  
CCR5  receptor expression was measured on the basis of the isotype control for each subset. 
Data is mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 



















































































Figure 47: Frequency of CXCR3 receptor on different subsets of migrated PBL isolated 
from atherosclerosis patients or age match control.  
Flow cytometry was used to measure the Frequency of CXCR3 receptors; Fresh blood was 
collected from atherosclerosis patients or age match control subjects. Subjects aged from 60-
75. Subjects were matched for age, sex, ethnicity, BMI, and Statin usage. PBL collected from 
transmigration assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. 
Then, TrypLE was used as cell-dissociation enzymes that make transmigrated PBL floating. 
The PBL was collected and stained with same antibodies panel. PBL was stained, and gated 
on their forward/side scatter profile. Direct conjugated antibodies were used for staining.  
CXCR3 receptor expression was measured on the basis of the isotype control for each subset. 
Data is mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 






















































































Figure 48: Frequency of CX3CR1 receptor on different subsets of migrated PBL isolated 
from atherosclerosis patients or age match control.  
Flow cytometry was used to measure the Frequency of CX3CR1 receptor; Fresh blood was 
collected from atherosclerosis patients or age match control subjects. Subjects aged from 60-
75. Subjects were matched for age, sex, ethnicity, BMI, and Statin usage. PBL collected from 
transmigration assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. 
Then, TrypLE was used as cell-dissociation enzymes that make transmigrated PBL floating. 
The PBL was collected and stained with same antibodies panel. PBL was stained, and gated 
on their forward/side scatter profile. Direct conjugated antibodies were used for staining.  
CX3CR1 receptor expression was measured on the basis of the isotype control for each 
subset. Data is mean ± SEM (N=6) and the differences between groups were determined by 
using an independent sample t test. The probability values of less than 0.05 were considered 








 Surface expression of adhesion molecules receptors on migrated PBL from 
patients with atherosclerosis or age matched controls: 
 
Figure 48: Frequency of Alpha-L receptor on different subsets of migrated PBL isolated 
from atherosclerosis patients or age match control. 
Flow cytometry was used to measure the Frequency of Alpha-L receptors; Fresh blood was 
collected from atherosclerosis patients or age match control subjects. Subjects aged from 60-
75. Subjects were matched for age, sex, ethnicity, BMI, and Statin usage. PBL collected from 
transmigration assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. 
Then, TrypLE was used as cell-dissociation enzymes that make transmigrated PBL floating. 
The PBL was collected and stained with same antibodies panel. PBL was stained, and gated 
on their forward/side scatter profile. Direct conjugated antibodies were used for staining.  
Alpha-L receptor expression was measured on the basis of the isotype control for each subset. 
Data is mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 

















































































Figure 49: Frequency of Alpha-4receptor on different subsets of migrated PBL isolated 
from atherosclerosis patients or age match control.  
Flow cytometry was used to measure the Frequency of Alpha-4 receptors; Fresh blood was 
collected from atherosclerosis patients or age match control subjects. Subjects aged from 60-
75. Subjects were matched for age, sex, ethnicity, BMI, and Statin usage. PBL collected from 
transmigration assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. 
Then, TrypLE was used as cell-dissociation enzymes that make transmigrated PBL floating. 
The PBL was collected and stained with same antibodies panel. PBL was stained, and gated 
on their forward/side scatter profile. Direct conjugated antibodies were used for staining.  
Alpha-4 receptor expression was measured on the basis of the isotype control for each subset. 
Data is mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 

































































































































































Figure 50: Frequency of Beta-1 receptor on different subsets of migrated PBL isolated 
from atherosclerosis patients or age match control.  
Flow cytometry was used to measure the Frequency of Beta-1 receptors; Fresh blood was 
collected from atherosclerosis patients or age match control subjects. Subjects aged from 60-
75. Subjects were matched for age, sex, ethnicity, BMI, and Statin usage. PBL collected from 
transmigration assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. 
Then, TrypLE was used as cell-dissociation enzymes that make transmigrated PBL floating. 
The PBL was collected and stained with same antibodies panel. PBL was stained, and gated 
on their forward/side scatter profile. Direct conjugated antibodies were used for staining.  
Beta-1 receptor expression was measured on the basis of the isotype control for each subset. 
Data is mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 




















































































Figure 51: Frequency of Beta-2 receptor on different subsets of migrated PBL isolated 
from atherosclerosis patients or age match control.  
Flow cytometry was used to measure the Frequency of Beta-2 receptors; Fresh blood was 
collected from atherosclerosis patients or age match control subjects. Subjects aged from 60-
75. Subjects were matched for age, sex, ethnicity, BMI, and Statin usage. PBL collected from 
transmigration assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. 
Then, TrypLE was used as cell-dissociation enzymes that make transmigrated PBL floating. 
The PBL was collected and stained with same antibodies panel. PBL was stained, and gated 
on their forward/side scatter profile. Direct conjugated antibodies were used for staining.  
Beta-2 receptor expression was measured on the basis of the isotype control for each subset. 
Data is mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 





















































































Figure 52: Frequency of PSGL-L receptor on different subsets of migrated PBL isolated 
from atherosclerosis patients or age match control.  
Flow cytometry was used to measure the Frequency of PSGL-1 receptors; Fresh blood was 
collected from atherosclerosis patients or age match control subjects. Subjects aged from 60-
75. Subjects were matched for age, sex, ethnicity, BMI, and Statin usage. PBL collected from 
transmigration assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. 
Then, TrypLE was used as cell-dissociation enzymes that make transmigrated PBL floating. 
The PBL was collected and stained with same antibodies panel. PBL was stained, and gated 
on their forward/side scatter profile. Direct conjugated antibodies were used for staining.  
PSGL-1 receptor expression was measured on the basis of the isotype control for each subset. 
Data is mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 
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Figure 53: Frequency of CCR5 receptor on different subsets of migrated PBL isolated 
from atherosclerosis patients or age match control.  
Flow cytometry was used to measure the Frequency of CCR5 receptors; Fresh blood was 
collected from atherosclerosis patients or age match control subjects. Subjects aged from 60-
75. Subjects were matched for age, sex, ethnicity, BMI, and Statin usage. PBL collected from 
transmigration assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. 
Then, TrypLE was used as cell-dissociation enzymes that make transmigrated PBL floating. 
The PBL was collected and stained with same antibodies panel. PBL was stained, and gated 
on their forward/side scatter profile. Direct conjugated antibodies were used for staining.  
CCR5 receptor expression was measured on the basis of the isotype control for each subset. 
Data is mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 




















































































Figure 54: Frequency of CXCR3 receptor on different subsets of migrated PBL isolated 
from atherosclerosis patients or age match control.  
Flow cytometry was used to measure the Frequency of CXCR3 receptors; Fresh blood was 
collected from atherosclerosis patients or age match control subjects. Subjects aged from 60-
75. Subjects were matched for age, sex, ethnicity, BMI, and Statin usage. PBL collected from 
transmigration assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. 
Then, TrypLE was used as cell-dissociation enzymes that make transmigrated PBL floating. 
The PBL was collected and stained with same antibodies panel. PBL was stained, and gated 
on their forward/side scatter profile. Direct conjugated antibodies were used for staining.  
CXCR3 receptor expression was measured on the basis of the isotype control for each subset. 
Data is mean ± SEM (N=6) and the differences between groups were determined by using an 
independent sample t test. The probability values of less than 0.05 were considered significant 






















































































Figure 55: Frequency of CX3CR1 receptor on different subsets of migrated PBL isolated 
from atherosclerosis patients or age match control.  
Flow cytometry was used to measure the Frequency of CX3CR1 receptors; Fresh blood was 
collected from atherosclerosis patients or age match control subjects. Subjects aged from 60-
75. Subjects were matched for age, sex, ethnicity, BMI, and Statin usage. PBL collected from 
transmigration assay where PBL are added on DMEC and incubated for 7 minutes at 37°C. 
Then, TrypLE was used as cell-dissociation enzymes that make transmigrated PBL floating. 
The PBL was collected and stained with same antibodies panel. PBL was stained, and gated 
on their forward/side scatter profile. Direct conjugated antibodies were used for staining.  
CX3CR1 receptor expression was measured on the basis of the isotype control for each 
subset. Data is mean ± SEM (N=6) and the differences between groups were determined by 
using an independent sample t test. The probability values of less than 0.05 were considered 
significant (* = P ≤ 0.05, **= P ≤ 0.01, *** = P ≤ 0.001). 
 
 
 
 
 
 
 
